JPH085914B2 - Glycosyl-protein derivative - Google Patents

Glycosyl-protein derivative

Info

Publication number
JPH085914B2
JPH085914B2 JP3040810A JP4081091A JPH085914B2 JP H085914 B2 JPH085914 B2 JP H085914B2 JP 3040810 A JP3040810 A JP 3040810A JP 4081091 A JP4081091 A JP 4081091A JP H085914 B2 JPH085914 B2 JP H085914B2
Authority
JP
Japan
Prior art keywords
compound
mmol
added
deoxy
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP3040810A
Other languages
Japanese (ja)
Other versions
JPH04211099A (en
Inventor
民雄 菅原
博行 岩沢
邦彦 入江
剛兆 吉川
哲 奥野
隆 加藤
Original Assignee
株式会社ディ・ディ・エス研究所
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式会社ディ・ディ・エス研究所 filed Critical 株式会社ディ・ディ・エス研究所
Priority to JP3040810A priority Critical patent/JPH085914B2/en
Publication of JPH04211099A publication Critical patent/JPH04211099A/en
Publication of JPH085914B2 publication Critical patent/JPH085914B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【産業上の利用分野】本発明は、薬物を標的組織とくに
骨髄又は脳に選択的に運搬させるための担体として有用
なグリコシル−蛋白誘導体及びその中間体に関する。
TECHNICAL FIELD The present invention relates to a glycosyl-protein derivative and an intermediate thereof which are useful as a carrier for selectively delivering a drug to a target tissue, particularly bone marrow or brain.

【0002】[0002]

【従来の技術】骨髄組織は、赤血球、リンパ球、単球、
顆粒球を作り出す組織であり、体内の造血、免疫を担う
最も重要な組織である。ガン患者における放射線治療及
び抗癌剤投与によって、骨髄機能低下が起こることは、
現在避けることのできない副作用であり、骨髄抑制が起
った結果、白血球や血小板の大幅な減少、特に顆粒球の
減少に伴った重症感染症は大きな問題となっている。
Bone marrow tissue is composed of red blood cells, lymphocytes, monocytes,
It is a tissue that produces granulocytes, and is the most important tissue responsible for hematopoiesis and immunity in the body. Radiation therapy and anticancer drug administration in cancer patients cause the decrease of bone marrow function.
It is an unavoidable side effect at present, and as a result of myelosuppression, a serious decrease in white blood cells and platelets, especially a severe infection associated with a decrease in granulocytes has become a serious problem.

【0003】また、脳組織へ薬剤が輸送されるためには
血液脳関門を通過しなければならないため、脳内への薬
剤の移行を妨げている。このため、脳内への薬剤の運搬
手段の開発が要望されている。
Further, in order for the drug to be transported to the brain tissue, it has to pass through the blood-brain barrier, which impedes the migration of the drug into the brain. Therefore, there is a demand for the development of means for delivering a drug into the brain.

【0004】一方、近年の免疫学の発展に伴い、多くの
生理活性蛋白が単離精製され、その薬理作用についても
明らかにされてきている。さらに遺伝子工学技術の発展
に伴い、多くのサイトカイン類、例えば赤血球の造血ホ
ルモンであるエリスロポエチン、白血球の造血因子であ
る数種類のコロニー刺激因子(CSF)、さらにα−、
β−、γ−インターフェロン、インターロイキン2など
が、大量生産できるようになり、医薬品への応用が試み
られてきている。
On the other hand, with the recent development of immunology, many physiologically active proteins have been isolated and purified, and their pharmacological actions have been clarified. Further, with the development of genetic engineering technology, many cytokines, for example, erythropoietin which is a hematopoietic hormone of erythrocytes, several kinds of colony stimulating factor (CSF) which is a hematopoietic factor of leukocytes, and α-,
β-, γ-interferon, interleukin 2 and the like have become possible to be mass-produced, and their application to pharmaceuticals has been attempted.

【0005】しかしながら、多くのサイトカイン類は、
生体内に投与した後、すばやく代謝されてしまうため、
目的とする組織での薬効発現が十分に達成できない問題
点がある。
However, many cytokines
After being administered in vivo, it is rapidly metabolized,
There is a problem that the manifestation of drug efficacy in the target tissue cannot be achieved sufficiently.

【0006】この問題点を解決するために、生理活性物
質や合成医薬品を標的部位に運搬する担体として、抗
体、糖蛋白、リポ蛋白、レクチン、ホルモン、リポソー
ム、デオキシリボ核酸、多糖類、合成ポリマー、ポリア
ミノ酸等、天然由来高分子、分子集合体及び合成ポリマ
ーに至る広い範囲の物質が提案されている。
In order to solve this problem, antibodies, glycoproteins, lipoproteins, lectins, hormones, liposomes, deoxyribonucleic acids, polysaccharides, synthetic polymers, as carriers for delivering physiologically active substances and synthetic drugs to target sites, A wide range of substances have been proposed, including naturally occurring polymers such as polyamino acids, molecular assemblies and synthetic polymers.

【0007】例えば、Proc. Nath. Acad. Sci. USA84,
1487-1491 (1987)には数種のサイトカイン類をポリエチ
レングリコールなどの合成ポリマーで修飾し、サイトカ
イン類自身の活性を失うことなく生体内での半減期を延
長させる研究が報告されている。
For example, Proc. Nath. Acad. Sci. USA 84,
1487-1491 (1987) reported a study in which some cytokines were modified with a synthetic polymer such as polyethylene glycol to prolong the half-life in vivo without losing the activity of the cytokines themselves.

【0008】また、特開昭63−152393号公報に
は、糖鎖を有するポリエチレングリコール誘導体がサイ
トカイン類の修飾に用いることができ、この修飾蛋白は
生体内におけるクリアランスを遅延させ、あるいは特定
の細胞・組織への送達を向上させるために使用すること
が示唆されている。しかしながら、骨髄又は脳指向性に
関する報告は存在しない。
Further, in Japanese Patent Laid-Open No. 63-152393, a polyethylene glycol derivative having a sugar chain can be used for modification of cytokines, and this modified protein delays clearance in a living body or can be used in specific cells. -It has been suggested to be used to improve delivery to tissues. However, there are no reports of bone marrow or brain tropism.

【0009】[0009]

【発明が解決しようとする課題】本発明は、骨髄又は脳
細胞表面の糖認識性を利用し、薬物(サイトカイン類及
び低分子の医薬品など)を標的組織である骨髄又は脳組
織により多く送達することを可能とし、並びに薬物の生
体内半減期を遅延させることを可能とする薬物運搬担体
の発明であり、目的とする薬物を標的とする組織に送達
するシステム(Targeting Drug Delivery System)の開
発を目的とするものである。
The present invention utilizes sugar recognition on the surface of bone marrow or brain cells to deliver more drugs (cytokines and low molecular weight pharmaceuticals) to the target tissue, bone marrow or brain tissue. It is an invention of a drug delivery carrier that makes it possible to delay the in vivo half-life of a drug, and develops a system (Targeting Drug Delivery System) for delivering a target drug to a target tissue. It is intended.

【0010】とくに本発明は、再生不良性貧血等の造血
機能の疾患、各種リンパ球疾患に伴う免疫不全症等の骨
髄機能異常を起こしている患者、さらには、骨髄性白血
病、ミエローム、形質細胞腫、多発性骨髄腫などの骨髄
性ガン患者やガンの治療等に伴う副作用により骨髄機能
低下を引き起こしている患者に対して、その治療に使わ
れる薬物を効率よく骨髄組織に集めることによって、ま
たその薬物の生体内半減期を遅延させることができる、
より高い有効性が期待できる薬物運搬担体の開発を目的
とするものである。
In particular, the present invention relates to patients with hematopoietic function diseases such as aplastic anemia and bone marrow dysfunction such as immunodeficiency associated with various lymphocyte diseases, as well as myeloid leukemia, myeloma and plasma cells. For patients with myelogenous cancer such as tumors and multiple myeloma and patients who have decreased bone marrow function due to side effects associated with cancer treatment, etc., by efficiently collecting drugs used for the treatment in bone marrow tissues, Can delay the in vivo half-life of the drug,
The purpose is to develop a drug delivery carrier that can be expected to have higher efficacy.

【0011】また、本発明は、アルツハイマー病等の治
療のため、脳内への直接的な薬剤運搬担体の開発を目的
とするものであり、これにより少量の薬剤であっても、
その活性を保持したままで、かつ副作用の可能性を少な
くして治療を可能にする。
Further, the present invention aims at the development of a carrier for drug delivery directly into the brain for the treatment of Alzheimer's disease and the like.
It enables treatment while maintaining its activity and reducing the possibility of side effects.

【0012】[0012]

【課題を解決するための手段】 本発明は、式:〔R−O−(CH2)n −CO−〕m −Z (I) (式中Rはグリコシル基を表し、Zは蛋白を表し、nは
3〜14を表し、mは10〜50を表す)で示されるグ
リコシル−蛋白誘導体を含有する薬剤運搬担体である。
特に、mが10〜50であるものは骨髄への運搬担体と
して、またmが20〜50であるものは脳への運搬担体
として好ましい。
The present invention SUMMARY OF] has the formula: [R-O- (CH 2) n -CO- ] m -Z (I) (wherein R represents a glycosyl group, Z is expressed protein , N represents 3 to 14, and m represents 10 to 50), which is a drug delivery carrier containing the glycosyl-protein derivative.
Particularly, those having m of 10 to 50 are preferable as carriers for delivery to bone marrow, and those having m of 20 to 50 are preferable as carriers for delivery to the brain.

【0013】 また、式:〔R−O−C64 −NH−CS−〕m −Z (II) (式中Rはグリコシル基を表し、Zは蛋白を表し、mは
5〜50を表す)で示されるグリコシル−蛋白誘導体。
In addition, the formula: [ROC 6 H 4 —NH-CS-] m -Z (II) (wherein R represents a glycosyl group, Z represents a protein, and m represents 5 to 50). Represents a glycosyl-protein derivative.

【0014】また、式: 〔R−O−(CH2)2 O(CH2)2 O(CH2)3 −CO−〕m −Z (III) (式中Rはグリコシル基を表し、Zは蛋白を表し、mは
5〜50を表す)で示されるグリコシル−蛋白誘導体で
ある。
[0014] wherein: [R-O- (CH 2) 2 O (CH 2) 2 O (CH 2) 3 -CO- ] m -Z (III) (wherein R represents a glycosyl group, Z Represents a protein and m represents 5 to 50), and is a glycosyl-protein derivative.

【0015】本発明の上記化合物は、薬物を目的とする
細胞、臓器、器官、とくに骨髄又は脳組織への薬物運搬
担体として利用することができる。薬物運搬担体は
(i)生体適合性が良いこと、(ii) 投与後、一定時間
は安定であること、(iii) 薬物が作用部位に到達したと
き化学的、酵素的反応により薬物が遊離されること、が
要求される。
The compound of the present invention can be used as a drug delivery carrier for target cells, organs, organs, particularly bone marrow or brain tissue. The drug carrier has (i) good biocompatibility, (ii) is stable for a certain period of time after administration, and (iii) is released by chemical or enzymatic reaction when the drug reaches its site of action. Is required.

【0016】上記式の運搬担体を構成する糖鎖は、標的
とする細胞臓器、器官等を特異的に認識する能力を持っ
た標的識別部位として利用することができる。Rで示さ
れるグリコシル基としては、キシロピラノシル基、マン
ノピラノシル基、フコピラノシル基、2−ガラクトピラ
ノシル基、2−アセトアミド−2−デオキシ−フコピラ
ノシル基、2−アセトアミド−2−デオキシ−マンノピ
ラノシル基、2−アセトアミド−2−デオキシ−ガラク
トピラノシル基のような単糖類;マンノピラノシル−マ
ンノピラノシル基、(2−アセトアミド−2−デオキシ
−マンノピラノシル)−マンノピラノシル基、(2−ア
セトアミド−2−デオキシ−グルコピラノシル)−マン
ノピラノシル基、フコピラノシル−(2−アセトアミド
−2−デオキシ−グルコピラノシル)基、ガラクトピラ
ノシル−(2−アセトアミド−2−デオキシ−グルコピ
ラノシル)基、ガラクトピラノシル−(2−アセトアミ
ド−2−デオキシ−マンノピラノシル)基、ガラクトピ
ラノシル−グルコピラノシル基のような二糖類又はジ
(2−アセトアミド−2−デオキシ−グルコピラノシ
ル)−マンノピラノシル基、ジ(ガラクトピラノシル)
−2−アセトアミド−2−デオキシ−グルコピラノシル
基のような三糖類をあげることができる。とくに好まし
くは、マンノピラノシル基、フコピラノシル基、2−ア
セトアミド−2−デオキシ−フコピラノシル基、マンノ
ピラノシル−マンノピラノシル基、(2−アセトアミド
−2−デオキシ−グルコピラノシル)−マンノピラノシ
ル基、及びガラクトピラノシル−グルコピラノシル基が
あげられる。
The sugar chain constituting the carrier of the above formula can be used as a target identification site having the ability to specifically recognize a target cell organ, organ or the like. Examples of the glycosyl group represented by R include a xylopyranosyl group, a mannopyranosyl group, a fucopyranosyl group, a 2-galactopyranosyl group, a 2-acetamido-2-deoxy-fucopyranosyl group, a 2-acetamido-2-deoxy-mannopyranosyl group, and a 2-acetamido-2-deoxy-mannopyranosyl group. Monosaccharides such as acetamido-2-deoxy-galactopyranosyl group; mannopyranosyl-mannopyranosyl group, (2-acetamido-2-deoxy-mannopyranosyl) -mannopyranosyl group, (2-acetamido-2-deoxy-glucopyranosyl) -mannopyranosyl Group, fucopyranosyl- (2-acetamido-2-deoxy-glucopyranosyl) group, galactopyranosyl- (2-acetamido-2-deoxy-glucopyranosyl) group, galactopyranosyl- (2-acetamido-2-) Oxy - mannopyranosyl) group, galactopyranosyl - disaccharide or di like glucopyranosyl group (2-acetamido-2-deoxy - glucopyranosyl) - mannopyranosyl group, di (galactopyranosyl)
Mention may be made of trisaccharides such as the 2-acetamido-2-deoxy-glucopyranosyl group. Particularly preferably, a mannopyranosyl group, a fucopyranosyl group, a 2-acetamido-2-deoxy-fucopyranosyl group, a mannopyranosyl-mannopyranosyl group, a (2-acetamido-2-deoxy-glucopyranosyl) -mannopyranosyl group, and a galactopyranosyl-glucopyranosyl group are can give.

【0017】式(I)の化合物において、糖鎖と蛋白を
結ぶ修飾剤のカルボン酸はアルキレン部分が3−14個
であり、好ましくはオクタン酸である。糖鎖とカルボン
酸との結合はα−結合でもβ−結合でもよい。Zの蛋白
としては、ヒト血清アルブミンのような蛋白である以外
に、それ自体生理活性蛋白であるサイトカイン類のイン
ターロイキン、エリスロポエチン、インターフェロン、
組織プラスミノーゲンアクチベーター、潰瘍壊死因子
(TNF)又はコロニー刺激因子(CSF)であっても
よい。これらの蛋白自体は臓器特異性を持たないが、標
的識別能力を持つ糖鎖で化学修飾することにより標的識
別性を有するものになる。
In the compound of the formula (I), the carboxylic acid as the modifier that connects the sugar chain and the protein has 3 to 14 alkylene moieties, preferably octanoic acid. The bond between the sugar chain and the carboxylic acid may be an α-bond or a β-bond. Examples of the Z protein include, in addition to proteins such as human serum albumin, cytokines interleukins, erythropoietin, interferon, which are physiologically active proteins themselves.
It may be a tissue plasminogen activator, ulcer necrosis factor (TNF) or colony stimulating factor (CSF). Although these proteins themselves do not have organ specificity, they become target-identifying by being chemically modified with sugar chains capable of target-identifying.

【0018】式(I)の運搬担体を製造するには、例え
ばグリコシル−アルカン酸のアルキルエステル又は2−
アセトアミド−2−デオキシ−グリコシル−アルカン酸
のアルキルエステルにヒドラジンを反応させ、得られた
酸ヒドラジドを常法で酸アジドに変換し、これを蛋白と
反応させてグリコシル−アルカン酸が蛋白中のアミノ基
の一部とアミド結合した目的物を得る。修飾基の結合数
は蛋白1分子当り5〜50モルである。修飾の程度は、
蛋白に対するグリコシル−アルカン酸のモル比を増減す
るか、または蛋白とグリコシル−アルカン酸の反応液濃
度を増減することによって選択することができる。
To prepare the carrier of formula (I), for example, an alkyl ester of glycosyl-alkanoic acid or 2-
Acetamide-2-deoxy-glycosyl-alkanoic acid alkyl ester is reacted with hydrazine, the obtained acid hydrazide is converted into an acid azide by a conventional method, and this is reacted with protein to react glycosyl-alkanoic acid with amino acid in protein. The desired product is obtained by amide bond with a part of the group. The number of modifying groups bonded is 5 to 50 mol per protein molecule. The degree of modification is
It can be selected by increasing or decreasing the molar ratio of glycosyl-alkanoic acid to protein or by increasing or decreasing the reaction solution concentration of protein and glycosyl-alkanoic acid.

【0019】反応に用いる溶媒は反応を妨害しないもの
であればいずれでもよいが、リン酸緩衝液、トリス緩衝
液、酢酸緩衝液、ホウ酸緩衝液などがあげられる。反応
は中性付近で0〜室温で行なわれる。反応液は透析、イ
オン交換クロマトグラフィー、ゲルろ過などの通常の蛋
白の精製法により精製して目的物を得る。修飾基の導入
数は、修飾蛋白を塩酸で加水分解後エルソン−モーガン
法などで測定することにより知ることができる。
The solvent used in the reaction may be any solvent as long as it does not interfere with the reaction, and examples thereof include phosphate buffer, Tris buffer, acetate buffer, borate buffer and the like. The reaction is carried out near neutrality at 0 to room temperature. The reaction solution is purified by a usual protein purification method such as dialysis, ion exchange chromatography, gel filtration, etc. to obtain the desired product. The number of modifying groups introduced can be known by hydrolyzing the modified protein with hydrochloric acid and then measuring by the Elson-Morgan method or the like.

【0020】グリコシル−アルカン酸と蛋白との反応
は、水溶性カルボジイミドなどの縮合剤の存在下に反応
させることによっても製造することができる。またアル
カン酸の他の活性誘導体を用いてもよく、そのような活
性誘導体としては、アミド化合物、活性エステル、活性
チオエステルなどがあげられる。これらの活性誘導体は
蛋白とアミド結合を形成させるために当業者において適
宜選択することができる。
The reaction of glycosyl-alkanoic acid with protein can also be produced by reacting in the presence of a condensing agent such as a water-soluble carbodiimide. Further, other active derivatives of alkanoic acid may be used, and examples of such active derivatives include amide compounds, active esters, active thioesters and the like. These active derivatives can be appropriately selected by those skilled in the art in order to form an amide bond with a protein.

【0021】中間体は式(IV)で示されるグリコシル−カ
ルボン酸又はその活性誘導体である。 R−O−(CH2 )n−COOH (IV) ここに、Rはとくにキシロピラノシル基、フコピラノシ
ル基、ガラクトピラノシル基、2−アセトアミド−2−
デオキシ−フコピラノシル基、2−アセトアミド−2−
デオキシ−マンノピラノシル基、2−アセトアミド−2
−デオキシ−ガラクトピラノシル基、(2−アセトアミ
ド−2−デオキシ−マンノピラノシル)−マンノピラノ
シル基、(2−アセトアミド−2−デオキシ−グルコピ
ラノシル)−マンノピラノシル基、フコピラノシル−
(2−アセトアミド−2−デオキシ−グルコピラノシ
ル)基、ガラクトピラノシル−(2−アセトアミド−2
−デオキシ−グルコピラノシル)基、ガラクトピラノシ
ル−(2−アセトアミド−2−デオキシ−マンノピラノ
シル)基、ガラクトピラノシル−グルコピラノシル基、
ジ(2−アセトアミド−2−デオキシ−グルコピラノシ
ル)−マンノピラノシル基又はジ(ガラクトピラノシ
ル)−2−アセトアミド−2−デオキシ−グルコピラノ
シル基のようなグリコシル基である。
The intermediate is a glycosyl-carboxylic acid of formula (IV) or its active derivative. R-O- (CH 2) n -COOH (IV) herein, R represents particularly xylopyranosyl group, fucopyranosyl group, galactopyranosyl group, 2-acetamido-2-
Deoxy-fucopyranosyl group, 2-acetamido-2-
Deoxy-mannopyranosyl group, 2-acetamido-2
-Deoxy-galactopyranosyl group, (2-acetamido-2-deoxy-mannopyranosyl) -mannopyranosyl group, (2-acetamido-2-deoxy-glucopyranosyl) -mannopyranosyl group, fucopyranosyl-
(2-acetamido-2-deoxy-glucopyranosyl) group, galactopyranosyl- (2-acetamido-2)
-Deoxy-glucopyranosyl) group, galactopyranosyl- (2-acetamido-2-deoxy-mannopyranosyl) group, galactopyranosyl-glucopyranosyl group,
A glycosyl group such as a di (2-acetamido-2-deoxy-glucopyranosyl) -mannopyranosyl group or a di (galactopyranosyl) -2-acetamido-2-deoxy-glucopyranosyl group.

【0022】式(IV)の中間体を製造するには、 (A)ヒドロキシル基を保護したグリコシルハライドに
ω−ヒドロキシアルカン酸アルキルエステルを反応させ
て、グリコシル−α(又はβ)−アルカン酸アルキルエ
ステルとし、これを脱保護して得られるか、 (B)また2−アセトアミド−2−デオキシ−グリコシ
ル−アルカン酸アルキルエステルは対応する2−アジド
−2−デオキシ−グリコシル−アルカン酸アルキルエス
テルをアセチル化して得られる。さらに必要により他の
活性誘導体に導くことができる。
To prepare the intermediate of formula (IV), (A) a hydroxyl group-protected glycosyl halide is reacted with a ω-hydroxyalkanoic acid alkyl ester to give a glycosyl-α (or β) -alkanoic acid alkyl ester. (B) Alternatively, the 2-acetamido-2-deoxy-glycosyl-alkanoic acid alkyl ester can be obtained by deprotecting it as an ester. Can be obtained. Further, if necessary, it can be led to another active derivative.

【0023】式(I)及び式(IV)の化合物の具体的な製
法は、以下の反応式を参照することにより明らかにな
る。
Specific methods for preparing the compounds of formula (I) and formula (IV) will become apparent by referring to the following reaction scheme.

【0024】[0024]

【化1】 Embedded image

【0025】[0025]

【化2】 Embedded image

【0026】[0026]

【化3】 [Chemical 3]

【0027】[0027]

【化4】 [Chemical 4]

【0028】[0028]

【化5】 [Chemical 5]

【0029】[0029]

【化6】 [Chemical 6]

【0030】[0030]

【化7】 [Chemical 7]

【0031】[0031]

【化8】 Embedded image

【0032】[0032]

【化9】 [Chemical 9]

【0033】[0033]

【化10】 [Chemical 10]

【0034】[0034]

【化11】 [Chemical 11]

【0035】[0035]

【化12】 [Chemical 12]

【0036】[0036]

【化13】 [Chemical 13]

【0037】[0037]

【化14】 Embedded image

【0038】[0038]

【化15】 [Chemical 15]

【0039】[0039]

【化16】 Embedded image

【0040】式(II)の運搬担体を製造するには、 式: R−O−C64 −NH2 (V) の中間体から、以下の反応式に示す方法により製造する
ことができる。
The carrier of the formula (II) can be produced from the intermediate of the formula: R—O—C 6 H 4 —NH 2 (V) by the method shown in the following reaction scheme. .

【0041】[0041]

【化17】 [Chemical 17]

【0042】式(III) の運搬担体を製造するには、 式:R−O−(CH2)2 O(CH2)2 O(CH2)3 −COOH (VI) の中間体から以下の反応式に示す方法により製造するこ
とができる。
To prepare a carrier of formula (III), the following intermediates of the formula: R--O-(CH 2 ) 2 O (CH 2 ) 2 O (CH 2 ) 3 --COOH (VI) It can be produced by the method shown in the reaction scheme.

【0043】[0043]

【化18】 Embedded image

【0044】[0044]

【化19】 [Chemical 19]

【0045】[0045]

【化20】 Embedded image

【0046】[0046]

【化21】 [Chemical 21]

【0047】[0047]

【発明の効果】本発明のグリコシル−蛋白誘導体は、後
記参考例56に示すように薬剤を結合させ、これを試験
例に示すように動物に投与したとき、薬剤を骨髄又は脳
組織に集中的に分布させることができる。
INDUSTRIAL APPLICABILITY The glycosyl-protein derivative of the present invention binds a drug as shown in Reference Example 56 below, and when this is administered to animals as shown in Test Examples, the drug is concentrated in bone marrow or brain tissue. Can be distributed in

【0048】[0048]

【実施例】以下に本発明の実施例、参考例及び試験例を
示す。
EXAMPLES Examples, reference examples and test examples of the present invention will be shown below.

【0049】参考例1 6−メトキシカルボニルヘキサノール(2) ピメリン酸モノメチルエステル(1)、25g(156
ミリモル)およびトリエチルアミン21.7ml(156
ミリモル)の無水テトラヒドロフラン100ml溶液を、
窒素気流下、−18℃に冷却する。この溶液に撹拌しな
がらクロル炭酸エチル15ml(156ミリモル)の無水
テトラヒドロフラン100ml溶液を滴下した。同温度で
20分間撹拌した後、析出した塩をろ去し、少量の無水
テトラヒドロフランで洗浄した。ろ液および洗液を合
せ、氷冷した水素化ホウ素ナトリウム14.7g(39
0ミリモル)の水溶液150mlに滴下した。更に同温度
で1時間撹拌した後、酢酸エチルと水層とに分配した。
有機層を水洗し、硫酸マグネシウムで乾燥後、減圧下濃
縮乾固してシロップ状残渣18gを得た。残渣をシリカ
ゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル
=2:1)で精製して化合物(2)3.45gを得た。
Reference Example 1 6-Methoxycarbonylhexanol (2) Pimelic acid monomethyl ester (1), 25 g (156)
Mmol) and 21.7 ml of triethylamine (156
100 ml of anhydrous tetrahydrofuran of
Cool to −18 ° C. under nitrogen stream. A solution of 15 ml (156 mmol) of ethyl chlorocarbonate in 100 ml of anhydrous tetrahydrofuran was added dropwise to this solution while stirring. After stirring for 20 minutes at the same temperature, the precipitated salt was filtered off and washed with a small amount of anhydrous tetrahydrofuran. The filtrate and washings were combined and ice-cooled sodium borohydride 14.7 g (39
(0 mmol) in 150 ml of water. After further stirring at the same temperature for 1 hour, the mixture was partitioned into ethyl acetate and an aqueous layer.
The organic layer was washed with water, dried over magnesium sulfate and then concentrated to dryness under reduced pressure to obtain 18 g of a syrup-like residue. The residue was purified by silica gel column chromatography (hexane: ethyl acetate = 2: 1) to obtain 3.45 g of compound (2).

【0050】 IR(film)cm-1:3400, 1737, 1438, 1207, 1174 1H-NMR (CDCl3,δppm): 3.68(3H, s, OMe), 3.66(2H, t, J=6.4Hz, HOCH2-), 2.34(2H, t, J=7.2Hz, -CH2CO-), 1.75〜 1.30(8H, m, -(CH2)4-)IR (film) cm −1 : 3400, 1737, 1438, 1207, 1174 1 H-NMR (CDCl 3 , δppm): 3.68 (3H, s, OMe), 3.66 (2H, t, J = 6.4Hz , HOCH 2 -), 2.34 ( 2H, t, J = 7.2Hz, -CH 2 CO-), 1.75~ 1.30 (8H, m, - (CH 2) 4 -)

【0051】 元素分析 C7H14O3 計算値 C 57.51% H 9.65% 実測値 C 57.64% H 9.82%Elemental analysis C 7 H 14 O 3 Calculated value C 57.51% H 9.65% Measured value C 57.64% H 9.82%

【0052】参考例2 6−メトキシカルボニルヘキシル 2,3,4,6−テ
トラ−O−ベンジル−β−D−マンノピラノシド(5)
および6−メトキシカルボニルヘキシル 2,3,4,
6−テトラ−O−ベンジル−α−D−マンノピラノシド
(6)
Reference Example 2 6-Methoxycarbonylhexyl 2,3,4,6-tetra-O-benzyl-β-D-mannopyranoside (5)
And 6-methoxycarbonylhexyl 2,3,4
6-Tetra-O-benzyl-α-D-mannopyranoside (6)

【0053】2,3,4,6−テトラ−O−ベンジル−
α−D−マンノピラノシルクロリド(3)、608mg
(1.087ミリモル)および6−メトキシカルボニル
ヘキサノール(2)159mg(1.087ミリモル)の
乾燥トルエン溶液に、モレキュラーシーブ4A750mg
を加えて、窒素気流下、室温で30分間撹拌した。次い
で銀シリケート500mgを加えて、72時間撹拌した。
反応混合物をセライトを用いてろ過した後、ろ液を減圧
下濃縮乾固してシロップ状残渣720mgを得た。残渣を
ローバーカラム(ヘキサン:酢酸エチル=4:1)を用
いて精製して化合物(5)380mg(収率52.2%)
および化合物(6)130mg(収率17.9%)をそれ
ぞれシロップ状物質として得た。
2,3,4,6-tetra-O-benzyl-
α-D-mannopyranosyl chloride (3), 608 mg
(1.087 mmol) and 6-methoxycarbonylhexanol (2) 159 mg (1.087 mmol) in dry toluene solution, molecular sieve 4A 750 mg.
Was added, and the mixture was stirred at room temperature for 30 minutes under a nitrogen stream. Then, 500 mg of silver silicate was added and stirred for 72 hours.
The reaction mixture was filtered through Celite, and the filtrate was concentrated to dryness under reduced pressure to give 720 mg of a syrupy residue. The residue was purified using a Rover column (hexane: ethyl acetate = 4: 1) to give compound (5) 380 mg (yield 52.2%).
And 130 mg of compound (6) (yield 17.9%) were obtained as syrupy substances.

【0054】 化合物(5) 〔α〕22.50 D-47.1 °(C 0.550, CHCl3) IR(film)cm-1:1740, 1440, 1365, 1105 1H-NMR (CDCl3,δppm): 7.5 〜7.1(20H, m, ph), 4.36(1H, s, H-1), 3.65(3H, s, OMe), 2.31(2H, t, J=7.5Hz, -CH2CO-) 1.7 〜1.4(8H, m, -(CH2)4-)Compound (5) [α] 22.50 D -47.1 ° (C 0.550, CHCl 3 ) IR (film) cm −1 : 1740, 1440, 1365, 1105 1 H-NMR (CDCl 3 , δppm): 7.5 〜 7.1 (20H, m, ph), 4.36 (1H, s, H-1), 3.65 (3H, s, OMe), 2.31 (2H, t, J = 7.5Hz, -CH 2 CO-) 1.7 ~ 1.4 ( 8H, m, - (CH 2 ) 4 -)

【0055】 元素分析 C41H68O8 計算値 C 73.62% H 7.23% 実測値 C 73.25% H 7.04%Elemental analysis C 41 H 68 O 8 Calculated value C 73.62% H 7.23% Measured value C 73.25% H 7.04%

【0056】 化合物(6) 〔α〕22.50 D+21.1 °(C 1.05, CHCl3) IR(film)cm-1:1738, 1455, 1275, 1105 1H-NMR (CDCl3,δppm): 7.4 〜7.2(20H, m, ph), 4.62(1H, s, H-1), 3.64(3H, s, OMe), 2.29(2H, t, J=7.5Hz, -CH2CO-) 1.8 〜1.2(12H, m, -(CH2)4-) Compound (6) [α] 22.50 D +21.1 ° (C 1.05, CHCl 3 ) IR (film) cm −1 : 1738, 1455, 1275, 1105 1 H-NMR (CDCl 3 , δppm): 7.4 〜 7.2 (20H, m, ph), 4.62 (1H, s, H-1), 3.64 (3H, s, OMe), 2.29 (2H, t, J = 7.5Hz, -CH 2 CO-) 1.8 ~ 1.2 ( 12H, m, - (CH 2 ) 4 -)

【0057】 元素分析 C41H68O8 計算値 C 73.62% H 7.23% 実測値 C 73.59% H 7.11%Elemental analysis C 41 H 68 O 8 Calculated value C 73.62% H 7.23% Measured value C 73.59% H 7.11%

【0058】参考例3 8−メトキシカルボニルオクチル 2,3,4,6−テ
トラ−O−ベンジル−β−D−マンノピラノシド(7)
および8−メトキシカルボニルオクチル 2,3,4,
6−テトラ−O−ベンジル−α−D−マンノピラノシド
(8)
Reference Example 3 8-Methoxycarbonyloctyl 2,3,4,6-tetra-O-benzyl-β-D-mannopyranoside (7)
And 8-methoxycarbonyloctyl 2,3,4,
6-Tetra-O-benzyl-α-D-mannopyranoside (8)

【0059】Bull. Chem. Soc. Jpn., 49, 2639(1976)
に記載の方法で合成した2,3,4,6−テトラ−O−
ベンジル−α/β−D−マンノピラノース1.0g
(1.85ミリモル)の無水テトラヒドロフラン溶液2
0mlに窒素気流下、氷冷しながら50%水素化ナトリウ
ムのオイル懸濁物90mg(1.87ミリモル)を加え、
同温度で40分間撹拌した。次いで8−メトキシカルボ
ニルオクチルトリフルオロメタンスルホン酸エステル6
00mg(1.87ミリモル)の無水テトラヒドロフラン
溶液4mlを滴下し、更に2時間撹拌した。反応液を氷水
中に注いだ後、生成物を酢酸エチルで抽出した。酢酸エ
チル相を水洗いし、硫酸マグネシウムで乾燥後、減圧下
溶媒留去してシロップ状残渣1.3gを得た。残渣をロ
ーバーカラム(ヘキサン:酢酸エチル=6:1)を用い
て精製して化合物(7)650mg(収率56.7%)お
よび化合物(8)171mg(収率14.9%)を得た。
Bull. Chem. Soc. Jpn., 49, 2639 (1976)
2,3,4,6-tetra-O- synthesized by the method described in 1.
Benzyl-α / β-D-mannopyranose 1.0 g
Anhydrous tetrahydrofuran solution 2 of (1.85 mmol)
90 ml (1.87 mmol) of an oil suspension of 50% sodium hydride was added to 0 ml under nitrogen flow while cooling with ice,
The mixture was stirred at the same temperature for 40 minutes. Then, 8-methoxycarbonyloctyltrifluoromethanesulfonic acid ester 6
4 ml of a solution of 00 mg (1.87 mmol) in anhydrous tetrahydrofuran was added dropwise, and the mixture was further stirred for 2 hours. After pouring the reaction solution into ice water, the product was extracted with ethyl acetate. The ethyl acetate phase was washed with water, dried over magnesium sulfate, and then the solvent was distilled off under reduced pressure to obtain 1.3 g of a syrup-like residue. The residue was purified using a Rover column (hexane: ethyl acetate = 6: 1) to obtain 650 mg of compound (7) (yield 56.7%) and 171 mg of compound (8) (yield 14.9%). .

【0060】 化合物(7) m.p. 54.5 〜55℃ 〔α〕25 D-46.7°(C 0.85, CHCl3) IR(CHCl3)cm-1 :1732, 1497, 1454, 1362, 1100 1H-NMR (CDCl3,δppm): 7.6 〜7.1(20H, m, ph), 4.61(1H, s, H-1), 3.66(3H, s, OMe), 2.30(2H, t, J=7.5Hz, -CH2CO-) 1.8 〜1.2(12H, m, -(CH2)6-) Compound (7) mp 54.5 to 55 ° C. [α] 25 D -46.7 ° (C 0.85, CHCl 3 ) IR (CHCl 3 ) cm −1 : 1732, 1497, 1454, 1362, 1100 1 H-NMR ( CDCl 3 , δppm): 7.6 ~ 7.1 (20H, m, ph), 4.61 (1H, s, H-1), 3.66 (3H, s, OMe), 2.30 (2H, t, J = 7.5Hz, -CH 2 CO-) 1.8 ~ 1.2 (12H, m,-(CH 2 ) 6- )

【0061】 元素分析 C44H54O8 計算値 C 74.38% H 7.66% 実測値 C 74.31% H 7.62%Elemental analysis C 44 H 54 O 8 Calculated value C 74.38% H 7.66% Actual value C 74.31% H 7.62%

【0062】 化合物(8) 〔α〕25 D+21.6°(C 1.10, CHCl3) IR(CHCl3)cm-1 :1732, 1497, 1454, 1100 1H-NMR (CDCl3,δppm): 7.5 〜7.1(20H, m, ph), 4.73(1H, s, H-1), 3.66(3H, s, OCH3), 2.30(2H, t, J=7.5Hz, -CH2CO-) 1.7 〜1.2(12H, m, -(CH2)6-) Compound (8) [α] 25 D + 21.6 ° (C 1.10, CHCl 3 ) IR (CHCl 3 ) cm −1 : 1732, 1497, 1454, 1100 1 H-NMR (CDCl 3 , δppm): 7.5 ~ 7.1 (20H, m, ph), 4.73 (1H, s, H-1), 3.66 (3H, s, OCH 3 ), 2.30 (2H, t, J = 7.5Hz, -CH 2 CO-) 1.7 ~ 1.2 (12H, m,-(CH 2 ) 6- )

【0063】 元素分析 C44H54O8 計算値 C 74.38% H 7.66% 実測値 C 73.95% H 7.65%Elemental analysis C 44 H 54 O 8 Calculated value C 74.38% H 7.66% Actual value C 73.95% H 7.65%

【0064】例 1 6−メトキシカルボニルヘキシル β−D−マンノピラ
ノシド(9) 化合物(5)350mg(0.523ミリモル)のメタノ
ール15mlおよび酢酸5ml混液に、10%パラジウム炭
素100mgを加え、室温で4.5kg/cm2 の加圧下で2
4時間水素添加した。触媒をろ去した後、ろ液を減圧下
濃縮乾固した。この残渣をシリカゲルカラムクロマトグ
ラフィー(クロロホルム:メタノール=10:1)で精
製して化合物(9)130mgを結晶として得た。
Example 1 6-Methoxycarbonylhexyl β-D-mannopyranoside (9) To a mixed solution of 350 mg (0.523 mmol) of compound (5) (15 ml of methanol and 5 ml of acetic acid) was added 10% of palladium carbon (100 mg), and the mixture was stirred at room temperature for 4. 2 under pressure of 5 kg / cm 2
Hydrogenated for 4 hours. After removing the catalyst by filtration, the filtrate was concentrated to dryness under reduced pressure. The residue was purified by silica gel column chromatography (chloroform: methanol = 10: 1) to obtain 130 mg of compound (9) as crystals.

【0065】 m.p. 113〜114 ℃ 〔α〕D -44.4 °(C 0.54, MeOH) IR(KBr)cm-1 :1732, 1084, 1026, 1H-NMR (CD3OD,δppm): 4.48(1H, d, J=0.5Hz, H-1) 3.64(3H, s, OMe), 2.33(2H, t, J=7.5Hz, -CH2CO-) 1.7 〜1.25(8H, m, -(CH2)4-) Mp 113-114 ° C. [α] D -44.4 ° (C 0.54, MeOH) IR (KBr) cm −1 : 1732, 1084, 1026, 1 H-NMR (CD 3 OD, δppm): 4.48 (1H , d, J = 0.5Hz, H-1) 3.64 (3H, s, OMe), 2.33 (2H, t, J = 7.5Hz, -CH 2 CO-) 1.7 ~ 1.25 (8H, m,-(CH 2 ) 4- )

【0066】 元素分析 C14H26O8 ・ 0.5H2O 計算値 C 50.74% H 8.21% 実測値 C 50.60% H 7.94%Elemental analysis C 14 H 26 O 8 0.5 H 2 O Calculated value C 50.74% H 8.21% Actual value C 50.60% H 7.94%

【0067】例 2 6−メトキシカルボニルヘキシル α−D−マンノピラ
ノシド(10) 化合物(6)130mg(0.19ミリモル)を例1の場
合と同様にして、メタノール−酢酸混液中、10%パラ
ジウム−炭素存在下に水素添加して脱O−ベンジル化し
て化合物(10)90mgを得た。
Example 2 6-Methoxycarbonylhexyl α-D-mannopyranoside (10) 130 mg (0.19 mmol) of compound (6) was treated in the same manner as in Example 1 in a methanol-acetic acid mixture to prepare 10% palladium-carbon. Hydrogenation was carried out in the presence of the compound to effect de-O-benzylation to obtain 90 mg of compound (10).

【0068】 〔α〕26 D+50.0°(C 0.49, MeOH) IR(film)cm-1:3446, 1728, 1438, 1060 1H-NMR (CD3OD,δppm): 4.73(1H, d, J=1.5Hz, H-1) 3.65(3H, s, OMe), 2.33(2H, t, J=7.5Hz, -CH2CO-) 1.7 〜1.35(8H, m, -(CH2)4-) [Α] 26 D + 50.0 ° (C 0.49, MeOH) IR (film) cm −1 : 3446, 1728, 1438, 1060 1 H-NMR (CD 3 OD, δppm): 4.73 (1H, d, J = 1.5Hz, H-1) 3.65 (3H, s, OMe), 2.33 (2H, t, J = 7.5Hz, -CH 2 CO-) 1.7 ~1.35 (8H, m, - (CH 2) 4 - )

【0069】 元素分析 C14H26O8 ・ 0.5H2O 計算値 C 50.74% H 8.21% 実測値 C 50.99% H 8.01%Elemental analysis C 14 H 26 O 8 0.5 H 2 O Calculated value C 50.74% H 8.21% Measured value C 50.99% H 8.01%

【0070】例 3 8−メトキシカルボニルオクチル β−D−マンノピラ
ノシド(11) 本化合物はCarbohydr. Res., 156, 1(1986) 記載の方法
により合成した。
Example 3 8-Methoxycarbonyloctyl β-D-mannopyranoside (11) This compound was synthesized by the method described in Carbohydr. Res., 156, 1 (1986).

【0071】例 4 8−メトキシカルボニルオクチル α−D−マンノピラ
ノシド(12) 化合物(8)300mg(0.483ミリモル)のメタノ
ール溶液15mlに、10%パラジウム炭素54mgを加
え、室温で8時間水素添加した。触媒をろ去した後、ろ
液を減圧下濃縮乾固した。得られた結晶を酢酸エチル−
エーテル混液で洗浄し、結晶をろ取して化合物(12)
120mg(収率71%)を得た。
Example 4 8-Methoxycarbonyloctyl α-D-mannopyranoside (12) To 15 ml of a methanol solution of 300 mg (0.483 mmol) of the compound (8), 54 mg of 10% palladium carbon was added, and hydrogenated at room temperature for 8 hours. . After removing the catalyst by filtration, the filtrate was concentrated to dryness under reduced pressure. The obtained crystals are ethyl acetate
The crystals are collected by filtration, washed with an ether mixture, and the compound (12) is obtained.
120 mg (71% yield) was obtained.

【0072】 m.p. 76 〜77℃ 〔α〕25 D+52.7°(C 0.423, MeOH) IR(KBr)cm-1 :1735, 1728, 1H-NMR (CD3OD,δppm): 4.73(1H, d, J=1.6Hz, H-1) 3.65(3H, s, OMe), 2.32(2H, t, J=7.5Hz, -CH2CO-) 1.7 〜1.2(12H, m, -(CH2)6-) Mp 76-77 ° C. [α] 25 D + 52.7 ° (C 0.423, MeOH) IR (KBr) cm −1 : 1735, 1728, 1 H-NMR (CD 3 OD, δppm): 4.73 (1H, d, J = 1.6Hz, H-1) 3.65 (3H, s, OMe), 2.32 (2H, t, J = 7.5Hz, -CH 2 CO-) 1.7 ~ 1.2 (12H, m,-(CH 2 ) 6- )

【0073】 元素分析 C16H30O8 計算値 C 54.84% H 8.63% 実測値 C 54.73% H 8.55%Elemental analysis C 16 H 30 O 8 Calculated value C 54.84% H 8.63% Actual value C 54.73% H 8.55%

【0074】参考例 4 8−メトキシカルボニルオクチル 3,4,6−トリ−
O−アセチル−2−アジド−2−デオキシ−α−D−マ
ンノピラノシド(14)および8−メトキシカルボニル
オクチル 3,4,6−トリ−O−アセチル−2−アジ
ド−2−デオキシ−β−D−マンノピラノシド(15)
Reference Example 4 8-Methoxycarbonyloctyl 3,4,6-tri-
O-acetyl-2-azido-2-deoxy-α-D-mannopyranoside (14) and 8-methoxycarbonyloctyl 3,4,6-tri-O-acetyl-2-azido-2-deoxy-β-D- Mannopyranoside (15)

【0075】8−メトキシカルボニルオクタノール24
1mg(1.27ミリモル)を乾燥トルエン20mlに溶解
した後、窒素気流下で溶媒5mlを留去した。この溶液を
氷浴中で冷却した後、Carbohydr. Res.,136, 153(1985)
記載の方法で合成した3,4,6−トリ−O−アセチル
−2−アジド−2−デオキシ−α−D−マンノピラノシ
ルブロマイド(13)505mg(1.27ミリモル)を
乾燥トルエン5mlに溶解した溶液を加えた。粉末状モレ
キュラーシーブ4A500mgを加えて15分間撹拌した
後、銀シリケート500mgを加え、更に同温度で18時
間撹拌した。反応混合物をセライトを用いてろ過した
後、ろ液を減圧下濃縮乾固してシロップ状残渣を得た。
残渣をローバ−カラムを用いてヘキサン:酢酸エチル=
3:1で各分画15mlずつ溶出した。分画No. 33−4
0を集めて化合物(14)250mg(収率45.2%)
を得た。
8-Methoxycarbonyloctanol 24
After dissolving 1 mg (1.27 mmol) in 20 ml of dry toluene, 5 ml of the solvent was distilled off under a nitrogen stream. After cooling this solution in an ice bath, Carbohydr. Res., 136, 153 (1985)
505 mg (1.27 mmol) of 3,4,6-tri-O-acetyl-2-azido-2-deoxy-α-D-mannopyranosyl bromide (13) synthesized by the method described in 5 ml of dry toluene. The solution dissolved in was added. After adding 500 mg of the powdery molecular sieve 4A and stirring for 15 minutes, 500 mg of silver silicate was added and further stirred at the same temperature for 18 hours. The reaction mixture was filtered through Celite, and the filtrate was concentrated to dryness under reduced pressure to give a syrup-like residue.
The residue was hexane: ethyl acetate = using a rover column
Elution with 15 ml of each fraction was performed at 3: 1. Fraction No. 33-4
Compounds (14) 250 mg (yield 45.2%)
I got

【0076】 化合物(14)〔α〕23 D+67.0°(C 1.3, CHCl3) IR(CHCl3)cm-1 :2028, 1745, 1439, 1370, 1053 1H-NMR (CDCl3,δppm): 5.42〜 5.25(2H, m, H-3, H-4), 4.83(1H, d, J1,2=1.6Hz, H-1), 4.25(1H, dd, J5,6a=4.8Hz, J6a,6b=12Hz, H-6a), 4.09(1H, dd, J5,6b=2.2Hz, H-6b), 4.01(1H, dd, J2.3=1.4Hz, H-2), 3.88〜 3.86(1H, m, H-5), 3.67(3H, s, OCH3), 2.30(2H, t, J=6Hz, -CH2CO-), 2.10(6H, s, 2×OAc), 2.05(3H, s, OAc), 1.2 〜1.7(12H, m, -(CH2)6-) Compound (14) (α) 23 D + 67.0 ° (C 1.3, CHCl 3 ) IR (CHCl 3 ) cm −1 : 2028, 1745, 1439, 1370, 1053 1 H-NMR (CDCl 3 , δppm) : 5.42~ 5.25 (2H, m, H-3, H-4), 4.83 (1H, d, J 1,2 = 1.6Hz, H-1), 4.25 (1H, dd, J 5,6a = 4.8Hz , J 6a, 6b = 12Hz, H-6a), 4.09 (1H, dd, J 5,6b = 2.2Hz, H-6b), 4.01 (1H, dd, J 2.3 = 1.4Hz, H-2), 3.88 ~ 3.86 (1H, m, H-5), 3.67 (3H, s, OCH 3 ), 2.30 (2H, t, J = 6Hz, -CH 2 CO-), 2.10 (6H, s, 2 × OAc), 2.05 (3H, s, OAc), 1.2 ~ 1.7 (12H, m,-(CH 2 ) 6- )

【0077】 元素分析 C22H35N3O10 計算値 C 52.68% H 7.03% N 8.38% 実測値 C 52.68% H 6.90% N 8.47% Elemental analysis C 22 H 35 N 3 O 10 Calculated value C 52.68% H 7.03% N 8.38% Actual value C 52.68% H 6.90% N 8.47%

【0078】分画No. 59−84を集めて化合物(1
5)273mg(収率42.6%)を得た。
Fraction No. 59-84 was collected to obtain compound (1
5) 273 mg (yield 42.6%) was obtained.

【0079】 化合物(15)〔α〕23 D-75.5°(C 0.83, CHCl3) IR(CHCl3)cm-1 :2028, 1745, 1439, 1370, 1053 1H-NMR (CDCl3,δppm): 5.25(1H, t, J3.4=10Hz, H-4), 4.98(1H, dd, J2.3=4Hz, H-3), 4.66(1H, d, J=1.5Hz, H-1), 4.28(1H, dd, J5,6b=4.8Hz, J6a,6b=12Hz, H-6a), 4.13(1H, dd, J5.6b=2.2Hz, H-6b), 2.30(2H, t, J=7Hz, -CH2CO-), 2.11(3H, s, OAc), 2.10(3H, s, OAc), 2.04(3H, s, OAc), 1.2 〜1.7(12H, m, -(CH2)6-) Compound (15) (α) 23 D -75.5 ° (C 0.83, CHCl 3 ) IR (CHCl 3 ) cm -1 : 2028, 1745, 1439, 1370, 1053 1 H-NMR (CDCl 3 , δppm) : 5.25 (1H, t, J 3.4 = 10Hz, H-4), 4.98 (1H, dd, J 2.3 = 4Hz, H-3), 4.66 (1H, d, J = 1.5Hz, H-1), 4.28 (1H, dd, J 5,6b = 4.8Hz, J 6a, 6b = 12Hz, H-6a), 4.13 (1H, dd, J 5.6b = 2.2Hz, H-6b), 2.30 (2H, t, J = 7Hz, -CH 2 CO-), 2.11 (3H, s, OAc), 2.10 (3H, s, OAc), 2.04 (3H, s, OAc), 1.2 ~ 1.7 (12H, m,-(CH 2 ) 6- )

【0080】 元素分析 C22H35N3O10 計算値 C 52.68% H 7.03% N 8.38% 実測値 C 52.55% H 7.08% N 8.39% Elemental analysis C 22 H 35 N 3 O 10 Calculated value C 52.68% H 7.03% N 8.38% Actual value C 52.55% H 7.08% N 8.39%

【0081】参考例 5 6−メトキシカルボニルヘキシル 3,4,6−トリ−
O−アセチル−2−アジド−2−デオキシ−α−D−マ
ンノピラノシド(16)
Reference Example 5 6-Methoxycarbonylhexyl 3,4,6-tri-
O-acetyl-2-azido-2-deoxy-α-D-mannopyranoside (16)

【0082】6−メトキシカルボニルヘキサノール
(2)271mg(1.85ミリモル)および3,4,6
−トリ−O−アセチル−2−アジド−2−デオキシ−α
−D−マンノピラノシルブロマイド(13)730mg
(1.85ミリモル)を、参考例4の場合と同様にトル
エン中、モレキュラーシーブ4Aの存在下に銀シリケー
トを用いて縮合させて化合物(16)424mg(収率4
9.9%)を得た。
271 mg (1.85 mmol) of 6-methoxycarbonylhexanol (2) and 3,4,6
-Tri-O-acetyl-2-azido-2-deoxy-α
-D-mannopyranosyl bromide (13) 730 mg
(1.85 mmol) was condensed with toluene in the same manner as in Reference Example 4 in toluene in the presence of molecular sieve 4A using silver silicate to give 424 mg of compound (16) (yield 4
9.9%).

【0083】 〔α〕25 D+67.8°(C 0.72, CHCl3) IR(film)cm-1:2110, 1747, 1436, 1369, 1228, 1053 1H-NMR (CDCl3,δppm): 5.44〜 5.26(2H, m, H-3, H-4), 4.82(1H, d, J1.2=1.5Hz, H-1), 4.24(1H, dd, J5,6a=4.5Hz, J6a,6b=10Hz, H-6a), 4.08(1H, dd, J5,6b=2.5Hz, H-6b), 4.00(1H, dd, J2.3=3.5Hz, H-2), 3.84〜 3.87(1H, m, H-5), 2.32(2H, t, J=7.5Hz, -CH2CO-), 2.09(6H, s, 2×OAc), 2.04(3H, s, OAc), 1.70〜 1.25(8H, m, -(CH2)4-)[Α] 25 D + 67.8 ° (C 0.72, CHCl 3 ) IR (film) cm −1 : 2110, 1747, 1436, 1369, 1228, 1053 1 H-NMR (CDCl 3 , δppm): 5.44 ~ 5.26 (2H, m, H- 3, H-4), 4.82 (1H, d, J 1.2 = 1.5Hz, H-1), 4.24 (1H, dd, J 5,6a = 4.5Hz, J 6a, 6b = 10Hz, H-6a), 4.08 (1H, dd, J 5,6b = 2.5Hz , H-6b), 4.00 (1H, dd, J 2.3 = 3.5Hz, H-2), 3.84 ~ 3.87 (1H, m, H-5), 2.32 (2H, t, J = 7.5Hz, -CH 2 CO-), 2.09 (6H, s, 2 × OAc), 2.04 (3H, s, OAc), 1.70 ~ 1.25 (8H , m, - (CH 2) 4 -)

【0084】 元素分析 C19H29N3O10 計算値 C 49.67% H 6.36% N 9.15% 実測値 C 49.33% H 6.05% N 9.01% Elemental analysis C 19 H 29 N 3 O 10 Calculated value C 49.67% H 6.36% N 9.15% Actual value C 49.33% H 6.05% N 9.01%

【0085】参考例 6 8−メトキシカルボニルオクチル 2−アジド−2−デ
オキシ−α−D−マンノピラノシド(17)
Reference Example 6 8-Methoxycarbonyloctyl 2-azido-2-deoxy-α-D-mannopyranoside (17)

【0086】化合物(14)283mg(0.564ミリ
モル)のメタノール溶液7mlに1Nナトリウムメトキシ
ド−メタノール溶液0.1mlを加え、室温に4時間放置
した。反応液にイオン交換樹脂アンバーライトIR−1
20B(H+ 型)を加えて中和した後、樹脂をろ去し、
少量のメタノールで洗浄した。ろ液および洗液を合して
減圧下で溶媒を留去してシロップ状残渣を得た。残渣を
メタノールに溶解した後、活性炭を加えてしばらく放置
した。ミリポアフィルターを用いてろ過した後、ろ液を
減圧下濃縮乾固して化合物(17)210mg(定量的)
をシロップ状物質として得た。
0.1 ml of a 1N sodium methoxide-methanol solution was added to 7 ml of a methanol solution of 283 mg (0.564 mmol) of the compound (14), and the mixture was allowed to stand at room temperature for 4 hours. Ion exchange resin Amberlite IR-1 for reaction liquid
After neutralizing by adding 20B (H + type), the resin was filtered off,
It was washed with a small amount of methanol. The filtrate and washings were combined and the solvent was distilled off under reduced pressure to obtain a syrupy residue. The residue was dissolved in methanol, activated carbon was added, and the mixture was left for a while. After filtering using a Millipore filter, the filtrate was concentrated to dryness under reduced pressure to give 210 mg of compound (17) (quantitative).
Was obtained as a syrupy material.

【0087】 〔α〕24 D+68.6°(C 0.614, MeOH) IR(CHCl3)cm-1 :3600, 3440, 2028, 1730 1H-NMR (CD3OD,δppm): 4.77(1H, d, J1,2=1.5Hz, H-1), 3.65(3H, s, OMe), 2.32(2H, t, J=7Hz, -CH2CO-), 1.7 〜1.2(12H, m, -(CH2)6-) [Α] 24 D + 68.6 ° (C 0.614, MeOH) IR (CHCl 3 ) cm −1 : 3600, 3440, 2028, 1730 1 H-NMR (CD 3 OD, δppm): 4.77 (1H, d , J 1,2 = 1.5Hz, H-1), 3.65 (3H, s, OMe), 2.32 (2H, t, J = 7Hz, -CH 2 CO-), 1.7 ~ 1.2 (12H, m,-( CH 2 ) 6- )

【0088】 元素分析 C16H29N3O7 計算値 C 51.19% H 7.79% N 11.19% 実測値 C 50.87% H 7.66% N 11.02% Elemental analysis C 16 H 29 N 3 O 7 Calculated value C 51.19% H 7.79% N 11.19% Actual value C 50.87% H 7.66% N 11.02%

【0089】参考例 7 8−メトキシカルボニルオクチル 2−アジド−2−デ
オキシ−β−D−マンノピラノシド(18) 化合物(15)273mg(0.54ミリモル)を参考例
6の場合と同様に、メタノール中触媒量のナトリウムメ
トキシドを用いて脱O−アセチル化して化合物(18)
133mgを結晶として得た。
Reference Example 7 8-methoxycarbonyloctyl 2-azido-2-deoxy-β-D-mannopyranoside (18) Compound (15) 273 mg (0.54 mmol) was added in methanol in the same manner as in Reference Example 6. De-O-acetylation with a catalytic amount of sodium methoxide to give compound (18)
133 mg were obtained as crystals.

【0090】 m.p. 47 〜49℃ 〔α〕24 D-83.8°(C 0.798, CHCl3) IR(CHCl3)cm-1 :3420, 2028, 1732 1H-NMR (CD3OD,δppm): 4.68(1H, d, J1,2=1.0Hz, H-1), 3.65(3H, s, OCH3), 2.31(2H, t, J=7Hz, -CH2CO-), 1.7 〜1.2(12H, m, -(CH2)6-) Mp 47-49 ° C. [α] 24 D -83.8 ° (C 0.798, CHCl 3 ) IR (CHCl 3 ) cm −1 : 3420, 2028, 1732 1 H-NMR (CD 3 OD, δppm): 4.68 (1H, d, J 1,2 = 1.0Hz, H-1), 3.65 (3H, s, OCH 3 ), 2.31 (2H, t, J = 7Hz, -CH 2 CO-), 1.7 ~ 1.2 (12H , m,-(CH 2 ) 6- )

【0091】 元素分析 C16H29N3O7 計算値 C 51.19% H 7.79% N 11.19% 実測値 C 51.00% H 7.82% N 10.55% Elemental analysis C 16 H 29 N 3 O 7 Calculated value C 51.19% H 7.79% N 11.19% Actual value C 51.00% H 7.82% N 10.55%

【0092】参考例 8 6−メトキシカルボニルヘキシル 2−アジド−2−デ
オキシ−α−D−マンノピラノシド(19) 化合物(16)420mg(0.914ミリモル)を参考
例6の場合と同様に、メタノール中触媒量のナトリウム
メトキシドを用いて脱O−アセチル化して化合物(1
9)265mg(収率87%)をシロップ状物質として得
た。
Reference Example 8 6-Methoxycarbonylhexyl 2-azido-2-deoxy-α-D-mannopyranoside (19) 420 mg (0.914 mmol) of the compound (16) was added to methanol in the same manner as in Reference Example 6. De-O-acetylation with a catalytic amount of sodium methoxide to give compound (1
9) 265 mg (yield 87%) was obtained as a syrup-like substance.

【0093】 〔α〕22.5 D+75.8°(C 0.89, MeOH) IR(film)cm-1:3400, 2120, 1735, 1270, 1060 1H-NMR (CD3OD,δppm): 4.77(1H, s, H-1), 3.65(3H, s, OCH3), 2.33(2H, t, J=7.5Hz, -CH2CO-), 1.28〜1.70(8H, m, -(CH2)4-) [Α] 22.5 D + 75.8 ° (C 0.89, MeOH) IR (film) cm −1 : 3400, 2120, 1735, 1270, 1060 1 H-NMR (CD 3 OD, δppm): 4.77 (1H, s, H-1), 3.65 (3H, s, OCH 3), 2.33 (2H, t, J = 7.5Hz, -CH 2 CO-), 1.28~1.70 (8H, m, - (CH 2) 4 - )

【0094】例 5 8−メトキシカルボニルオクチル 2−アセトアミド−
2−デオキシ−α−D−マンノピラノシド(20) (i)化合物(17)180mg(0.477ミリモル)
のメタノール溶液10mlに無水酢酸0.5mlを加えて、
10%パラジウム−炭素30mgの存在下に、室温で1時
間水素添加した。触媒をろ去した後、ろ液を減圧下で濃
縮乾固した。残渣をシリカゲルカラムクロマトグラフィ
ー(クロロホルム:メタノ−ル=10:1)で精製して
化合物(20)85mg(収率45.4%)を無定形粉末
として得た。
Example 5 8-Methoxycarbonyloctyl 2-acetamido-
2-Deoxy-α-D-mannopyranoside (20) (i) Compound (17) 180 mg (0.477 mmol)
0.5 ml of acetic anhydride was added to 10 ml of methanol solution of
Hydrogenated in the presence of 30% 10% palladium on carbon for 1 hour at room temperature. After removing the catalyst by filtration, the filtrate was concentrated to dryness under reduced pressure. The residue was purified by silica gel column chromatography (chloroform: methanol = 10: 1) to obtain 85 mg of compound (20) (yield 45.4%) as an amorphous powder.

【0095】 〔α〕25 D+37.1°(C 0.421, MeOH) IR(CHCl3)cm-1 :1732, 1655, 1439, 1375, 1130, 1070,1027 1H-NMR (CD3OD,δppm): 4.66(1H, d, J1.2=1.6Hz, H-1), 4.28(1H, dd, J3.4=4.8Hz, H-2), 3.65(3H, s, OMe), 2.32(2H, t, J=7.5Hz, -CH2CO-), 2.00(3H, s, NAc), 1.25〜 1.70(12H, m, -(CH2)6-) [Α] 25 D + 37.1 ° (C 0.421, MeOH) IR (CHCl 3 ) cm −1 : 1732, 1655, 1439, 1375, 1130, 1070, 1027 1 H-NMR (CD 3 OD, δppm) : 4.66 (1H, d, J 1.2 = 1.6Hz, H-1), 4.28 (1H, dd, J 3.4 = 4.8Hz, H-2), 3.65 (3H, s, OMe), 2.32 (2H, t, J = 7.5Hz, -CH 2 CO-), 2.00 (3H, s, NAc), 1.25 ~ 1.70 (12H, m,-(CH 2 ) 6- )

【0096】 元素分析 C18H33NO8・0.2H2O 計算値 C 54.72% H 8.52% N 3.55% 実測値 C 54.60% H 8.41% N 3.72% Elemental analysis C 18 H 33 NO 8・ 0.2H 2 O Calculated value C 54.72% H 8.52% N 3.55% Measured value C 54.60% H 8.41% N 3.72%

【0097】(ii)化合物(17)210mg(0.55
9ミリモル)のエタノール5ml溶液に、塩化ニッケル六
水和物380mg(1.6ミリモル)をエタノール10ml
に溶解した液0.1mlを加えた後、水素化ホウ素ナトリ
ウム63mg(1.677ミリモル)のエタノール溶液5
mlを撹拌しながら加えた。室温で30分間撹拌した後、
反応液に酢酸を加えて中和した。次いで無水酢酸0.2
mlを加えて室温に1時間放置した。反応混合物を減圧下
で濃縮乾固して、残渣をシリカゲルカラムクロマトグラ
フィー(クロロホルム:メタノール=10:1)で精製
して上記と同一の化合物(20)147mg(収率67.
4%)を得た。
(Ii) 210 mg (0.55) of compound (17)
(9 mmol) in 5 ml of ethanol, 380 mg (1.6 mmol) of nickel chloride hexahydrate in 10 ml of ethanol.
0.1 ml of the solution dissolved in was added, and then 63 mg (1.677 mmol) of sodium borohydride in ethanol solution 5
ml was added with stirring. After stirring at room temperature for 30 minutes,
Acetic acid was added to the reaction solution to neutralize it. Then acetic anhydride 0.2
ml was added and left at room temperature for 1 hour. The reaction mixture was concentrated to dryness under reduced pressure, and the residue was purified by silica gel column chromatography (chloroform: methanol = 10: 1) to obtain 147 mg of the same compound (20) as above (yield 67.
4%).

【0098】例 6 8−メトキシカルボニルオクチル 2−アセトアミド−
2−デオキシ−β−D−マンノピラノシド(21) 化合物(18)149mg(0.396ミリモル)を例5
(ii)の場合と同様に、エタノール中触媒量の塩化ニッ
ケル六水和物の存在下に、水素化ホウ素ナトリウムでア
ジド基をアミノ基に還元した後、無水酢酸でN−アセチ
ル化して化合物(21)101mg(収率65.1%)を
シロップ状物質として得た。
Example 6 8-Methoxycarbonyloctyl 2-acetamido-
2-Deoxy-β-D-mannopyranoside (21) 149 mg (0.396 mmol) of compound (18) was used in Example 5
As in the case of (ii), the azide group was reduced to an amino group with sodium borohydride in the presence of a catalytic amount of nickel chloride hexahydrate in ethanol, and then N-acetylated with acetic anhydride to obtain a compound ( 21) 101 mg (yield 65.1%) was obtained as a syrup-like substance.

【0099】 〔α〕24 D-49.4°(C 0.842, MeOH) IR(KBr)cm-1 :1740, 1645, 1550, 1100 1H-NMR (CD3OD,δppm): 4.60(1H, d, J1.2=1.6Hz, H-1), 4.42(1H, dd, J2.3=4.2Hz, H-2), 3.64(3H, s, OMe), 2.30(2H, t, J=7.5Hz, -CH2CO-), 2.01(3H, s, NAc), 1.7 〜1.2(12H, m, -(CH2)6-) [Α] 24 D -49.4 ° (C 0.842, MeOH) IR (KBr) cm -1 : 1740, 1645, 1550, 1100 1 H-NMR (CD 3 OD, δppm): 4.60 (1H, d, J 1.2 = 1.6Hz, H-1), 4.42 (1H, dd, J 2.3 = 4.2Hz, H-2), 3.64 (3H, s, OMe), 2.30 (2H, t, J = 7.5Hz, -CH 2 CO-), 2.01 (3H, s, NAc), 1.7 ~ 1.2 (12H, m,-(CH 2 ) 6- )

【0100】 元素分析 C18H33NO8・0.3H2O 計算値 C 54.47% H 8.53% N 3.53% 実測値 C 54.55% H 8.36% N 3.59% Elemental analysis C 18 H 33 NO 8・ 0.3H 2 O Calculated value C 54.47% H 8.53% N 3.53% Measured value C 54.55% H 8.36% N 3.59%

【0101】例 7 6−メトキシカルボニルヘキシル 2−アセトアミド−
2−デオキシ−α−D−マンノピラノシド(22) 化合物(19)265mg(0.795ミリモル)を例5
(ii)の場合と同様に、エタノール中触媒量の塩化ニッ
ケル六水和物の存在下に、水素化ホウ素ナトリウムでア
ジド基をアミノ基に還元した後、無水酢酸でN−アセチ
ル化して化合物(22)228mg(収率82%)をシロ
ップ状物質として得た。
Example 7 6-Methoxycarbonylhexyl 2-acetamido-
2-Deoxy-α-D-mannopyranoside (22) 265 mg (0.795 mmol) of compound (19) was used in Example 5
As in the case of (ii), the azide group was reduced to an amino group with sodium borohydride in the presence of a catalytic amount of nickel chloride hexahydrate in ethanol, and then N-acetylated with acetic anhydride to obtain a compound ( 22) 228 mg (82% yield) was obtained as a syrupy substance.

【0102】 〔α〕23.5 D+38.3°(C 0.52, MeOH) IR(film)cm-1:3328, 1730, 1650, 1552, 1438, 1377 1H-NMR (CD3OD,δppm): 4.65(1H, d, J1.2=1.2Hz, H-1), 4.27(1H, dd, J2.3=4.3Hz, H-2), 3.65(3H, s, OMe), 2.33(2H, t, J=7.5Hz, -CH2CO-), 1.99(3H, s, NAc), 1.70〜 1.35(8H, m, -(CH2)4-)[Α] 23.5 D + 38.3 ° (C 0.52, MeOH) IR (film) cm −1 : 3328, 1730, 1650, 1552, 1438, 1377 1 H-NMR (CD 3 OD, δppm): 4.65 ( 1H, d, J 1.2 = 1.2Hz, H-1), 4.27 (1H, dd, J 2.3 = 4.3Hz, H-2), 3.65 (3H, s, OMe), 2.33 (2H, t, J = 7.5 Hz, -CH 2 CO-), 1.99 (3H, s, NAc), 1.70~ 1.35 (8H, m, - (CH 2) 4 -)

【0103】 元素分析 C15H27NO8・H2O 計算値 C 49.04% H 7.96% N 3.81% 実測値 C 49.34% H 8.02% N 3.65% Elemental analysis C 15 H 27 NO 8 · H 2 O Calculated value C 49.04% H 7.96% N 3.81% Actual value C 49.34% H 8.02% N 3.65%

【0104】参考例9 8−メトキシカルボニルオクチル 2−O−(2,3,
4,6−テトラ−O−ベンジル−β−D−マンノピラノ
シル)−3,4,6−トリ−O−ベンジル−α−D−マ
ンノピラノシド(24)および8−メトキシカルボニル
オクチル 2−O−(2,3,4,6−テトラ−O−ベ
ンジル−α−D−マンノピラノシル)−3,4,6−ト
リ−O−ベンジル−α−D−マンノピラノシド(25)
Reference Example 9 8-Methoxycarbonyloctyl 2-O- (2,3,
4,6-Tetra-O-benzyl-β-D-mannopyranosyl) -3,4,6-tri-O-benzyl-α-D-mannopyranoside (24) and 8-methoxycarbonyloctyl 2-O- (2. 3,4,6-Tetra-O-benzyl-α-D-mannopyranosyl) -3,4,6-tri-O-benzyl-α-D-mannopyranoside (25)

【0105】8−メトキシカルボニルオクチル 3,
4,6−トリ−O−ベンジル−α−D−マンノピラノシ
ド(23)(Carbohydr. Res., 156, 1 (1986)) 600
mg(0.966ミリモル)および2,3,4,6−テト
ラ−O−ベンジル−α−D−マンノピラノシルクロライ
ド(3)602mg(1.08ミリモル)の無水ベンゼン
溶液(20ml)に、窒素気流下、粉末状モレキュラーシ
ーブ4Aを2g加え、室温で30分間撹拌した。次いで
銀シリケート1.0gを加え、室温で48時間撹拌し
た。反応混合物をセライトを用いてろ過した後、ろ液を
減圧下濃縮乾固して残渣1.09gを得た。残渣をロー
バーカラムを用いて分離精製して化合物(24)484
mg(収率42.3%)および化合物(25)120mg
(収率10%)をそれぞれシロップ状物質として得た。
8-methoxycarbonyloctyl 3,
4,6-Tri-O-benzyl-α-D-mannopyranoside (23) (Carbohydr. Res., 156, 1 (1986)) 600
mg (0.966 mmol) and 602 mg (1.08 mmol) 2,3,4,6-tetra-O-benzyl-α-D-mannopyranosyl chloride (3) in anhydrous benzene (20 ml). Then, 2 g of powdery molecular sieve 4A was added under a nitrogen stream, and the mixture was stirred at room temperature for 30 minutes. Next, 1.0 g of silver silicate was added, and the mixture was stirred at room temperature for 48 hours. The reaction mixture was filtered through Celite, and the filtrate was concentrated under reduced pressure to dryness to obtain 1.09 g of a residue. The residue was separated and purified using a Rover column to give compound (24) 484.
mg (yield 42.3%) and compound (25) 120 mg
(Yield 10%) was obtained as a syrup-like substance.

【0106】 化合物(25)〔α〕25 D+15.0°(C 0.808, CHCl3) IR(CHCl3)cm-1 :1732, 1498, 1455, 1315, 1105, 1029 1H-NMR (CDCl3,δppm): 7.4 〜7.1(35H, m, ph), 5.18(1H, d, J=1.0Hz, H-1 or H- 1′), 4.86(1H, d, J=1.0Hz, H-1 or H- 1′), 3.66(3H, s, OMe), 2.30(2H, t, J=7.5Hz, -CH2CO-), 1.7〜 1.15(12H, m, -(CH2)6-) Compound (25) [α] 25 D + 15.0 ° (C 0.808, CHCl 3 ) IR (CHCl 3 ) cm −1 : 1732, 1498, 1455, 1315, 1105, 1029 1 H-NMR (CDCl 3 , δppm): 7.4 ~ 7.1 (35H, m, ph), 5.18 (1H, d, J = 1.0Hz, H-1 or H-1 '), 4.86 (1H, d, J = 1.0Hz, H-1 or H-1 ′), 3.66 (3H, s, OMe), 2.30 (2H, t, J = 7.5Hz, -CH 2 CO-), 1.7 to 1.15 (12H, m,-(CH 2 ) 6- )

【0107】 元素分析 C71H82O13 計算値 C 74.58% H 7.23% 実測値 C 74.46% H 7.22% Elemental analysis C 71 H 82 O 13 Calculated value C 74.58% H 7.23% Actual value C 74.46% H 7.22%

【0108】 化合物(24)〔α〕25 D-38.5°(C 0.924, CHCl3) IR(CHCl3)cm-1 :1731, 1498, 1452, 1362, 1100, 1065 1H-NMR (CDCl3,δppm): 7.6 〜7.0(35H, m, ph), 4.90(1H, s, H-1 or H-1′), 3.67(3H, s, OMe), 2.30(2H, t, J=7.5Hz, -CH2CO-), 1.7 〜1.2(12H, m, -(CH2)6-) Compound (24) [α] 25 D -38.5 ° (C 0.924, CHCl 3 ) IR (CHCl 3 ) cm −1 : 1731, 1498, 1452, 1362, 1100, 1065 1 H-NMR (CDCl 3 , δppm): 7.6 ~ 7.0 (35H, m, ph), 4.90 (1H, s, H-1 or H-1 ′), 3.67 (3H, s, OMe), 2.30 (2H, t, J = 7.5Hz, -CH 2 CO-), 1.7 ~ 1.2 (12H, m,-(CH 2 ) 6- )

【0109】 元素分析 C71H82O13 計算値 C 74.58% H 7.23% 実測値 C 74.32% H 7.30% Elemental analysis C 71 H 82 O 13 Calculated value C 74.58% H 7.23% Actual value C 74.32% H 7.30%

【0110】例 8 8−メトキシカルボニルオクチル 2−O−(β−D−
マンノピラノシル)−α−D−マンノピラノシド(2
6) 化合物(24)480mg(0.42ミリモル)をメタノ
ール中10%パラジウム炭素の存在下に水素添加して脱
O−ベンジル化して化合物(26)181mg(収率84
%)を無色粉末として得た。
Example 8 8-Methoxycarbonyloctyl 2-O- (β-D-
Mannopyranosyl) -α-D-mannopyranoside (2
6) 480 mg (0.42 mmol) of compound (24) was hydrogenated in the presence of 10% palladium carbon in methanol to de-O-benzylate to give 181 mg of compound (26) (yield 84
%) As a colorless powder.

【0111】 〔α〕24 D-4.9 °(C 0.658, MeOH) IR(KBr)cm-1 :3400, 1740, 1060 1H-NMR (CD3OD,δppm): 4.86(1H, overlapped with CD3OH, H-1 or H-1′), 4.65(1H, d, J=0.8Hz, H-1′ or H-1) 3.65(3H, s, OMe), 2.31(2H, t, J=7.5Hz, -CH2CO-), 1.7 〜1.2(12H, m, -(CH2)6-) [Α] 24 D -4.9 ° (C 0.658, MeOH) IR (KBr) cm −1 : 3400, 1740, 1060 1 H-NMR (CD 3 OD, δppm): 4.86 (1H, overlapped with CD 3 OH, H-1 or H-1 ′), 4.65 (1H, d, J = 0.8Hz, H-1 ′ or H-1) 3.65 (3H, s, OMe), 2.31 (2H, t, J = 7.5 Hz, -CH 2 CO-), 1.7 ~ 1.2 (12H, m,-(CH 2 ) 6- )

【0112】 元素分析 C22H40O13・H2O 計算値 C 49.80% H 7.98% 実測値 C 50.10% H 7.67% Elemental analysis C 22 H 40 O 13 · H 2 O Calculated value C 49.80% H 7.98% Actual value C 50.10% H 7.67%

【0113】例 9 8−メトキシカルボニルオクチル 2−O−(α−D−
マンノピラノシル)−α−D−マンノピラノシド(2
7) 本化合物は Carbohydr. Res., 156, 1 (1986) に記載の
方法で合成した。
Example 9 8-Methoxycarbonyloctyl 2-O- (α-D-
Mannopyranosyl) -α-D-mannopyranoside (2
7) This compound was synthesized by the method described in Carbohydr. Res., 156, 1 (1986).

【0114】参考例10 8−メトキシカルボニルオクチル 2,3,4−トリ−
O−ベンジル−β−D−マンノピラノシド(28)
Reference Example 10 8-Methoxycarbonyloctyl 2,3,4-tri-
O-benzyl-β-D-mannopyranoside (28)

【0115】(i)J. Carbohydr. Chem., 6, 645-660
(1987) に記載の方法で合成した1,6−ジ−O−アセ
チル−2,3,4−トリ−O−ベンジル−α−D−マン
ノピラノシド5.00g(9.35ミリモル)の塩化メ
チレン60ml溶液に、−20℃で塩化水素ガスを吹き込
み飽和させた。反応液を室温に戻して2時間放置した
後、減圧下濃縮して6−O−アセチル−2,3,4−ト
リ−O−ベンジル−α−D−マンノピラノシルクロライ
ド4.69g(収率98.2%)をシロップ状物質とし
て得た。このクロライド4.69gの1,2−ジクロロ
エタン100ml溶液にシアン化第二水銀7.09g(2
8.1ミリモル)、粉末モレキュラーシーブ4A30g
と8−メトキシカルボニルオクタノール1.76g
(9.35ミリモル)を加え、アルゴン気流中、80℃
で22時間撹拌した。沈澱をろ去後、ろ液を減圧下濃縮
乾固してシロップ状残渣を得た。残渣をシリカゲルカラ
ムクロマトグラフィー(n−ヘキサン:酢酸エチル=
7:1)で精製して8−メトキシカルボニルオクチル
6−O−アセチル−2,3,4−トリ−O−ベンジル−
α/β−D−マンノピラノシド混合物3.24g(収率
52.2%)を得た。
(I) J. Carbohydr. Chem., 6, 645-660
(1987) 1,6-di-O-acetyl-2,3,4-tri-O-benzyl-α-D-mannopyranoside 5.00 g (9.35 mmol) of methylene chloride in 60 ml. Hydrogen chloride gas was blown into the solution at −20 ° C. to be saturated. After the reaction solution was returned to room temperature and left for 2 hours, it was concentrated under reduced pressure and 6-O-acetyl-2,3,4-tri-O-benzyl-α-D-mannopyranosyl chloride 4.69 g ( Yield 98.2%) was obtained as a syrup-like substance. To a solution of 4.69 g of this chloride in 100 ml of 1,2-dichloroethane, 7.09 g of mercuric cyanide (2
8.1 mmol), 30 g of powdered molecular sieve 4A
And 8-methoxycarbonyloctanol 1.76g
(9.35 mmol) was added, and the mixture was heated at 80 ° C. in an argon stream.
And stirred for 22 hours. After removing the precipitate by filtration, the filtrate was concentrated to dryness under reduced pressure to obtain a syrupy residue. The residue was subjected to silica gel column chromatography (n-hexane: ethyl acetate =
7: 1) and purified with 8-methoxycarbonyloctyl
6-O-acetyl-2,3,4-tri-O-benzyl-
3.24 g (yield 52.2%) of an α / β-D-mannopyranoside mixture was obtained.

【0116】(ii)上記で得た混合物2.45g(3.
70ミリモル)のメタノール50ml溶液に2Nナトリウ
ムメチラート5mlを加え、室温で1.5時間撹拌した。
反応液をアンバーライトIR−120B(H+ 型)で中
和した後樹脂をろ去した。ろ液を減圧下濃縮乾固してシ
ロップ状残渣を得た。残渣をシリカゲルカラムクロマト
グラフィー(トルエン:酢酸エチル=16:1)で精製
して化合物(28)1.20g(収率52.2%)を得
た。同時に Carbohydr. Res., 161, 195 (1987) に公知
の化合物(29)834mg(収率36.2%)を得た。
(Ii) 2.45 g (3.
(70 mmol) in 50 ml of methanol was added with 5 ml of 2N sodium methylate and stirred at room temperature for 1.5 hours.
The reaction solution was neutralized with Amberlite IR-120B (H + type), and the resin was filtered off. The filtrate was concentrated to dryness under reduced pressure to obtain a syrupy residue. The residue was purified by silica gel column chromatography (toluene: ethyl acetate = 16: 1) to obtain 1.20 g of compound (28) (yield 52.2%). At the same time, 834 mg (yield 36.2%) of the known compound (29) was obtained from Carbohydr. Res., 161, 195 (1987).

【0117】 〔α〕24 D-38.7°(C 1, CHCl3) IR(KBr)cm-1 :3500, 2930, 2850, 1740 1H-NMR (CDCl3,δppm): 2.28(2H, t, J=7.6Hz, CH2COOCH3), 3.65(3H, s, OCH3) [Α] 24 D -38.7 ° (C 1, CHCl 3 ) IR (KBr) cm −1 : 3500, 2930, 2850, 1740 1 H-NMR (CDCl 3 , δppm): 2.28 (2H, t, J = 7.6Hz, CH 2 COOCH 3 ), 3.65 (3H, s, OCH 3 )

【0118】参考例11 8−メトキシカルボニルオクチル 2,3,4−トリ−
O−ベンジル−6−O−(2,3,4,6−テトラ−O
−ベンジル−β−D−マンノピラノシル)−α−D−マ
ンノピラノシド(30)および8−メトキシカルボニル
オクチル 2,3,4−トリ−O−ベンジル−6−O−
(2,3,4,6−テトラ−O−ベンジル−α−D−マ
ンノピラノシル)−α−D−マンノピラノシド(31)
Reference Example 11 8-Methoxycarbonyloctyl 2,3,4-tri-
O-benzyl-6-O- (2,3,4,6-tetra-O
-Benzyl-β-D-mannopyranosyl) -α-D-mannopyranoside (30) and 8-methoxycarbonyloctyl 2,3,4-tri-O-benzyl-6-O-
(2,3,4,6-Tetra-O-benzyl-α-D-mannopyranosyl) -α-D-mannopyranoside (31)

【0119】(i)2,3,4,6−テトラ−O−ベン
ジル−α−D−マンノピラノシルクロライド(3)26
5mg(0.47ミリモル)と化合物(29)300mg
(0.483ミリモル)の1,2−ジクロロエタン5ml
溶液に銀トリフレート496mg(1.93ミリモル)と
1,1,3,3−テトラメチル尿素337mg(2.90
ミリモル)を加え、アルゴン気流中、室温で3時間撹拌
した。さらに、化合物(3)265mg(0.474ミリ
モル)を加えて2日間撹拌した。反応液を減圧濃縮して
得られたシロップをシリカゲルカラムクロマトグラフィ
ー(トルエン:酢酸エチル=30:1)で精製して化合
物(30)151mg(収率27.3%)および化合物
(31)273mg(収率42.9%)を得た。
(I) 2,3,4,6-tetra-O-benzyl-α-D-mannopyranosyl chloride (3) 26
5 mg (0.47 mmol) and compound (29) 300 mg
5 ml of (0.483 mmol) of 1,2-dichloroethane
496 mg (1.93 mmol) of silver triflate and 337 mg (2.90) of 1,1,3,3-tetramethylurea were added to the solution.
Was added and the mixture was stirred at room temperature for 3 hours in an argon stream. Further, 265 mg (0.474 mmol) of compound (3) was added and stirred for 2 days. The syrup obtained by concentrating the reaction solution under reduced pressure was purified by silica gel column chromatography (toluene: ethyl acetate = 30: 1) to obtain 151 mg of compound (30) (yield 27.3%) and 273 mg of compound (31) ( The yield was 42.9%).

【0120】 化合物(30)〔α〕24 D-5.3 °(C 1, CHCl3) IR(KBr)cm-1 :2930, 2850, 1740 1H-NMR (CDCl3,δppm): 2.28(2H, t, J=7.6Hz, CH2COOCH3), 3.65(3H, s, OCH3) Compound (30) [α] 24 D -5.3 ° (C 1, CHCl 3 ) IR (KBr) cm −1 : 2930, 2850, 1740 1 H-NMR (CDCl 3 , δppm): 2.28 (2H, t, J = 7.6Hz, CH 2 COOCH 3 ), 3.65 (3H, s, OCH 3 )

【0121】 化合物(31)〔α〕24 D+56.2°(C 1, CHCl3) IR(KBr)cm-1 :2930, 2850, 1740 1H-NMR (CDCl3,δppm): 2.28(2H, t, J=7.6Hz, CH2COOCH3), 3.65(3H, s, OCH3), 4.70(1H, d, J=1.8Hz, H-1) Compound (31) [α] 24 D + 56.2 ° (C 1, CHCl 3 ) IR (KBr) cm −1 : 2930, 2850, 1740 1 H-NMR (CDCl 3 , δppm): 2.28 (2H, t, J = 7.6Hz, CH 2 COOCH 3 ), 3.65 (3H, s, OCH 3 ), 4.70 (1H, d, J = 1.8Hz, H-1)

【0122】(ii)化合物(3)90mg(0.161ミ
リモル)と化合物(29)100mg(0.161ミリモ
ル)の1,2−ジクロロエタン2.5ml溶液に銀シリケ
ート325mgと粉末モレキュラーシーブ4A1.5gを
加え、3時間撹拌した。さらに化合物(3)90mg
(0.161ミリモル)を加え21時間撹拌した。沈澱
をろ去後、ろ液を減圧下濃縮乾固してシロップ状残渣を
得た。残渣をシリカゲルカラムクロマトグラフィー(ト
ルエン:酢酸エチル=30:1)で精製して上記と同一
の化合物(30)103mg(収率55.9%)および化
合物(31)44mg(収率23.9%)を得た。
(Ii) 90 mg (0.161 mmol) of compound (3) and 100 mg (0.161 mmol) of compound (29) in 2.5 ml of 1,2-dichloroethane were added to 325 mg of silver silicate and 1.5 g of powdered molecular sieve 4A. Was added and stirred for 3 hours. Compound (3) 90mg
(0.161 mmol) was added and stirred for 21 hours. After removing the precipitate by filtration, the filtrate was concentrated to dryness under reduced pressure to obtain a syrupy residue. The residue was purified by silica gel column chromatography (toluene: ethyl acetate = 30: 1) to obtain 103 mg of the same compound (30) (yield 55.9%) and 44 mg of compound (31) (yield 23.9%). ) Got.

【0123】参考例12 8−メトキシカルボニルオクチル 2,3,4−トリ−
O−ベンジル−6−O−(2,3,4,6−テトラ−O
−ベンジル−β−D−マンノピラノシル)−β−D−マ
ンノピラノシド(32)および8−メトキシカルボニル
オクチル 2,3,4−トリ−O−ベンジル−6−O−
(2,3,4,6−テトラ−O−ベンジル−α−D−マ
ンノピラノシル)−β−D−マンノピラノシド(33)
Reference Example 12 8-Methoxycarbonyloctyl 2,3,4-tri-
O-benzyl-6-O- (2,3,4,6-tetra-O
-Benzyl-β-D-mannopyranosyl) -β-D-mannopyranoside (32) and 8-methoxycarbonyloctyl 2,3,4-tri-O-benzyl-6-O-
(2,3,4,6-Tetra-O-benzyl-α-D-mannopyranosyl) -β-D-mannopyranoside (33)

【0124】(i)化合物(3)180mg(0.322
ミリモル)と化合物(28)200mg(0.322ミリ
モル)とを、参考例11(i)の方法と同様にして、
1,2−ジクロロエタン5ml溶液中、1,1,3,3−
テトラメチル尿素の存在下、銀トリフレートを用いて縮
合して化合物(32)25mg(収率6.8%)および化
合物(33)228mg(収率61.9%)を得た。
(I) Compound (3) 180 mg (0.322)
Mmol) and 200 mg (0.322 mmol) of compound (28) in the same manner as in Reference Example 11 (i),
1,1,3,3- in 1,2-dichloroethane 5 ml solution
Condensation using silver triflate in the presence of tetramethylurea gave compound (32) 25 mg (yield 6.8%) and compound (33) 228 mg (yield 61.9%).

【0125】 化合物(32)〔α〕24 D-41.9°(C 0.5, CHCl3) IR(KBr)cm-1 :2930, 2850, 1740 1H-NMR (CDCl3,δppm): 2.28(2H, t, J=7.6Hz, CH2COOCH3), 3.65(3H, s, OCH3) Compound (32) [α] 24 D -41.9 ° (C 0.5, CHCl 3 ) IR (KBr) cm −1 : 2930, 2850, 1740 1 H-NMR (CDCl 3 , δppm): 2.28 (2H, t, J = 7.6Hz, CH 2 COOCH 3 ), 3.65 (3H, s, OCH 3 )

【0126】 化合物(33)〔α〕24 D-5.2 °(C 1, CHCl3) IR(KBr)cm-1 :2930, 2850, 1740 1H-NMR (CDCl3,δppm): 2.28(2H, t, J=7.6Hz, CH2COOCH3), 3.65(3H, s, OCH3) Compound (33) [α] 24 D -5.2 ° (C 1, CHCl 3 ) IR (KBr) cm −1 : 2930, 2850, 1740 1 H-NMR (CDCl 3 , δppm): 2.28 (2H, t, J = 7.6Hz, CH 2 COOCH 3 ), 3.65 (3H, s, OCH 3 )

【0127】(ii)化合物(3)180mg(0.322
ミリモル)と化合物(28)200mg(0.322ミリ
モル)とを、参考例11(ii)の方法と同様に、1,2
−ジクロロエタン5ml溶液中、粉末モレキュラーシーブ
4Aの存在下、銀シリケートを用いて縮合して上記と同
一の化合物(32)196mg(収率53.2%)および
化合物(33)94mg(収率25.5%)を得た。
(Ii) Compound (3) 180 mg (0.322)
1) and 200 mg (0.322 mmol) of the compound (28) in the same manner as in the method of Reference Example 11 (ii).
196 mg (53.2% yield) of the same compound (32) and 94 mg (yield 25.25%) of the same compound as above, condensed by using silver silicate in the presence of powdered molecular sieve 4A in a 5 ml solution of dichloroethane. 5%) was obtained.

【0128】例 10 8−メトキシカルボニルオクチル 6−O−(β−D−
マンノピラノシル)−α−D−マンノピラノシド(3
4) 化合物(30)117mg(0.102ミリモル)のメタ
ノール20ml溶液に10%パラジウム炭素100mgを加
え、パールの装置(50psi )で2日間接触還元した。
触媒をろ去後、ろ液を減圧下濃縮乾固してシロップ状残
渣を得た。残渣をシリカゲルカラムクロマトグラフィー
(クロロホルム:メタノール:濃アンモニア水=5:
5:1)で精製して化合物(34)45.1mg(収率8
6.3%)を得た。
Example 10 8-Methoxycarbonyloctyl 6-O- (β-D-
Mannopyranosyl) -α-D-mannopyranoside (3
4) To a solution of 117 mg (0.102 mmol) of compound (30) in 20 ml of methanol was added 100 mg of 10% palladium carbon, and catalytic reduction was carried out for 2 days using a Parr apparatus (50 psi).
After removing the catalyst by filtration, the filtrate was concentrated to dryness under reduced pressure to obtain a syrupy residue. The residue was subjected to silica gel column chromatography (chloroform: methanol: concentrated aqueous ammonia = 5:
5: 1) and compound (34) 45.1 mg (yield 8
6.3%) was obtained.

【0129】 〔α〕24 D+0.1 °(C 0.9, MeOH) 1H-NMR (CD3OD,δppm): 2.31(2H, t, J=7.6Hz, CH2COOCH3), 3.65(3H, s, OCH3), 4.59(1H, s, H- 1′) 4.70(1H, d, J=1.8Hz, H-1) MS(SIMS):m/z 535(M+Na)+ [Α] 24 D + 0.1 ° (C 0.9, MeOH) 1 H-NMR (CD 3 OD, δppm): 2.31 (2H, t, J = 7.6Hz, CH 2 COOCH 3 ), 3.65 (3H, s, OCH 3 ), 4.59 (1H, s, H- 1 ′) 4.70 (1H, d, J = 1.8Hz, H-1) MS (SIMS): m / z 535 (M + Na) +

【0130】例 11 8−メトキシカルボニルオクチル 6−O−(α−D−
マンノピラノシル)−α−D−マンノピラノシド(3
5) 化合物(31)183mg(0.160ミリモル)を例1
0の場合と同様に、メタノール中10%パラジウム炭素
の存在下に水素添加して、脱O−ベンジル化して化合物
(35)38.6mg(収率47.1%)を得た。
Example 11 8-Methoxycarbonyloctyl 6-O- (α-D-
Mannopyranosyl) -α-D-mannopyranoside (3
5) Example 1 containing 183 mg (0.160 mmol) of compound (31)
In the same manner as in the case of 0, hydrogenation was performed in the presence of 10% palladium carbon in methanol, and de-O-benzylation was performed to obtain 38.6 mg of compound (35) (yield 47.1%).

【0131】 〔α〕24 D+55.1°(C 0.8, MeOH) 1H-NMR (CD3OD,δppm): 2.31(2H, t, J=7.6Hz, CH2COOCH3), 3.65(3H, s, OCH3), 4.70(1H, d, J=1.8Hz, H-1) MS(SIMS):m/z 535(M+Na)+ [Α] 24 D + 55.1 ° (C 0.8, MeOH) 1 H-NMR (CD 3 OD, δppm): 2.31 (2H, t, J = 7.6Hz, CH 2 COOCH 3 ), 3.65 (3H, s, OCH 3 ), 4.70 (1H, d, J = 1.8Hz, H-1) MS (SIMS): m / z 535 (M + Na) +

【0132】例 12 8−メトキシカルボニルオクチル 6−O−(β−D−
マンノピラノシル)−β−D−マンノピラノシド(3
6) 化合物(32)151mg(0.132ミリモル)を例1
0の場合と同様に、メタノール中10%パラジウム炭素
の存在下に水素添加して、脱O−ベンジル化して化合物
(36)49.0mg(収率72.4%)を得た。
Example 12 8-Methoxycarbonyloctyl 6-O- (β-D-
Mannopyranosyl) -β-D-mannopyranoside (3
6) 151 mg (0.132 mmol) of compound (32) was used in Example 1
In the same manner as in the case of 0, hydrogenation was performed in the presence of 10% palladium carbon in methanol, and de-O-benzylation was performed to obtain 49.0 mg of compound (36) (yield 72.4%).

【0133】 〔α〕24 D-53.3°(C 1, MeOH) 1H-NMR (CD3OD,δppm): 2.31(2H, t, J=7.6Hz, CH2COOCH3), 3.65(3H, s, OCH3), 4.48(1H, s, H-1) 4.61(1H, s, H- 1′) MS(SIMS):m/z 535(M+Na)+ [Α] 24 D -53.3 ° (C 1, MeOH) 1 H-NMR (CD 3 OD, δppm): 2.31 (2H, t, J = 7.6Hz, CH 2 COOCH 3 ), 3.65 (3H, s, OCH 3 ), 4.48 (1H, s, H-1) 4.61 (1H, s, H-1 ′) MS (SIMS): m / z 535 (M + Na) +

【0134】例 13 8−メトキシカルボニルオクチル 6−O−(α−D−
マンノピラノシル)−β−D−マンノピラノシド(3
7) 化合物(33)196mg(0.171ミリモル)を例1
0の場合と同様に、メタノール中10%パラジウム炭素
の存在下に水素添加して、脱O−ベンジル化して化合物
(37)49.0mg(収率72.4%)を得た。
Example 13 8-Methoxycarbonyloctyl 6-O- (α-D-
Mannopyranosyl) -β-D-mannopyranoside (3
7) 196 mg (0.171 mmol) of compound (33) was used in Example 1
In the same manner as in the case of 0, hydrogenation was performed in the presence of 10% palladium carbon in methanol, and de-O-benzylation was performed to obtain 49.0 mg of compound (37) (yield 72.4%).

【0135】 〔α〕24 D-53.3°(C 1, MeOH) 1H-NMR (CD3OD,δppm): 2.31(2H, t, J=7.6Hz, CH2COOCH3), 3.65(3H, s, OCH3), 4.48(1H, s, H-1) MS(SIMS):m/z 535(M+Na+) [Α] 24 D -53.3 ° (C 1, MeOH) 1 H-NMR (CD 3 OD, δppm): 2.31 (2H, t, J = 7.6Hz, CH 2 COOCH 3 ), 3.65 (3H, s, OCH 3 ), 4.48 (1H, s, H-1) MS (SIMS): m / z 535 (M + Na + )

【0136】参考例13 8−メトキシカルボニルオクチル 2−O−(3,4,
6−トリ−O−アセチル−2−アジド−2−デオキシ−
α−D−マンノピラノシル)−3,4,6−トリ−O−
ベンジル−α−D−マンノピラノシド(38) Carbohydr. Res., 156, 1 (1986)に記載の方法で合成し
た8−メトキシカルボニルオクチル 3,4,6−トリ
−O−ベンジル−α−D−マンノピラノシド(23)7
93mg(1.278ミリモル)のトルエン溶液20mlを
窒素気流下氷冷した。これに粉末状モレキュラーシーブ
4A800mgおよび銀シリケート800mgを加えて30
分間撹拌した。次いで3,4,6−トリ−O−アセチル
−2−アジド−2−デオキシ−α−D−マンノピラノシ
ルブロマイド(13)505mg(1.278ミリモル)
のトルエン溶液5mlを加え、同温度で更に48時間撹拌
した。反応混合物をセライトを用いてろ過した後、ろ液
を減圧下濃縮乾固して残渣1.22gを得た。残渣をロ
ーバーカラム(ヘキサン:酢酸エチル=3:1)を用い
て精製して化合物(38)557mg(収率59.7%)
を得た。
Reference Example 13 8-Methoxycarbonyloctyl 2-O- (3,4,
6-tri-O-acetyl-2-azido-2-deoxy-
α-D-mannopyranosyl) -3,4,6-tri-O-
Benzyl-α-D-mannopyranoside (38) 8-Methoxycarbonyloctyl 3,4,6-tri-O-benzyl-α-D-mannopyranoside synthesized by the method described in Carbohydr. Res., 156, 1 (1986). (23) 7
20 ml of a 93 mg (1.278 mmol) toluene solution was ice-cooled under a nitrogen stream. To this, add 800 mg of powdered molecular sieve 4A and 800 mg of silver silicate, and add 30
Stir for minutes. Then 3,4,6-tri-O-acetyl-2-azido-2-deoxy-α-D-mannopyranosyl bromide (13) 505 mg (1.278 mmol)
5 ml of a toluene solution of was added, and the mixture was stirred at the same temperature for 48 hours. The reaction mixture was filtered through Celite, and the filtrate was concentrated under reduced pressure to dryness to obtain 1.22 g of a residue. The residue was purified using a Rover column (hexane: ethyl acetate = 3: 1) to give 557 mg of compound (38) (yield 59.7%).
I got

【0137】 〔α〕25 D+37.4°(C 0.901, CHCl3) IR(CHCl3)cm-1 :2028, 1745, 1452, 1369, 1045. 1H-NMR (CDCl3,δppm): 7.5 〜7.1(15H, m,ph), 5.43(1H, dd, J3',4'=9.4Hz, J2',3'=3.7Hz, H- 3 ′), 5.29(1H, t, H-4), 4.98(1H, d, J1',2'=1.8Hz, H- 1′), 4.85(1H, d, J1,2=1.7Hz, H-1), 3.66(3H, s, OMe), 2.30(2H, t, J=7Hz, -CH2CO-), 2.10(3H, s, OAc), 2.09(3H, s, OAc), 1.99(3H, s, OAc), 1.8 〜1.2(12H, m, -(CH2)6-) [Α] 25 D + 37.4 ° (C 0.901, CHCl 3 ) IR (CHCl 3 ) cm −1 : 2028, 1745, 1452, 1369, 1045. 1 H-NMR (CDCl 3 , δppm): 7.5 ~ 7.1 (15H, m, ph), 5.43 (1H, dd, J 3 ', 4' = 9.4Hz, J 2 ', 3' = 3.7Hz, H- 3 '), 5.29 (1H, t, H-4 ), 4.98 (1H, d, J 1 ', 2' = 1.8Hz, H-1 '), 4.85 (1H, d, J 1,2 = 1.7Hz, H-1), 3.66 (3H, s, OMe ), 2.30 (2H, t, J = 7Hz, -CH 2 CO-), 2.10 (3H, s, OAc), 2.09 (3H, s, OAc), 1.99 (3H, s, OAc), 1.8 ~ 1.2 ( 12H, m,-(CH 2 ) 6- )

【0138】 元素分析 C49H63N3O15 計算値 C 62.94% H 6.79% N 4.49% 実測値 C 62.76% H 6.83% N 4.61%Elemental analysis C 49 H 63 N 3 O 15 Calculated value C 62.94% H 6.79% N 4.49% Actual value C 62.76% H 6.83% N 4.61%

【0139】参考例14 8−メトキシカルボニルオクチル 2−O−(2−アジ
ド−2−デオキシ−α−D−マンノピラノシル)−3,
4,6−トリ−O−ベンジル−α−D−マンノピラノシ
ド(39)
Reference Example 14 8-Methoxycarbonyloctyl 2-O- (2-azido-2-deoxy-α-D-mannopyranosyl) -3,
4,6-Tri-O-benzyl-α-D-mannopyranoside (39)

【0140】化合物(38)557mg(0.596ミリ
モル)のメタノール溶液20mlに1M ナトリウムメトキ
シド−メタノ−ル溶液0.15mlを加え、室温に2時間
放置した。反応液にイオン交換樹脂アンバーライトIR
−120B(H+ 型)を加えて中和した後、樹脂をろ去
し、少量のメタノールで洗浄した。ろ液および洗液を合
し、減圧下で濃縮乾固して化合物(39)447mg(収
率93%)をシロップ状物質として得た。
To 20 ml of a methanol solution of 557 mg (0.596 mmol) of the compound (38) was added 0.15 ml of a 1M sodium methoxide-methanol solution, and the mixture was allowed to stand at room temperature for 2 hours. Ion exchange resin Amberlite IR for reaction liquid
After adding -120B (H + type) for neutralization, the resin was filtered off and washed with a small amount of methanol. The filtrate and washings were combined and concentrated to dryness under reduced pressure to obtain 447 mg (yield 93%) of compound (39) as a syrup-like substance.

【0141】 〔α〕24 D+46.7°(C 0.559, CHCl3) IR(CHCl3)cm-1 :3600, 3460, 2027, 1731, 1498, 1453, 1065 1H-NMR (CD3OD,δppm): 7.40〜 7.15(15H, ph), 4.99(1H, d, J1',2'=1.4Hz, H- 1′), 4.93(1H, d, J1,2=1.8Hz, H-1), 3.62(3H, s, OMe), 2.30(2H, t, J=7Hz, -CH 2 CO-), 1.7 〜1.2(12H, m, -(CH2)6-) [Α] 24 D + 46.7 ° (C 0.559, CHCl 3 ) IR (CHCl 3 ) cm −1 : 3600, 3460, 2027, 1731, 1498, 1453, 1065 1 H-NMR (CD 3 OD, δppm ): 7.40 ~ 7.15 (15H, ph), 4.99 (1H, d, J 1 ', 2' = 1.4Hz, H-1 '), 4.93 (1H, d, J 1,2 = 1.8Hz, H-1 ), 3.62 (3H, s, OMe), 2.30 (2H, t, J = 7Hz, -C H 2 C O-), 1.7 ~ 1.2 (12H, m,-(CH 2 ) 6- )

【0142】 元素分析 C43H57N3O12 計算値 C 63.92% H 7.11% N 5.20% 実測値 C 63.17% H 7.09% N 5.22%Elemental analysis C 43 H 57 N 3 O 12 Calculated value C 63.92% H 7.11% N 5.20% Actual value C 63.17% H 7.09% N 5.22%

【0143】参考例15 8−メトキシカルボニルオクチル 2−O−(2−アセ
トアミド−2−デオキシ−α−D−マンノピラノシル)
−3,4,6−トリ−O−ベンジル−α−D−マンノピ
ラノシド(40)
Reference Example 15 8-Methoxycarbonyloctyl 2-O- (2-acetamido-2-deoxy-α-D-mannopyranosyl)
-3,4,6-Tri-O-benzyl-α-D-mannopyranoside (40)

【0144】化合物(39)310mg(0.384ミリ
モル)のエタノール溶液8mlに、0.16M 塩化ニッケ
ル六水和物のエタノール溶液0.07mlを加えた後、室
温で撹拌下に水素化ホウ素ナトリウム44mg(1.15
ミリモル)をエタノール5mlに溶かした液を加えた。反
応混合物を40分間撹拌した後、酢酸を加えて中和し
た。次いで無水酢酸0.2mlを加えて室温に1時間放置
した。反応混合物を減圧下濃縮乾固した後、残渣をシリ
カゲルカラムクロマトグラフィー(クロロホルム:メタ
ノール=10:1)で精製して化合物(40)184mg
(収率58.2%)をシロップ状物質として得た。
0.08 ml of an ethanol solution of 0.16M nickel chloride hexahydrate was added to 8 ml of an ethanol solution of 310 mg (0.384 mmol) of the compound (39), and then 44 mg of sodium borohydride was stirred at room temperature. (1.15
A solution prepared by dissolving (mmol) in 5 ml of ethanol was added. The reaction mixture was stirred for 40 minutes and then acetic acid was added to neutralize it. Next, 0.2 ml of acetic anhydride was added and the mixture was left at room temperature for 1 hour. The reaction mixture was concentrated to dryness under reduced pressure, and the residue was purified by silica gel column chromatography (chloroform: methanol = 10: 1) to give compound (40) 184 mg.
(Yield 58.2%) was obtained as a syrup-like substance.

【0145】 〔α〕24 D+42.3°(C 0.522, MeOH) 1H-NMR (CD3OD,δppm):7.40〜 7.10(15H, m, ph), 4.95(1H, d, J=1.8Hz, H-1 or H- 1′), 4.93(1H, d, J=1.6Hz, H-1′ or H-1), 3.62(3H, s, OMe), 2.28(2H, t, J=7Hz, -CH 2 CO-), 2.01(3H, s, NAc), 1.7〜 1.2(12H, m, -(CH2)6-)[Α] 24 D + 42.3 ° (C 0.522, MeOH) 1 H-NMR (CD 3 OD, δppm): 7.40 to 7.10 (15H, m, ph), 4.95 (1H, d, J = 1.8Hz , H-1 or H- 1 '), 4.93 (1H, d, J = 1.6Hz, H-1' or H-1), 3.62 (3H, s, OMe), 2.28 (2H, t, J = 7Hz , -C H 2 C O-), 2.01 (3H, s, NAc), 1.7 ~ 1.2 (12H, m,-(CH 2 ) 6- )

【0146】 元素分析 C45H61NO13 計算値 C 65.59% H 7.46% N 1.70% 実測値 C 65.23% H 7.33% N 1.95%Elemental analysis C 45 H 61 NO 13 Calculated value C 65.59% H 7.46% N 1.70% Actual value C 65.23% H 7.33% N 1.95%

【0147】例14 8−メトキシカルボニルオクチル 2−O−(2−アセ
トアミド−2−デオキシ−α−D−マンノピラノシル)
−α−D−マンノピラノシド(41)
Example 14 8-Methoxycarbonyloctyl 2-O- (2-acetamido-2-deoxy-α-D-mannopyranosyl)
-Α-D-mannopyranoside (41)

【0148】化合物(40)170mg(0.206ミリ
モル)のメタノール溶液15mlに、10%パラジウム−
炭素50mgを加え、室温で27時間水素添加した。反応
混合物をろ過した後、ろ液を減圧下濃縮乾固して化合物
(41)86mg(収率75.4%)を不定型粉末として
得た。
To 15 ml of a solution of 170 mg (0.206 mmol) of compound (40) in methanol was added 10% palladium-
50 mg of carbon was added and hydrogenated at room temperature for 27 hours. After filtering the reaction mixture, the filtrate was concentrated to dryness under reduced pressure to obtain 86 mg (yield 75.4%) of compound (41) as an amorphous powder.

【0149】 〔α〕25 D+49.3°(C 0.708, MeOH) IR(KBr)cm-1 :3400, 1740, 1650, 1545, 1125, 1060, 1020 1H-NMR (CD3OD,δppm): 5.01(1H, s, H-1), 4.90(1H, d, J1',2'=1.5Hz, H- 1′), 4.44(1H, dd, J2',3'=4.6Hz, H-2′), 3.65(3H, s, OMe), 2.31(2H, t, J=7Hz, -CH 2 CO-), 2.00(3H, s, NAc), 1.7 〜 1.2(12H, m, -(CH2)6-)[Α] 25 D + 49.3 ° (C 0.708, MeOH) IR (KBr) cm −1 : 3400, 1740, 1650, 1545, 1125, 1060, 1020 1 H-NMR (CD 3 OD, δppm): 5.01 (1H, s, H-1), 4.90 (1H, d, J 1 ', 2' = 1.5Hz, H-1 '), 4.44 (1H, dd, J 2', 3 ' = 4.6Hz, H -2 ′), 3.65 (3H, s, OMe), 2.31 (2H, t, J = 7Hz, -C H 2 C O-), 2.00 (3H, s, NAc), 1.7 ~ 1.2 (12H, m, -(CH 2 ) 6- )

【0150】 元素分析 C24H43NO13・H2O 計算値 C 50.43% H 7.94% N 2.45% 実測値 C 50.52% H 7.76% N 2.62%Elemental analysis C 24 H 43 NO 13・ H 2 O Calculated value C 50.43% H 7.94% N 2.45% Actual value C 50.52% H 7.76% N 2.62%

【0151】参考例16 8−メトキシカルボニルオクチル 3,6−ジ−O−ア
セチル−2,4−ジ−O−ベンジル−α−D−マンノピ
ラノシド(43)
Reference Example 16 8-Methoxycarbonyloctyl 3,6-di-O-acetyl-2,4-di-O-benzyl-α-D-mannopyranoside (43)

【0152】Tetrahedron, 37, 2779 (1981)に記載の方
法で合成した3,6−ジ−O−アセチル−2,4−ジ−
O−ベンジル−α−D−マンノピラノシルクロライド
(42)3.24g(7.58ミリモル)および8−メ
トキシカルボニルオクタノール1.43g(7.58ミ
リモル)を無水ベンゼン60mlに溶解した後、窒素気流
下で溶媒10mlを留去した。室温まで冷却した後、粉末
状モレキュラーシーブ4A2.0gを加え15分間撹拌
した。次いで銀シリケート3.25gを加えて室温で1
8時間撹拌した。反応混合物をセライトを用いてろ過し
た後、ろ液を減圧下濃縮乾固した。残渣4.51gをロ
ーバーカラム(ヘキサン:酢酸エチル=3:1)を用い
て精製して化合物(43)2.93g(収率63%)を
シロップ状物質として得た。
3,6-di-O-acetyl-2,4-di-synthesized by the method described in Tetrahedron, 37, 2779 (1981).
After dissolving 3.24 g (7.58 mmol) of O-benzyl-α-D-mannopyranosyl chloride (42) and 1.43 g (7.58 mmol) of 8-methoxycarbonyloctanol in 60 ml of anhydrous benzene, Under a nitrogen stream, 10 ml of solvent was distilled off. After cooling to room temperature, 2.0 g of powdery molecular sieve 4A was added and stirred for 15 minutes. Then add 3.25 g of silver silicate and add 1 at room temperature.
Stir for 8 hours. The reaction mixture was filtered through Celite, and the filtrate was concentrated under reduced pressure to dryness. The residue (4.51 g) was purified using a Rover column (hexane: ethyl acetate = 3: 1) to obtain 2.93 g (yield 63%) of compound (43) as a syrup-like substance.

【0153】 〔α〕25 D+4.4 °(C 1.128, CHCl3) IR(CHCl3)cm-1 :1735, 1455, 1365, 1075. 1H-NMR (CDCl3,δppm): 7.45〜 7.2(10H, m, ph), 5.25(1H, dd, J2,3=3.4Hz, J3,4=8.8Hz, H-3), 4.82(1H, d, J=1.6Hz, H-1), 3.67(3H, s, OMe). 2.31(2H, t, J=7.5Hz, -CH 2 CO-), 2.08(3H, s, OAc), 2.00(3H, s, OAc), 1.7 〜1.2(12H, m, -(CH2)6-) [Α] 25 D +4.4 ° (C 1.128, CHCl 3 ) IR (CHCl 3 ) cm −1 : 1735, 1455, 1365, 1075. 1 H-NMR (CDCl 3 , δppm): 7.45 to 7.2 ( 10H, m, ph), 5.25 (1H, dd, J 2,3 = 3.4Hz, J 3,4 = 8.8Hz, H-3), 4.82 (1H, d, J = 1.6Hz, H-1), 3.67 (3H, s, OMe). 2.31 (2H, t, J = 7.5Hz, -C H 2 C O-), 2.08 (3H, s, OAc), 2.00 (3H, s, OAc), 1.7 ~ 1.2 (12H, m,-(CH 2 ) 6- )

【0154】 元素分析 C34H46O10 計算値 C 66.43% H 7.54% 実測値 C 66.10% H 7.41% Elemental analysis C 34 H 46 O 10 Calculated value C 66.43% H 7.54% Actual value C 66.10% H 7.41%

【0155】参考例17 8−メトキシカルボニルオクチル 2,4−ジ−O−ベ
ンジル−α−D−マンノピラノシド(44) 化合物(43)1.48g(2.40ミリモル)のメタ
ノール30ml溶液に1Mナトリウムメトキシド−メタノ
ール溶液0.6mlを加えて、室温に8時間放置した。反
応液にイオン交換樹脂アンバーライトIR−120B
(H+ 型)を加えて中和した後、樹脂をろ去した。ろ液
を減圧下で濃縮乾固して残渣1.34gを得た。残渣を
シリカゲルカラムクロマトグラフィー(ヘキサン:酢酸
エチル=2:1)で精製して化合物(44)876mg
(収率69%)をシロップ状物質として得た。
Reference Example 17 8-Methoxycarbonyloctyl 2,4-di-O-benzyl-α-D-mannopyranoside (44) 1M sodium methoxy was added to a solution of 1.48 g (2.40 mmol) of the compound (43) in 30 ml of methanol. 0.6 ml of de-methanol solution was added, and the mixture was left at room temperature for 8 hours. Ion exchange resin Amberlite IR-120B for reaction liquid
(H + type) was added for neutralization, and the resin was filtered off. The filtrate was concentrated to dryness under reduced pressure to obtain 1.34 g of residue. The residue was purified by silica gel column chromatography (hexane: ethyl acetate = 2: 1) to give compound (44) 876 mg.
(Yield 69%) was obtained as a syrup-like substance.

【0156】 〔α〕25 D+18.2°(C 0.626, CHCl3) IR(CHCl3)cm-1 :3560, 1731, 1498, 1455, 1438, 1100, 1075 1H-NMR (CDCl3,δppm): 7.45〜 7.20(10H, m, ph), 4.84(1H, d, J=1.2Hz, H-1), 3.67(3H, s, OMe), 2.30(2H, t, J=7.5Hz, -CH2CO-), 1.7 〜1.2(12H, m, -(CH2)6-) [Α] 25 D + 18.2 ° (C 0.626, CHCl 3 ) IR (CHCl 3 ) cm −1 : 3560, 1731, 1498, 1455, 1438, 1100, 1075 1 H-NMR (CDCl 3 , δppm) : 7.45 ~ 7.20 (10H, m, ph), 4.84 (1H, d, J = 1.2Hz, H-1), 3.67 (3H, s, OMe), 2.30 (2H, t, J = 7.5Hz, -CH 2 CO-), 1.7 ~ 1.2 (12H, m,-(CH 2 ) 6- )

【0157】 元素分析 C30H42O8 計算値 C 67.90% H 7.98% 実測値 C 67.39% H 8.03% Elemental analysis C 30 H 42 O 8 Calculated value C 67.90% H 7.98% Actual value C 67.39% H 8.03%

【0158】参考例18 8−メトキシカルボニルオクチル 6−O−(3,4,
6−トリ−O−アセチル−2−アジド−2−デオキシ−
α−D−マンノピラノシル)−2,4−ジ−O−ベンジ
ル−α−D−マンノピラノシド(45)
Reference Example 18 8-Methoxycarbonyloctyl 6-O- (3,4,
6-tri-O-acetyl-2-azido-2-deoxy-
α-D-mannopyranosyl) -2,4-di-O-benzyl-α-D-mannopyranoside (45)

【0159】化合物(44)710mg(1.339ミリ
モル)、銀トリフラート757mg(2.94ミリモル)
およびテトラ−N−メチル尿素1.4ml(11.78ミ
リモル)のジクロロメタン溶液(15ml)を、窒素気流
下で−78℃に冷却した後、3,4,6−トリ−O−ア
セチル−2−アジド−2−デオキシ−α−D−マンノピ
ラノシルブロミド(13)1.01g(2.678ミリ
モル)のジクロロメタン溶液5mlを加えた。その後冷却
浴を除き、反応温度を徐々に室温まで上昇させ、18時
間撹拌した後、反応混合物をセライトを用いてろ過し
た。ろ液を炭酸水素ナトリウム水溶液および水で順次洗
浄した後、硫酸マグネシウムで乾燥し、溶媒を減圧下留
去してシロップ状残渣を得た。残渣をローバーカラム
(ヘキサン:酢酸エチル=1:1)を用いて精製して化
合物(45)486mg(収率43%)をシロップ状物質
として得た。
710 mg (1.339 mmol) of compound (44) and 757 mg (2.94 mmol) of silver triflate.
A solution of 1.4 ml (11.78 mmol) of tetra-N-methylurea in dichloromethane (15 ml) was cooled to -78 ° C under a stream of nitrogen, and then 3,4,6-tri-O-acetyl-2-. 5 ml of a dichloromethane solution of 1.01 g (2.678 mmol) of azido-2-deoxy-α-D-mannopyranosyl bromide (13) was added. Then, the cooling bath was removed, the reaction temperature was gradually raised to room temperature, the mixture was stirred for 18 hours, and then the reaction mixture was filtered through Celite. The filtrate was washed successively with aqueous sodium hydrogen carbonate solution and water, dried over magnesium sulfate, and the solvent was evaporated under reduced pressure to give a syrup-like residue. The residue was purified using a Rover column (hexane: ethyl acetate = 1: 1) to obtain 486 mg of compound (45) (yield 43%) as a syrup-like substance.

【0160】 〔α〕25 D+62.3°(C 0.925, CHCl3) IR(CHCl3)cm-1 :3560, 2110, 1745, 1455, 1370, 1060 1H-NMR (CDCl3,δppm): 7.5 〜7.25(10H, m, ph), 5.42〜 5.22(2H, m, H-3′, H- 4′), 5.04(1H, d, J=1.6Hz, H-1 or H- 1′), 4.81(1H, d, J=1.4Hz, H-1′ or H-1), 3.66(3H, s, OMe), 2.30(2H, t, J=7.5Hz, -CH2CO-), 2.08(3H, s, OAc), 2.06(3H, s, OAc), 2.03(3H, s, OAc), 1.7 〜1.2(12H, m, -(CH2)6-) [Α] 25 D + 62.3 ° (C 0.925, CHCl 3 ) IR (CHCl 3 ) cm −1 : 3560, 2110, 1745, 1455, 1370, 1060 1 H-NMR (CDCl 3 , δppm): 7.5 ~ 7.25 (10H, m, ph), 5.42 ~ 5.22 (2H, m, H-3 ', H-4'), 5.04 (1H, d, J = 1.6Hz, H-1 or H-1 '), 4.81 (1H, d, J = 1.4Hz, H-1 ′ or H-1), 3.66 (3H, s, OMe), 2.30 (2H, t, J = 7.5Hz, -CH 2 CO-), 2.08 ( 3H, s, OAc), 2.06 (3H, s, OAc), 2.03 (3H, s, OAc), 1.7 ~ 1.2 (12H, m,-(CH 2 ) 6- )

【0161】 元素分析 C42H57N3O15・0.5H2O 計算値 C 59.14% H 6.85% N 4.93% 実測値 C 59.07% H 6.77% N 5.07%Elemental analysis C 42 H 57 N 3 O 15・ 0.5H 2 O Calculated value C 59.14% H 6.85% N 4.93% Measured value C 59.07% H 6.77% N 5.07%

【0162】参考例19 8−メトキシカルボニルオクチル 6−O−(2−アジ
ドー2−デオキシ−α−D−マンノピラノシル)−2,
4−ジ−O−ベンジル−α−D−マンノピラノシド(4
6)
Reference Example 19 8-Methoxycarbonyloctyl 6-O- (2-azido 2-deoxy-α-D-mannopyranosyl) -2,
4-di-O-benzyl-α-D-mannopyranoside (4
6)

【0163】化合物(45)470mg(0.557ミリ
モル)を参考例14の場合と同様に、メタノール中触媒
量のナトリウムメトキシドを用いて脱O−アセチル化し
て化合物(46)333mg(収率83.2%)をシロッ
プ状物質として得た。
470 mg (0.557 mmol) of the compound (45) was de-O-acetylated with a catalytic amount of sodium methoxide in methanol in the same manner as in Reference Example 14 to give 333 mg of the compound (46) (yield 83 .2%) as a syrup.

【0164】 〔α〕25 D+69.1°(C 0.739, MeOH) IR(CHCl3)cm-1 :3560, 2120, 1731, 1075 1H-NMR (CD3OD,δppm): 7.5 〜7.2(10H, m, ph), 3.64(3H, s, OMe), 2.30(2H, t, J=7.5Hz, -CH2CO-), 1.7 〜1.25(12H, m, -(CH2)6-)[Α] 25 D + 69.1 ° (C 0.739, MeOH) IR (CHCl 3 ) cm −1 : 3560, 2120, 1731, 1075 1 H-NMR (CD 3 OD, δppm): 7.5 to 7.2 (10H , m, ph), 3.64 (3H, s, OMe), 2.30 (2H, t, J = 7.5Hz, -CH 2 CO-), 1.7 ~ 1.25 (12H, m,-(CH 2 ) 6- )

【0165】 元素分析 C36H51N3O12・0.6H2O 計算値 C 59.34% H 7.22% N 5.77% 実測値 C 59.04% H 7.02% N 5.80%Elemental analysis C 36 H 51 N 3 O 12・ 0.6H 2 O Calculated value C 59.34% H 7.22% N 5.77% Measured value C 59.04% H 7.02% N 5.80%

【0166】参考例20 8−メトキシカルボニルオクチル 6−O−(2−アセ
トアミドー2−デオキシ−α−D−マンノピラノシル)
−2,4−ジ−O−ベンジル−α−D−マンノピラノシ
ド(47)
Reference Example 20 8-Methoxycarbonyloctyl 6-O- (2-acetamido-2-deoxy-α-D-mannopyranosyl)
-2,4-Di-O-benzyl-α-D-mannopyranoside (47)

【0167】化合物(46)320mg(0.446ミリ
モル)を参考例15の場合と同様に、エタノール中触媒
量の塩化ニッケル六水和物の存在下に、水素化ホウ素ナ
トリウムでアジド基をアミノ基に還元した後、無水酢酸
でN−アセチル化して化合物(47)234mg(収率7
1.5%)を無定型粉末として得た。
320 mg (0.446 mmol) of the compound (46) was treated with sodium borohydride in the same manner as in Reference Example 15 in the presence of a catalytic amount of nickel chloride hexahydrate to convert an azide group into an amino group. And then N-acetylated with acetic anhydride to obtain 234 mg of compound (47) (yield 7
1.5%) was obtained as an amorphous powder.

【0168】 〔α〕25 D+54.7°(C 0.569, MeOH) IR(CHCl3)cm-1 :1730, 1660, 1455, 1075. 1H-NMR (CD3OD,δppm): 7.5 〜7.2(10H, m, ph), 4.41(1H, dd, J1',2'=1.2Hz, J2',3'=5Hz, H- 2 ′), 3.64(3H, s, OMe), 2.31(2H, t, J=7.5Hz, -CH2CO-), 2.00(3H, s, NAc), 1.7 〜1.25(12H, m, -(CH2)6-)[Α] 25 D + 54.7 ° (C 0.569, MeOH) IR (CHCl 3 ) cm −1 : 1730, 1660, 1455, 1075. 1 H-NMR (CD 3 OD, δppm): 7.5 to 7.2 ( 10H, m, ph), 4.41 (1H, dd, J 1 ', 2' = 1.2Hz, J 2 ', 3' = 5Hz, H-2 '), 3.64 (3H, s, OMe), 2.31 (2H , t, J = 7.5Hz, -CH 2 CO-), 2.00 (3H, s, NAc), 1.7 ~ 1.25 (12H, m,-(CH 2 ) 6- )

【0169】 元素分析 C38H55NO13・H2O 計算値 C 60.70% H 7.64% N 1.86% 実測値 C 60.84% H 7.56% N 2.02%Elemental analysis C 38 H 55 NO 13・ H 2 O Calculated value C 60.70% H 7.64% N 1.86% Actual value C 60.84% H 7.56% N 2.02%

【0170】例 15 8−メトキシカルボニルオクチル 6−O−(2−アセ
トアミドー2−デオキシ−α−D−マンノピラノシル)
−α−D−マンノピラノシド(48) 化合物(47)230mg(0.313ミリモル)を例1
4の場合と同様に、メタノール中10%パラジウム−炭
素存在下に水素添加して脱O−ベンジル化して化合物
(48)118mgを無定形粉末として得た。
Example 15 8-Methoxycarbonyloctyl 6-O- (2-acetamido-2-deoxy-α-D-mannopyranosyl)
-Α-D-mannopyranoside (48) Compound (47) 230 mg (0.313 mmol) was used in Example 1
In the same manner as in the case of 4, hydrogenation was carried out in the presence of 10% palladium-carbon in methanol to carry out de-O-benzylation to obtain 118 mg of compound (48) as an amorphous powder.

【0171】 〔α〕24 D+56.6°(C 0.758, MeOH) IR(KBr)cm-1 :1740, 1650, 1545. 1H-NMR (CDCl3,δppm): 4.74(1H, d, J1',2'=1.2Hz, H- 1′), 4.71(1H, d, J1,2=1.4Hz, H-1), 4.36(1H, dd, J2',3'=5Hz, H-2′), 3.65(3H, s, OMe), 2.32(2H, t, J=7.5Hz, -CH 2 CO-), 2.01(3H, s, NAc), 1.70〜 1.25(12H, m, -(CH2)6-) [Α] 24 D + 56.6 ° (C 0.758, MeOH) IR (KBr) cm −1 : 1740, 1650, 1545. 1 H-NMR (CDCl 3 , δppm): 4.74 (1H, d, J 1 ', 2' = 1.2Hz, H- 1 '), 4.71 (1H, d, J 1,2 = 1.4Hz, H-1), 4.36 (1H, dd, J 2', 3 ' = 5Hz, H- 2 ′), 3.65 (3H, s, OMe), 2.32 (2H, t, J = 7.5Hz, -C H 2 C O-), 2.01 (3H, s, NAc), 1.70 ~ 1.25 (12H, m, -(CH 2 ) 6- )

【0172】 元素分析 C24H43NO13・H2O 計算値 C 50.43% H 7.94% N 2.45% 実測値 C 50.55% H 7.76% N 2.58%Elemental analysis C 24 H 43 NO 13・ H 2 O Calculated value C 50.43% H 7.94% N 2.45% Actual value C 50.55% H 7.76% N 2.58%

【0173】参考例21 8−メトキシカルボニルオクチル 2−O−(3,4,
6−トリ−O−アセチル−2−デオキシ−2−フタルイ
ミド−β−D−グルコピラノシル)−3,4,6−トリ
−O−ベンジル−α−D−マンノピラノシド(50)
Reference Example 21 8-Methoxycarbonyloctyl 2-O- (3,4,
6-tri-O-acetyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl) -3,4,6-tri-O-benzyl-α-D-mannopyranoside (50)

【0174】Synthetic Methods for Carbohydrate Che
mistry, 1976に記載の方法で合成した2,3,4−トリ
−O−アセチル−2−デオキシ−2−フタルイミド−β
−D−グルコピラノシルブロマイド(49)410mg
(0.66ミリモル)および化合物(23)427mg
(0.85ミリモル)を無水ジクロロメタン20mlに溶
解した後、窒素気流下、モレキュラーシーブ4A10g
を加え1時間撹拌した。次いで銀シリケート400mgを
加えて、室温で16時間撹拌した。反応混合物をセライ
トを用いてろ過した後、ろ液を減圧下濃縮乾固してシロ
ップ状残渣710mgを得た。残渣をシリカゲルカラムク
ロマトグラフィー(ヘキサン:酢酸エチル=2:1)で
精製して化合物(50)400mg(収率58.3%)を
得た。
Synthetic Methods for Carbohydrate Che
2,3,4-tri-O-acetyl-2-deoxy-2-phthalimido-β synthesized by the method described in mistry, 1976.
-D-glucopyranosyl bromide (49) 410 mg
(0.66 mmol) and compound (23) 427 mg
(0.85 mmol) was dissolved in 20 ml of anhydrous dichloromethane and then under a nitrogen stream, molecular sieve 4A (10 g)
Was added and stirred for 1 hour. Next, 400 mg of silver silicate was added, and the mixture was stirred at room temperature for 16 hours. The reaction mixture was filtered through Celite, and the filtrate was concentrated under reduced pressure to dryness to obtain 710 mg of a syrupy residue. The residue was purified by silica gel column chromatography (hexane: ethyl acetate = 2: 1) to give compound (50) 400 mg (yield 58.3%).

【0175】 〔α〕24 D+13.7°(C 0.35, CHCl3) 1H-NMR (CDCl3,δppm): 6.9 〜7.9(19H, m, aromatic H), 5.82(1H, t, J=10Hz, H- 4′), 5.51(1H, d, J=8.5Hz, H-1′), 5.20(1H, t, J=10Hz, H- 3′), 3.65(3H, s, OMe), 2.28(2H, t, J=7.5Hz), 2.04(6H, s, 2 × Ac), 1.87(3H, s, Ac), 1.7 〜1.0(12H, m, -(CH2)6-) [Α] 24 D + 13.7 ° (C 0.35, CHCl 3 ) 1 H-NMR (CDCl 3 , δppm): 6.9 to 7.9 (19H, m, aromatic H), 5.82 (1H, t, J = 10Hz , H-4 ′), 5.51 (1H, d, J = 8.5Hz, H-1 ′), 5.20 (1H, t, J = 10Hz, H-3 ′), 3.65 (3H, s, OMe), 2.28 (2H, t, J = 7.5Hz), 2.04 (6H, s, 2 × Ac), 1.87 (3H, s, Ac), 1.7 ~ 1.0 (12H, m,-(CH 2 ) 6- )

【0176】参考例22 8−メトキシカルボニルオクチル 2−O−(2−デオ
キシ−2−フタルイミド−β−D−グルコピラノシル)
−3,4,6−トリ−O−ベンジル−α−D−マンノピ
ラノシド(51)
Reference Example 22 8-Methoxycarbonyloctyl 2-O- (2-deoxy-2-phthalimido-β-D-glucopyranosyl)
-3,4,6-Tri-O-benzyl-α-D-mannopyranoside (51)

【0177】化合物(50)275mg(0.265ミリ
モル)を参考例6の場合と同様に、メタノール中触媒量
のナトリウムメトキシドを用いて脱O−アセチル化して
化合物(51)240mgを得た。
275 mg (0.265 mmol) of the compound (50) was de-O-acetylated with a catalytic amount of sodium methoxide in methanol in the same manner as in Reference Example 6 to obtain 240 mg of the compound (51).

【0178】 1H-NMR (CDCl3,δppm): 7.8 〜7.1(19H, m, aromatic H), 5.30(1H, d, J=7.5Hz, H-1′), 4.49(1H, d, J=1.6Hz, H-1), 3.65(3H, s, OMe), 2.28(2H, t, J=7.5Hz, -CH 2 CO-), 1.7 〜1.1(12H, m, -(CH2)6-) 1 H-NMR (CDCl 3 , δppm): 7.8 to 7.1 (19H, m, aromatic H), 5.30 (1H, d, J = 7.5Hz, H-1 ′), 4.49 (1H, d, J = 1.6Hz, H-1), 3.65 (3H, s, OMe), 2.28 (2H, t, J = 7.5Hz, -C H 2 C O-), 1.7 ~ 1.1 (12H, m,-(CH 2 ) 6- )

【0179】参考例23 8−メトキシカルボニルオクチル 2−O−(2−アセ
トアミド−2−デオキシ−β−D−グルコピラノシル)
−3,4,6−トリ−O−ベンジル−α−D−マンノピ
ラノシド(52)
Reference Example 23 8-Methoxycarbonyloctyl 2-O- (2-acetamido-2-deoxy-β-D-glucopyranosyl)
-3,4,6-Tri-O-benzyl-α-D-mannopyranoside (52)

【0180】化合物(51)230mg(0.252ミリ
モル)の無水メタノール溶液(50ml)にヒドラジンア
セテート1.53g(16.6ミリモル)を加え、窒素
気流下で5時間加熱還流した。室温まで冷却した後、反
応液を減圧下で濃縮乾固した。残渣を酢酸エチル層と水
層とに分配した。有機層を分離し、水洗後、硫酸マグネ
シウムで乾燥し、溶媒を留去して残渣210mgを得た。
残渣を無水メタノール20mlに溶解した後、無水酢酸2
mlを加えて、室温に16時間放置した。反応混合物を減
圧下で濃縮乾固して残渣236mgを得た。残渣をシリカ
ゲルカラムクロマトグラフィー(クロロホルム:メタノ
ール=10:1)で精製して化合物(52)154mg
(74.4%)を得た。
To a solution of the compound (51) (230 mg, 0.252 mmol) in anhydrous methanol (50 ml) was added hydrazine acetate (1.53 g, 16.6 mmol), and the mixture was heated under reflux for 5 hours under a nitrogen stream. After cooling to room temperature, the reaction solution was concentrated to dryness under reduced pressure. The residue was partitioned between an ethyl acetate layer and an aqueous layer. The organic layer was separated, washed with water, dried over magnesium sulfate, and the solvent was distilled off to obtain 210 mg of a residue.
The residue was dissolved in 20 ml of anhydrous methanol, and then acetic anhydride 2
ml was added and left at room temperature for 16 hours. The reaction mixture was concentrated to dryness under reduced pressure to give 236 mg of residue. The residue was purified by silica gel column chromatography (chloroform: methanol = 10: 1) to obtain 154 mg of compound (52).
(74.4%) was obtained.

【0181】 〔α〕25 D-6.1 °(C 0.676, MeOH) 1H-NMR (CD3OD,δppm): 7.5 〜7.1(15H, m, aromatic H), 4.53(1H, d, J=1.6Hz, H-1), 3.62(3H, s, OMe), 2.27(2H, t, J=7.5Hz, -CH 2 CO-), 1.94(3H, s, NAc), 1.7 〜1.2(12H, m, -(CH2)6-) [Α] 25 D -6.1 ° (C 0.676, MeOH) 1 H-NMR (CD 3 OD, δppm): 7.5-7.1 (15H, m, aromatic H), 4.53 (1H, d, J = 1.6 Hz, H-1), 3.62 (3H, s, OMe), 2.27 (2H, t, J = 7.5Hz, -C H 2 C O-), 1.94 (3H, s, NAc), 1.7 ~ 1.2 (12H , m,-(CH 2 ) 6- )

【0182】例 16 8−メトキシカルボニルオクチル 2−O−(2−アセ
トアミド−2−デオキシ−β−D−グルコピラノシル)
−α−D−マンノピラノシド(53) 化合物(52)144mg(0.174ミリモル)をメタ
ノール中10%パラジウム炭素の存在下に水素添加して
脱O−ベンジル化して化合物(53)84mgを得た。
Example 16 8-Methoxycarbonyloctyl 2-O- (2-acetamido-2-deoxy-β-D-glucopyranosyl)
-Α-D-Mannopyranoside (53) 144 mg (0.174 mmol) of compound (52) was hydrogenated in the presence of 10% palladium carbon in methanol to effect de-O-benzylation to obtain 84 mg of compound (53).

【0183】 〔α〕24 D+4.7 °(C 0.838, MeOH) IR(KBr)cm-1 :1740, 1645, 1560, 1065. 1H-NMR (CD3OD,δppm): 4.77(1H, d, J=1.5Hz, H-1), 4.45(1H, d, J=8.1Hz, H-1′), 3.65(3H, s, OMe), 2.32(2H, t, J=7.5Hz, -CH 2 CO-), 1.99(3H, s, NAc), 1.7 〜1.2(12H, m, -(CH2)6-) [Α] 24 D +4.7 ° (C 0.838, MeOH) IR (KBr) cm −1 : 1740, 1645, 1560, 1065. 1 H-NMR (CD 3 OD, δppm): 4.77 (1H, d , J = 1.5Hz, H-1), 4.45 (1H, d, J = 8.1Hz, H-1 ′), 3.65 (3H, s, OMe), 2.32 (2H, t, J = 7.5Hz, -C H 2 C O-), 1.99 (3H, s, NAc), 1.7 ~ 1.2 (12H, m,-(CH 2 ) 6- )

【0184】参考例24 8−メトキシカルボニルオクチル 6−O−(3,4,
6−トリ−O−アセチル−2−デオキシ−2−フタルイ
ミド−β−D−グルコピラノシル)−2,4−ジ−O−
ベンジル−α−D−マンノピラノシド(54)および8
−メトキシカルボニルオクチル 3,6−ジ−O−
(3,4,6−トリ−O−アセチル−2−デオキシ−2
−フタルイミド−β−D−グルコピラノシル)−2,4
−ジ−O−ベンジル−α−D−マンノピラノシド(5
5)
Reference Example 24 8-Methoxycarbonyloctyl 6-O- (3,4,
6-tri-O-acetyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl) -2,4-di-O-
Benzyl-α-D-mannopyranoside (54) and 8
-Methoxycarbonyloctyl 3,6-di-O-
(3,4,6-tri-O-acetyl-2-deoxy-2
-Phthalimido-β-D-glucopyranosyl) -2,4
-Di-O-benzyl-α-D-mannopyranoside (5
5)

【0185】化合物(44)564mg(1.06ミリモ
ル)の無水ベンゼン溶液25mlに、銀シリケート1.0
gおよび粉末状モレキュラーシーブ4A1.0gを加
え、窒素気流下、室温で30分間撹拌した。次いで化合
物(49)1.05g(2.12ミリモル)の無水ベン
ゼン溶液5mlを加え、室温で16時間撹拌した。反応混
合物をセライトを用いてろ過した後、ろ液を減圧下濃縮
乾固して残渣1.6gを得た。残渣をローバーカラム
(ヘキサン:酢酸エス=1:1)を用いて精製して化合
物(54)184mg(収率18.9%)および化合物
(55)693mg(収率48.9%)を得た。
To 25 ml of a solution of 564 mg (1.06 mmol) of compound (44) in anhydrous benzene was added 1.0 part of silver silicate.
g and powdery molecular sieve 4A (1.0 g) were added, and the mixture was stirred under a nitrogen stream at room temperature for 30 minutes. Then, 5 ml of an anhydrous benzene solution containing 1.05 g (2.12 mmol) of the compound (49) was added, and the mixture was stirred at room temperature for 16 hours. The reaction mixture was filtered through Celite, and the filtrate was concentrated under reduced pressure to dryness to give 1.6 g of a residue. The residue was purified using a Rover column (hexane: acetic acid S = 1: 1) to obtain 184 mg of compound (54) (yield 18.9%) and 693 mg of compound (55) (yield 48.9%). .

【0186】 化合物(54)〔α〕24 D+22.3°(C 0.783, MeOH) IR(CHCl3)cm-1 :1750, 1721, 1389, 1369, 1080, 1040. 1H-NMR (CDCl3,δppm): 5.83(1H, dd, J=10.0Hz, J=9.0Hz, H- 3′), 5.45(1H, d, J=8.6Hz, H-1′), 5.19(1H, t, J=9.6Hz, H-4′), 3.6 (3H, s, OMe), 2.30(2H, t, J=7.5Hz, -CH2CO-), 2.09, 2.04, 1.87(each 3H, each s, 3 ×OAc), 1.7 〜1.1(12H, m, -CH2)6- Compound (54) [α] 24 D + 22.3 ° (C 0.783, MeOH) IR (CHCl 3 ) cm −1 : 1750, 1721, 1389, 1369, 1080, 1040. 1 H-NMR (CDCl 3 , δppm): 5.83 (1H, dd, J = 10.0Hz, J = 9.0Hz, H-3 ′), 5.45 (1H, d, J = 8.6Hz, H-1 ′), 5.19 (1H, t, J = 9.6Hz, H-4 ′), 3.6 (3H, s, OMe), 2.30 (2H, t, J = 7.5Hz, -CH 2 CO-), 2.09, 2.04, 1.87 (each 3H, each s, 3 × OAc), 1.7 ~ 1.1 (12H, m, -CH 2 ) 6-

【0187】 元素分析 C50H61NO17・H2O 計算値 C 62.11% H 6.57% N 1.45% 実測値 C 61.87% H 6.27% N 1.50%Elemental analysis C 50 H 61 NO 17 · H 2 O Calculated value C 62.11% H 6.57% N 1.45% Actual value C 61.87% H 6.27% N 1.50%

【0188】 化合物(55)〔α〕25 D+16.0°(C 0.688, CHCl3) 1H-NMR (CDCl3,δppm): 5.78(1H, dd, J=9.2Hz, 11Hz, H-3′or H-3"), 5.76(1H, dd, J=9.2Hz, 11Hz, H-3"or H-3′), 5.47(1H, d, J=8Hz, H-1′or H-1"), 5.35(1H, d, J=8.4Hz, H-1" or H- 1′), 5.14(1H, t, J=9.4Hz, H-4′ or H-4"), 5.13(1H, t, J=9.6Hz, H-4" or H- 4′), 3.68(3H, s, OMe), 2.05, 2.01, 1.99, 1.84, 1.82 (total 18H, 6×Ac).Compound (55) [α] 25 D + 16.0 ° (C 0.688, CHCl 3 ) 1 H-NMR (CDCl 3 , δppm): 5.78 (1H, dd, J = 9.2Hz, 11Hz, H-3 ′ or H-3 "), 5.76 (1H, dd, J = 9.2Hz, 11Hz, H-3" or H-3 '), 5.47 (1H, d, J = 8Hz, H-1' or H-1 " ), 5.35 (1H, d, J = 8.4Hz, H-1 "or H-1 '), 5.14 (1H, t, J = 9.4Hz, H-4' or H-4"), 5.13 (1H, t, J = 9.6Hz, H-4 "or H-4 '), 3.68 (3H, s, OMe), 2.05, 2.01, 1.99, 1.84, 1.82 (total 18H, 6 × Ac).

【0189】 元素分析 C70H80N2O26・H2O 計算値 C 60.77% H 5.97% N 2.03% 実測値 C 60.63% H 5.85% N 1.96%Elemental analysis C 70 H 80 N 2 O 26・ H 2 O Calculated value C 60.77% H 5.97% N 2.03% Measured value C 60.63% H 5.85% N 1.96%

【0190】参考例25 8−メトキシカルボニルオクチル 6−O−(2−デオ
キシ−2−フタルイミド−β−D−グルコピラノシル)
−2,4−ジ−O−ベンジル−α−D−マンノピラノシ
ド(56)
Reference Example 25 8-Methoxycarbonyloctyl 6-O- (2-deoxy-2-phthalimido-β-D-glucopyranosyl)
-2,4-Di-O-benzyl-α-D-mannopyranoside (56)

【0191】化合物(54)161mg(0.176ミリ
モル)を参考例6の場合と同様に、メタノール中触媒量
のナトリウムメトキシドの存在下に脱O−アセチル化し
て化合物(56)111mgを得た。
In the same manner as in Reference Example 6, 161 mg (0.176 mmol) of compound (54) was de-O-acetylated in the presence of a catalytic amount of sodium methoxide in methanol to obtain 111 mg of compound (56). .

【0192】 〔α〕24 D+5.5 °(C 0.667, CHCl3) 1H-NMR (CDCl3,δppm): 7.72〜 7.15(14H, m, aromatic H), 5.31(1H, d, J=8.1Hz, H-1′), 3.65(3H, s, OMe), 2.30(2H, t, J=7.5Hz, -CH 2 CO-), 1.7 〜1.1(12H, m, -(CH2)6-) [Α] 24 D +5.5 ° (C 0.667, CHCl 3 ) 1 H-NMR (CDCl 3 , δppm): 7.72 to 7.15 (14H, m, aromatic H), 5.31 (1H, d, J = 8.1 Hz, H-1 ′), 3.65 (3H, s, OMe), 2.30 (2H, t, J = 7.5Hz, -C H 2 C O-), 1.7 ~ 1.1 (12H, m,-(CH 2 ) 6- )

【0193】参考例26 8−メトキシカルボニルオクチル 6−O−(2−アセ
トアミド−2−デオキシ−β−D−グルコピラノシル)
−2,4−ジ−O−ベンジル−α−D−マンノピラノシ
ド(57)
Reference Example 26 8-Methoxycarbonyloctyl 6-O- (2-acetamido-2-deoxy-β-D-glucopyranosyl)
-2,4-di-O-benzyl-α-D-mannopyranoside (57)

【0194】化合物(56)104mg(0.132ミリ
モル)を参考例23の場合と同様に、メタノール中ヒド
ラジンアセテートと加熱還流して脱フタロイル化した
後、無水酢酸でN−アセチル化して化合物(57)66
mgを得た。
In the same manner as in Reference Example 23, 104 mg (0.132 mmol) of the compound (56) was heated to reflux with hydrazine acetate in methanol to dephthaloylate and then N-acetylated with acetic anhydride to give the compound (57). ) 66
to obtain mg.

【0195】 〔α〕25 D+12.3°(C 0.733, MeOH) IR(KBr)cm-1 :1740, 1652, 1555 1H-NMR (CD3OD,δppm): 7.25〜 7.48(10H, m, aromatic H), 4.69(1H, d, J=1.6Hz, H-1), 4.47(1H, d, J=8.2Hz, H-1′), 3.63(3H, s, OMe), 2.30(2H, t, J=7.5Hz, -CH 2 CO-), 1.98, 1.86(total 3H, NAc), 1.7 〜1.2(12H, m, -(CH2)6-) [Α] 25 D + 12.3 ° (C 0.733, MeOH) IR (KBr) cm −1 : 1740, 1652, 1555 1 H-NMR (CD 3 OD, δppm): 7.25 to 7.48 (10H, m, aromatic H), 4.69 (1H, d, J = 1.6Hz, H-1), 4.47 (1H, d, J = 8.2Hz, H-1 '), 3.63 (3H, s, OMe), 2.30 (2H, t, J = 7.5Hz, -C H 2 C O-), 1.98, 1.86 (total 3H, NAc), 1.7 ~ 1.2 (12H, m,-(CH 2 ) 6- )

【0196】例 17 8−メトキシカルボニルオクチル 6−O−(2−アセ
トアミド−2−デオキシ−β−D−グルコピラノシル)
−α−D−マンノピラノシド(58) 化合物(57)54mg(0.0826ミリモル)をメタ
ノール中10%パラジウム炭素の存在下に水素添加し
て、脱O−ベンジル化して化合物(58)36mgを得
た。
Example 17 8-Methoxycarbonyloctyl 6-O- (2-acetamido-2-deoxy-β-D-glucopyranosyl)
-Α-D-Mannopyranoside (58) 54 mg (0.0826 mmol) of compound (57) was hydrogenated in the presence of 10% palladium on carbon in methanol and de-O-benzylated to give 36 mg of compound (58). .

【0197】 〔α〕24 D-12.4°(C 0.723, MeOH) 1H-NMR (CD3OD,δppm): 4.68(1H, d, J=1.2Hz, H-1), 4.44(1H, d, J=8.4Hz, H-1′), 3.65(3H, s, OMe), 2.23(2H, t, J=7.5Hz, -CH 2 CO-), 1.98(3H, s, NAc), 1.7 〜1.25(12H, m, -(CH2)6-)[Α] 24 D -12.4 ° (C 0.723, MeOH) 1 H-NMR (CD 3 OD, δppm): 4.68 (1H, d, J = 1.2Hz, H-1), 4.44 (1H, d , J = 8.4Hz, H-1 ′), 3.65 (3H, s, OMe), 2.23 (2H, t, J = 7.5Hz, -CH 2 C O-), 1.98 (3H, s, NAc), 1.7 ~ 1.25 (12H, m,-(CH 2 ) 6- )

【0198】参考例27 8−メトキシカルボニルオクチル 3,6−ジ−O−
(2−デオキシ−2−フタルイミド−β−D−グルコピ
ラノシル)−2,4−ジ−O−ベンジル−α−D−マン
ノピラノシド(59)
Reference Example 27 8-Methoxycarbonyloctyl 3,6-di-O-
(2-Deoxy-2-phthalimido-β-D-glucopyranosyl) -2,4-di-O-benzyl-α-D-mannopyranoside (59)

【0199】粗生成物(55)1.0g(0.732ミ
リモル)を参考例6の場合と同様に、メタノール中触媒
量のナトリウムメトキシドの存在下に脱O−アセチル化
して化合物(59)277mgを得た。
In the same manner as in Reference Example 6, 1.0 g (0.732 mmol) of the crude product (55) was de-O-acetylated in the presence of a catalytic amount of sodium methoxide in methanol to give compound (59). 277 mg were obtained.

【0200】 〔α〕25 D+2.1 °(C 0.973, MeOH) IR(KBr)cm-1 :1775, 1712, 1390, 1072. 1H-NMR (CD3OD,δppm): 5.34(1H, d, J=8.2Hz, H-1′or H-1"), 5.21(1H, d, J=8.4Hz, H-1" or H-1′), 3.65(3H, s, OMe), 2.35(2H, t, J=7.5Hz, -CH 2 CO-), 1.7 〜1.1(12H, m, -(CH2)6-) [Α] 25 D + 2.1 ° (C 0.973, MeOH) IR (KBr) cm −1 : 1775, 1712, 1390, 1072. 1 H-NMR (CD 3 OD, δppm): 5.34 (1H, d , J = 8.2Hz, H-1 'or H-1 "), 5.21 (1H, d, J = 8.4Hz, H-1" or H-1'), 3.65 (3H, s, OMe), 2.35 ( 2H, t, J = 7.5Hz, -C H 2 C O-), 1.7 ~ 1.1 (12H, m,-(CH 2 ) 6- )

【0201】 元素分析 C58H68N2O20・H2O 計算値 C 61.58% H 6.24% N 2.48% 実測値 C 61.70% H 6.23% N 2.66%Elemental analysis C 58 H 68 N 2 O 20 H 2 O Calculated value C 61.58% H 6.24% N 2.48% Actual value C 61.70% H 6.23% N 2.66%

【0202】参考例28 8−メトキシカルボニルオクチル 3,6−ジ−O−
(3,4,6−トリ−O−アセチル−2−アセトアミド
−2−デオキシ−β−D−グルコピラノシル)−2,4
−ジ−O−ベンジル−α−D−マンノピラノシド(6
0)
Reference Example 28 8-Methoxycarbonyloctyl 3,6-di-O-
(3,4,6-Tri-O-acetyl-2-acetamido-2-deoxy-β-D-glucopyranosyl) -2,4
-Di-O-benzyl-α-D-mannopyranoside (6
0)

【0203】化合物(59)277mg(0.256ミリ
モル)のメタノール溶液50mlに、ヒドラジンアセテー
ト3.06g(33.28ミリモル)を加え、窒素気流
下、3時間加熱撹拌した。室温まで冷却した後、反応液
を減圧下で濃縮乾固して残渣3.59gを得た。残渣を
ピリジン15mlに溶解した後、無水酢酸15mlを加え
て、室温に48時間放置した。反応混合物を氷水中に注
ぎ、生成物を酢酸エチルで抽出した。酢酸エチル相を、
希塩酸、炭酸水素ナトリウム水溶液および水で順次洗浄
した。硫酸マグネシウムで乾燥した後、減圧下で溶媒を
留去した。残渣をシリカゲルカラムクロマトグラフィー
(酢酸エチル)で精製して化合物(60)212mg(収
率71.6%)を得た。
3.06 g (33.28 mmol) of hydrazine acetate was added to 50 ml of a methanol solution of 277 mg (0.256 mmol) of compound (59), and the mixture was heated and stirred under a nitrogen stream for 3 hours. After cooling to room temperature, the reaction solution was concentrated to dryness under reduced pressure to obtain 3.59 g of a residue. The residue was dissolved in 15 ml of pyridine, 15 ml of acetic anhydride was added, and the mixture was left at room temperature for 48 hours. The reaction mixture was poured into ice water and the product was extracted with ethyl acetate. The ethyl acetate phase,
It was washed successively with dilute hydrochloric acid, an aqueous sodium hydrogen carbonate solution and water. After drying over magnesium sulfate, the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate) to obtain 212 mg of the compound (60) (yield 71.6%).

【0204】 〔α〕25 D+1.3 °(C 1.085, CHCl3) 1H-NMR (CDCl3,δppm): 7.5 〜7.2(10H, m, aromatic H), 3.67(3H, s, OMe), 2.42, 2.16, 2.05, 2.02, 2.00, 1.84, 1.75, 1.72 (each 3H, each s, NAc and OAc), 2.30(2H, t, J=7.5Hz, -CH 2 CO-), 1.7 〜1.2(12H, m, -(CH2)6-) [Α] 25 D + 1.3 ° (C 1.085, CHCl 3 ) 1 H-NMR (CDCl 3 , δppm): 7.5 to 7.2 (10H, m, aromatic H), 3.67 (3H, s, OMe), 2.42, 2.16, 2.05, 2.02, 2.00, 1.84, 1.75, 1.72 (each 3H, each s, NAc and OAc), 2.30 (2H, t, J = 7.5Hz, -C H 2 CO-), 1.7 ~ 1.2 ( 12H, m,-(CH 2 ) 6- )

【0205】参考例29 8−メトキシカルボニルオクチル 3,6−ジ−O−
(2−アセトアミド−2−デオキシ−β−D−グルコピ
ラノシル)−2,4−ジ−O−ベンジル−α−D−マン
ノピラノシド(61)
Reference Example 29 8-Methoxycarbonyloctyl 3,6-di-O-
(2-acetamido-2-deoxy-β-D-glucopyranosyl) -2,4-di-O-benzyl-α-D-mannopyranoside (61)

【0206】化合物(60)190mg(0.164ミリ
モル)を参考例6の場合と同様に、メタノール中触媒量
のナトリウムメトキシドを用いて脱O−アセチル化して
化合物(61)134mgを得た。
In the same manner as in Reference Example 6, 190 mg (0.164 mmol) of compound (60) was de-O-acetylated using a catalytic amount of sodium methoxide in methanol to obtain 134 mg of compound (61).

【0207】 〔α〕25 D+3.4 °(C 0.698, MeOH) IR(KBr)cm-1 :1735, 1655, 1555, 1070. 1H-NMR (CD3OD,δppm): 7.6 〜7.25(10H, m, aromatic H), 3.64(3H, s, OMe), 2.30(2H, t, J=7.5Hz, -CH2CO-), 1.98(3H, s, NAc), 1.88, 1.76(total 3H, NAc), 1.7 〜1.2(12H, m, -(CH2)6-) [Α] 25 D + 3.4 ° (C 0.698, MeOH) IR (KBr) cm −1 : 1735, 1655, 1555, 1070. 1 H-NMR (CD 3 OD, δppm): 7.6 to 7.25 (10H , m, aromatic H), 3.64 (3H, s, OMe), 2.30 (2H, t, J = 7.5Hz, -CH 2 CO-), 1.98 (3H, s, NAc), 1.88, 1.76 (total 3H, NAc), 1.7 to 1.2 (12H, m,-(CH 2 ) 6- )

【0208】 元素分析 C46H68N2O18・2.2H2O 計算値 C 56.57% H 7.47% N 2.87% 実測値 C 56.87% H 7.24% N 2.70%Elemental analysis C 46 H 68 N 2 O 18・ 2.2H 2 O Calculated value C 56.57% H 7.47% N 2.87% Actual value C 56.87% H 7.24% N 2.70%

【0209】例 18 8−メトキシカルボニルオクチル 3,6−ジ−O−
(2−アセトアミド−2−デオキシ−β−D−グルコピ
ラノシル)−α−D−マンノピラノシド(62) 化合物(61)143mgを、メタノール中10%パラジ
ウム炭素存在下に水素添加して脱O−ベンジル化して化
合物(62)68mgを得た。
Example 18 8-Methoxycarbonyloctyl 3,6-di-O-
(2-Acetamido-2-deoxy-β-D-glucopyranosyl) -α-D-mannopyranoside (62) 143 mg of compound (61) was hydrogenated in methanol in the presence of 10% palladium carbon to de-O-benzylate. 68 mg of compound (62) was obtained.

【0210】 〔α〕28 D+6.1 °(C 0.23, MeOH) 1H-NMR (CD3OD,δppm): 4.70(1H, d, J=1.5Hz, H-1), 4.56(1H, d, J=8.5Hz, H-1′ or H-1"), 4.46(1H, d, J=8.5Hz, H-1" or H- 1′), 3.65(3H, s, OMe), 2.32(2H, t, J=7.5Hz, -CH 2 CO-), 1.98(3H, s, NAc), 2.00, 1.89(total 3H, s, NAc), 1.65〜 1.30(12H, m, -(CH2)6-) [Α] 28 D +6.1 ° (C 0.23, MeOH) 1 H-NMR (CD 3 OD, δppm): 4.70 (1H, d, J = 1.5Hz, H-1), 4.56 (1H, d , J = 8.5Hz, H-1 ′ or H-1 "), 4.46 (1H, d, J = 8.5Hz, H-1" or H-1 '), 3.65 (3H, s, OMe), 2.32 ( 2H, t, J = 7.5Hz, -C H 2 C O-), 1.98 (3H, s, NAc), 2.00, 1.89 (total 3H, s, NAc), 1.65 ~ 1.30 (12H, m,-(CH 2 ) 6- )

【0211】 元素分析 C32H56N2O18・3H2O 計算値 C 47.40% H 7.71% N 3.46% 実測値 C 47.12% H 7.55% N 3.13%[0211] Elemental analysis C 32 H 56 N 2 O 18 · 3H 2 O Calculated C 47.40% H 7.71% N 3.46 % Found C 47.12% H 7.55% N 3.13 %

【0212】参考例30 8−メトキシカルボニルオクチル 2,3,4−トリ−
O−ベンジル−α−L−フコピラノシド(65)および
8−メトキシカルボニルオクチル 2,3,4−トリ−
O−ベンジル−β−L−フコピラノシド(67)
Reference Example 30 8-Methoxycarbonyloctyl 2,3,4-tri-
O-benzyl-α-L-fucopyranoside (65) and 8-methoxycarbonyloctyl 2,3,4-tri-
O-benzyl-β-L-fucopyranoside (67)

【0213】2,3,4−トリ−O−ベンジル−1−p
−ニトロベンゾイル−β−L−フコピラノース4.00
g(6.85ミリモル)より調製した新しい2,3,4
−トリ−O−ベンジル−α−L−フコピラノシルブロマ
イド(63)〔Carbohydr,Res., 18, 219-226 (1971).]
のベンゼン40ml溶液に、8−メトキシカルボニルオク
タノール1.29g(6.85ミリモル)、シアン化第
二水銀1.73g(6.85ミリモル)および粉末無水
硫酸カルシウム3.60gを加え、アルゴン気流中室温
で2日間撹拌した。沈殿をろ去した後、ろ液に酢酸エチ
ル60mlを加え、飽和炭酸水素ナトリウム水溶液60m
l、水60mlで順次洗浄した。無水硫酸マグネシウムで
脱水後、減圧濃縮して得たシロップをシリカゲルカラム
クロマトグラフィー(n−ヘキサン:酢酸エチル=1
5:1)で精製して化合物(65)1.66g(収率4
0.1%)と化合物(67)(収率12.6%)を得
た。
2,3,4-tri-O-benzyl-1-p
-Nitrobenzoyl-β-L-fucopyranose 4.00
New 2,3,4 prepared from g (6.85 mmol)
-Tri-O-benzyl-α-L-fucopyranosyl bromide (63) [Carbohydr, Res., 18, 219-226 (1971).]
To a 40 ml solution of benzene in the above solution, 1.29 g (6.85 mmol) of 8-methoxycarbonyloctanol, 1.73 g (6.85 mmol) of mercuric cyanide and 3.60 g of powdered anhydrous calcium sulfate were added, and the mixture was stirred at room temperature in an argon stream. And stirred for 2 days. After removing the precipitate by filtration, 60 ml of ethyl acetate was added to the filtrate, and a saturated aqueous solution of sodium hydrogencarbonate 60 m was added.
1 and 60 ml of water were sequentially washed. The syrup obtained by dehydration over anhydrous magnesium sulfate and concentration under reduced pressure was subjected to silica gel column chromatography (n-hexane: ethyl acetate = 1).
The compound (65) 1.66 g (yield 4
0.1%) and the compound (67) (yield 12.6%) were obtained.

【0214】 化合物(65) 〔α〕24 D-34.0°(C 1.0, CHCl3) IR(NaCl)cm-1:1725 1H-NMR (CDCl3,δppm): 1.10(3H, d, J=7.5Hz, H-6, CH3), 2.28(2H, t, J=7.6Hz, CH 2 COOCH3), 3.65(3H, s, OCH3) Compound (65) [α] 24 D −34.0 ° (C 1.0, CHCl 3 ) IR (NaCl) cm −1 : 1725 1 H-NMR (CDCl 3 , δppm): 1.10 (3H, d, J = 7.5Hz, H-6, CH 3 ), 2.28 (2H, t, J = 7.6Hz, C H 2 C OOCH 3 ), 3.65 (3H, s, OCH 3 )

【0215】 化合物(67)〔α〕24 D+6.2 °(C 1.0, CHCl3) IR(NaCl)cm-1:1725 1H-NMR (CDCl3,δppm): 1.15(3H, d, J=7.5Hz, H-6), 2.28(2H, t, J=7.6Hz, CH 2 COOCH3), 3.65(3H, s, OCH3), 4.32(1H, d, J=8.6Hz, H-1) Compound (67) [α] 24 D + 6.2 ° (C 1.0, CHCl 3 ) IR (NaCl) cm −1 : 1725 1 H-NMR (CDCl 3 , δppm): 1.15 (3H, d, J = 7.5Hz, H-6), 2.28 (2H, t, J = 7.6Hz, C H 2 C OOCH 3 ), 3.65 (3H, s, OCH 3 ), 4.32 (1H, d, J = 8.6Hz, H- 1)

【0216】例 19 8−メトキシカルボニルオクチル α−L−フコピラノ
シド(66) 化合物(65)1.89g(3.12ミリモル)の酢酸
50ml溶液に10%パラジウム炭素1.0gを加え、パ
ールの装置(50psi)を用い室温で3日間接触還元し
た。沈殿をろ去した後、ろ液を減圧濃縮して得られた固
体をシリカゲルカラムクロマトグラフィー(クロロホル
ム:メタノール=30:1)で精製して化合物(66)
848mg(収率81.3%)を得た。
Example 19 8-Methoxycarbonyloctyl α-L-fucopyranoside (66) To a solution of 1.89 g (3.12 mmol) of the compound (65) in 50 ml of acetic acid was added 1.0 g of 10% palladium carbon, and Parr's apparatus ( 50 psi) at room temperature for 3 days. After removing the precipitate by filtration, the solid obtained by concentrating the filtrate under reduced pressure was purified by silica gel column chromatography (chloroform: methanol = 30: 1) to give compound (66).
848 mg (yield 81.3%) was obtained.

【0217】 〔α〕23 D-110.1 °(C 1.0, MeOH) IR(NaCl)cm-1:3350, 1740 1H-NMR (CD3OD,δppm): 1.18(3H, d, J=7.5Hz, H-6,), 2.31(2H, t, J=7.6Hz, CH 2 COOCH3), 3.65(3H, s, OCH3), 4.74(1H, d, J=2.7Hz, H-1) [Α] 23 D -110.1 ° (C 1.0, MeOH) IR (NaCl) cm −1 : 3350, 1740 1 H-NMR (CD 3 OD, δppm): 1.18 (3H, d, J = 7.5Hz , H-6,), 2.31 (2H, t, J = 7.6Hz, C H 2 C OOCH 3 ), 3.65 (3H, s, OCH 3 ), 4.74 (1H, d, J = 2.7Hz, H-1 )

【0218】例 20 8−メトキシカルボニルオクチル β−L−フコピラノ
シド(68) 化合物(67)596mg(0.985ミリモル)を例2
と同様な方法で接触還元して化合物(68)226mg
(収率68.6%)を得た。
Example 20 8-Methoxycarbonyloctyl β-L-fucopyranoside (68) Compound (67) (596 mg, 0.985 mmol) was added to Example 2.
226 mg of compound (68) by catalytic reduction in the same manner as
(Yield 68.6%) was obtained.

【0219】 〔α〕23 D+4.5 °(C 1.0, MeOH) IR(NaCl)cm-1:3350, 1740 1H-NMR (CD3OD,δppm): 1.21(3H, d, J=7.5Hz, H-6,), 2.31(2H, t, J=7.6Hz, CH 2 COOCH3), 3.65(3H, s, OCH3), 4.17(1H, d, J=8.1Hz, H-1) [Α] 23 D + 4.5 ° (C 1.0, MeOH) IR (NaCl) cm −1 : 3350, 1740 1 H-NMR (CD 3 OD, δppm): 1.21 (3H, d, J = 7.5Hz , H-6,), 2.31 (2H, t, J = 7.6Hz, C H 2 C OOCH 3 ), 3.65 (3H, s, OCH 3 ), 4.17 (1H, d, J = 8.1Hz, H-1 )

【0220】参考例31 6−メトキシカルボニルヘキシル 2,3,4−トリ−
O−アセチル−β−L−フコピラノシド(69)
Reference Example 31 6-Methoxycarbonylhexyl 2,3,4-tri-
O-acetyl-β-L-fucopyranoside (69)

【0221】1,2,3,4−テトラ−O−アセチル−
L−フコピラノース1.00g(3.01ミリモル)よ
り調製した新しい2,3,4−トリ−O−アセチル−α
−L−フコピラノシルブロマイド(64)〔Carbohydr,
Res., 4, 189-195 (1967)〕のベンゼン10ml溶液に、
6−メトキシカルボニルヘキサノール241mg(1.5
0ミリモル)、シアン化第二水銀380mg(1.50ミ
リモル)および粉末無水硫酸カルシウム900mgを加
え、アルゴン気流中室温で24時間撹拌した。沈殿をろ
去した後、ろ液に酢酸エチル15mlを加え、飽和炭酸水
素ナトリウム水溶液15ml、水15mlで順次洗浄した。
無水硫酸マグネシウムで脱水後、減圧濃縮して得たシロ
ップをシリカゲルカラムクロマトグラフィー(トルエ
ン:酢酸エチル=8:1)で精製して化合物(69)4
01mg(収率61.6%)を得た。
1,2,3,4-tetra-O-acetyl-
New 2,3,4-tri-O-acetyl-α prepared from 1.00 g (3.01 mmol) of L-fucopyranose
-L-fucopyranosyl bromide (64) [Carbohydr,
Res., 4, 189-195 (1967)] in 10 ml of benzene,
241 mg of 6-methoxycarbonylhexanol (1.5
0 mmol), 380 mg (1.50 mmol) of mercuric cyanide and 900 mg of anhydrous powdery calcium sulfate were added, and the mixture was stirred at room temperature in an argon stream for 24 hours. After removing the precipitate by filtration, 15 ml of ethyl acetate was added to the filtrate, and the mixture was washed successively with 15 ml of saturated aqueous sodium hydrogen carbonate solution and 15 ml of water.
The syrup obtained by dehydration over anhydrous magnesium sulfate and concentration under reduced pressure was purified by silica gel column chromatography (toluene: ethyl acetate = 8: 1) to give compound (69) 4.
01 mg (yield 61.6%) was obtained.

【0222】 〔α〕23 D+1.7 °(C 1.0, CHCl3) IR(NaCl)cm-1:1740 1H-NMR (CDCl3,δppm): 1.22(3H, d, J=6.4Hz, H-6), 1.99, 2.05, 2.17(3H, s, CH3CO), 2.31(2H, t, H=7.6Hz, CH 2 COOCH3), 3.67(3H, s, OCH3), 4.42(1H, d, J=8.1Hz, H-1) [Α] 23 D +1.7 ° (C 1.0, CHCl 3 ) IR (NaCl) cm −1 : 1740 1 H-NMR (CDCl 3 , δppm): 1.22 (3H, d, J = 6.4Hz, H -6), 1.99, 2.05, 2.17 (3H, s, CH 3 CO), 2.31 (2H, t, H = 7.6Hz, C H 2 C OOCH 3 ), 3.67 (3H, s, OCH 3 ), 4.42 ( 1H, d, J = 8.1Hz, H-1)

【0223】例 21 6−メトキシカルボニルヘキシル β−L−フコピラノ
シド(70) 化合物(69)389mg(0.899ミリモル)のメタ
ノール4ml溶液に28%ナトリウムメチラート0.1ml
を加え、室温で2時間撹拌した。アンバーライトIR−
120B(H+ 型) で中和後、樹脂をろ去し、ろ液を減
圧濃縮してシロップ状の化合物(70)268mg(収率
97.3%)を得た。
Example 21 6-Methoxycarbonylhexyl β-L-fucopyranoside (70) Compound (69) 389 mg (0.899 mmol) in methanol 4 ml solution 28% sodium methylate 0.1 ml
Was added and the mixture was stirred at room temperature for 2 hours. Amber Light IR-
After neutralization with 120B (H + type), the resin was filtered off and the filtrate was concentrated under reduced pressure to obtain 268 mg (yield 97.3%) of syrupy compound (70).

【0224】 〔α〕23 D+3.3 °(C 0.64, MeOH) IR(NaCl)cm-1:3450, 1740 1H-NMR (CD3OD,δppm): 1.23(3H, d, J=6.6Hz, H-6,), 2.37(2H, t, J=7.6Hz, CH 2 COOCH3), 3.67(3H, s, OCH3), 4.19(1H, d, J=7.3Hz, H-1) [Α] 23 D +3.3 ° (C 0.64, MeOH) IR (NaCl) cm −1 : 3450, 1740 1 H-NMR (CD 3 OD, δppm): 1.23 (3 H, d, J = 6.6 Hz) , H-6,), 2.37 (2H, t, J = 7.6Hz, CH 2 C OOCH 3 ), 3.67 (3H, s, OCH 3 ), 4.19 (1H, d, J = 7.3Hz, H-1)

【0225】参考例32 8−メトキシカルボニルオクチル 2−アセトアミド−
3−O−(2,3,4−トリ−O−アセチル−β−L−
フコピラノシル)−4,6−O−ベンジリデン−2−デ
オキシ−β−D−グルコピラノシド(72)
Reference Example 32 8-Methoxycarbonyloctyl 2-acetamido-
3-O- (2,3,4-tri-O-acetyl-β-L-
Fucopyranosyl) -4,6-O-benzylidene-2-deoxy-β-D-glucopyranoside (72)

【0226】1,2,3,4−テトラ−O−アセチル−
L−フコピラノース156mg(0.469ミリモル)よ
り調製した新しい2,3,4−トリ−O−アセチル−α
−L−フコピラノシルブロマイド(64)のベンゼン−
ニトロメタン(10ml−10ml)溶液に、8−メトキシ
カルボニルオクチル 2−アセトアミド−4,6−O−
ベンジリデン−2−デオキシ−β−D−グルコピラノシ
ド(71)〔J. Am. Chem. Soc., 97, 4076-4083 (197
5) 〕150mg(0.313ミリモル)およびシアン化
第二水銀79mg(0.313ミリモル)を加え、アルゴ
ン気流中室温で24時間撹拌した。沈殿をろ去した後、
ろ液に酢酸エチル10mlを加え、飽和炭酸水素ナトリウ
ム水溶液10ml、水10mlで順次洗浄した。無水硫酸マ
グネシウムで脱水後、減圧濃縮して得たシロップをシリ
カゲルカラムクロマトグラフィー(クロロホルム:メタ
ノール=150:1)で精製して粉末状の化合物(7
2)205mg(収率87.1%)を得た。
1,2,3,4-tetra-O-acetyl-
New 2,3,4-tri-O-acetyl-α prepared from 156 mg (0.469 mmol) L-fucopyranose
-Benzene of L-fucopyranosyl bromide (64)-
8-Methoxycarbonyloctyl 2-acetamido-4,6-O- was added to a nitromethane (10 ml-10 ml) solution.
Benzylidene-2-deoxy-β-D-glucopyranoside (71) [J. Am. Chem. Soc., 97, 4076-4083 (197)
5)] 150 mg (0.313 mmol) and mercuric cyanide 79 mg (0.313 mmol) were added, and the mixture was stirred at room temperature in an argon stream for 24 hours. After filtering off the precipitate,
10 ml of ethyl acetate was added to the filtrate, and the mixture was washed successively with 10 ml of saturated aqueous sodium hydrogen carbonate solution and 10 ml of water. The syrup obtained by dehydration over anhydrous magnesium sulfate and concentration under reduced pressure was purified by silica gel column chromatography (chloroform: methanol = 150: 1) to obtain a powdery compound (7
2) 205 mg (yield 87.1%) was obtained.

【0227】 〔α〕27 D-15.2°(C 1.1, CHCl3) IR(KBr) cm-1:1750, 1230, 1080 1H-NMR (CDCl3,δppm): 1.18(3H, d, J=5.9Hz, H-6′), 1.81(3H, s, NCOCH3), 1.97, 1.98, 2.16(3H, s, OCOCH3), 2.30(2H, t, J=7.1Hz, CH 2 COOCH3), 3.67(3H, s, OCH3), 4.67(1H, d, J=7.8Hz, H-1), 5.86(1H, d, J=6.8Hz, NH)[Α] 27 D -15.2 ° (C 1.1, CHCl 3 ) IR (KBr) cm -1 : 1750, 1230, 1080 1 H-NMR (CDCl 3 , δppm): 1.18 (3H, d, J = 5.9Hz, H-6 ′), 1.81 (3H, s, NCOCH 3 ), 1.97, 1.98, 2.16 (3H, s, OCOCH 3 ), 2.30 (2H, t, J = 7.1Hz, CH 2 C OOCH 3 ) , 3.67 (3H, s, OCH 3 ), 4.67 (1H, d, J = 7.8Hz, H-1), 5.86 (1H, d, J = 6.8Hz, NH)

【0228】例 22 8−メトキシカルボニルオクチル 2−アセトアミド−
2−デオキシ−3−O−(β−L−フコピラノシル)−
β−D−グルコピラノシド(73) 化合物(72)124mg(0.165ミリモル)のジオ
キサン10ml溶液に0.5M 硫酸3.3mlを加え、90
℃で20分間撹拌した。クロロホルム20mlを加え、飽
和炭酸水素ナトリウム水溶液20ml、水20mlで順次洗
浄した。無水硫酸マグネシウムで脱水後、減圧濃縮して
得た残渣をメタノール2mlに溶解し、28%ナトリウム
メチラート0.02mlを加え、室温で2時間撹拌した。
アンバーライトIR−120B(H+ 型) で中和後、樹
脂をろ去し、ろ液を減圧濃縮して得たシロップをシリカ
ゲルカラムクロマトグラフィー(クロロホルム:メタノ
ール:水=16:4:1)で精製して化合物(73)3
3.5mg(収率47.0%)を得た。
Example 22 8-Methoxycarbonyloctyl 2-acetamido-
2-deoxy-3-O- (β-L-fucopyranosyl)-
β-D-glucopyranoside (73) To a solution of 124 mg (0.165 mmol) of compound (72) in 10 ml of dioxane, 3.3 ml of 0.5M sulfuric acid was added, and 90
Stir at 20 ° C. for 20 minutes. Chloroform (20 ml) was added, and the mixture was washed successively with saturated aqueous sodium hydrogen carbonate solution (20 ml) and water (20 ml). The residue obtained by dehydration over anhydrous magnesium sulfate and concentration under reduced pressure was dissolved in 2 ml of methanol, 0.02 ml of 28% sodium methylate was added, and the mixture was stirred at room temperature for 2 hours.
After neutralization with Amberlite IR-120B (H + type), the resin was filtered off, and the syrup obtained by concentrating the filtrate under reduced pressure was subjected to silica gel column chromatography (chloroform: methanol: water = 16: 4: 1). Compound (73) 3 after purification
3.5 mg (yield 47.0%) was obtained.

【0229】 〔α〕25 D-26.9°(C 0.82, MeOH) IR(KBr)cm-1 :3400, 1740, 1660, 1080 1H-NMR (CD3OD,δppm): 1.27(3H, d, J=6.4Hz, H-6′), 1.95(3H, s, NCOCH3), 2.30(2H, t, J=7.6Hz, CH2COOCH3), 3.65(3H, s, OCH3), 4.39(1H, d, J=7.3Hz, H-1′), 4.51(1H, d, J=8.5Hz, H-1) [Α] 25 D -26.9 ° (C 0.82, MeOH) IR (KBr) cm -1 : 3400, 1740, 1660, 1080 1 H-NMR (CD 3 OD, δppm): 1.27 (3H, d, J = 6.4Hz, H-6 ′), 1.95 (3H, s, NCOCH 3 ), 2.30 (2H, t, J = 7.6Hz, CH 2 COOCH 3 ), 3.65 (3H, s, OCH 3 ), 4.39 ( 1H, d, J = 7.3Hz, H-1 ′), 4.51 (1H, d, J = 8.5Hz, H-1)

【0230】参考例33 8−メトキシカルボニルオクチル 2−アセトアミド−
3,4−ジ−O−アセチル−2−デオキシ−6−O−ト
リチル−β−D−グルコピラノシド(74)
Reference Example 33 8-Methoxycarbonyloctyl 2-acetamido-
3,4-di-O-acetyl-2-deoxy-6-O-trityl-β-D-glucopyranoside (74)

【0231】8−メトキシカルボニルオクチル 2−ア
セトアミド−2−デオキシ−β−D−グルコピラノシド
〔J. Am. Chem. Soc., 97, 4076-4083 (1975) 〕895
mg(2.29ミリモル)のピリジン20ml溶液を約5ml
になるまで減圧濃縮した。塩化トリチル715mg(2.
56ミリモル)を加え、室温で一晩撹拌した。水0.1
mlを加え室温で10分間撹拌した後、減圧濃縮した。残
渣にクロロホルム30mlを加え、飽和炭酸水素ナトリウ
ム30ml、水30mlで順次洗浄した。無水硫酸マグネシ
ウムで脱水後、減圧濃縮してシロップ状の化合物を得
た。ピリジン5mlおよび無水酢酸5mlを加え、室温で4
時間撹拌した。氷冷下メタノール2mlを加え20分間撹
拌した。減圧濃縮して得た残渣にクロロホルム30mlを
加え、飽和炭酸水素ナトリウム30ml、水30mlで順次
洗浄した。無水硫酸マグネシウムで脱水後、減圧濃縮し
て得たシロップをシリカゲルカラムクロマトグラフィー
(クロロホルム:メタノール=120:1)で精製して
化合物(74)1.12g(収率68.3%)を得た。
8-Methoxycarbonyloctyl 2-acetamido-2-deoxy-β-D-glucopyranoside [J. Am. Chem. Soc., 97, 4076-4083 (1975)] 895
About 5 ml of a 20 ml solution of mg (2.29 mmol) in pyridine
It was concentrated under reduced pressure until. Trityl chloride 715 mg (2.
(56 mmol) was added, and the mixture was stirred at room temperature overnight. Water 0.1
After adding ml, the mixture was stirred at room temperature for 10 minutes and then concentrated under reduced pressure. Chloroform (30 ml) was added to the residue, and the mixture was washed successively with saturated sodium hydrogen carbonate (30 ml) and water (30 ml). After dehydration over anhydrous magnesium sulfate, the mixture was concentrated under reduced pressure to obtain a syrupy compound. Add 5 ml of pyridine and 5 ml of acetic anhydride, and add 4 at room temperature.
Stirred for hours. 2 ml of methanol was added under ice cooling and the mixture was stirred for 20 minutes. Chloroform (30 ml) was added to the residue obtained by concentration under reduced pressure, and the mixture was washed successively with saturated sodium hydrogencarbonate (30 ml) and water (30 ml). The syrup obtained by dehydration over anhydrous magnesium sulfate and concentration under reduced pressure was purified by silica gel column chromatography (chloroform: methanol = 120: 1) to obtain 1.12 g of compound (74) (yield 68.3%). .

【0232】 m.p. 159〜160 ℃ 〔α〕25 D+31.8°(C 0.86, CHCl3) IR(KBr)cm-1 :1740 1H-NMR (CDCl3,δppm): 1.71(3H, s, NCOCH3), 1.94, 2.00(3H, s, OCOCH3), 2.27(2H, t, J=7.3Hz, CH2COOCH3), 3.65(3H, s, OCH3), 4.61(1H, d, J=8.3Hz, H-1), 5.51(1H, d, J=8.8Hz, NH), 7.2 〜7.3 及び7.4 〜7.5(15H, m, C6H5) Mp 159 to 160 ° C. [α] 25 D + 31.8 ° (C 0.86, CHCl 3 ) IR (KBr) cm −1 : 1740 1 H-NMR (CDCl 3 , δppm): 1.71 (3H, s, NCOCH 3 ), 1.94, 2.00 (3H, s, OCOCH 3 ), 2.27 (2H, t, J = 7.3Hz, CH 2 COOCH 3 ), 3.65 (3H, s, OCH 3 ), 4.61 (1H, d, J = 8.3Hz, H-1), 5.51 (1H, d, J = 8.8Hz, NH), 7.2 ~7.3 and 7.4 ~7.5 (15H, m, C 6 H 5)

【0233】参考例34 8−メトキシカルボニルオクチル 2−アセトアミド−
3,4−ジ−O−アセチル−2−デオキシ−β−D−グ
ルコピラノシド(75) 化合物(74)1.00g(1.39ミリモル)の酢酸
5ml溶液に、15℃で25%臭化水素の酢酸溶液1mlを
加え、1.5分間撹拌した。沈殿をろ去した後、ろ液を
氷水30mlに加え、クロロホルム10mlで3回抽出し
た。クロロホルム溶液を水30mlで洗浄した後、無水硫
酸マグネシウムで脱水後、減圧濃縮して得たシロップを
シリカゲルカラムクロマトグラフィ−(クロロホルム:
メタノール=40:1)で精製して化合物(75)49
3mg(収率74.6%)を得た。
Reference Example 34 8-Methoxycarbonyloctyl 2-acetamido-
3,4-Di-O-acetyl-2-deoxy-β-D-glucopyranoside (75) To a solution of 1.00 g (1.39 mmol) of compound (74) in 5 ml of acetic acid was added 25% hydrogen bromide at 15 ° C. 1 ml of acetic acid solution was added and stirred for 1.5 minutes. After removing the precipitate by filtration, the filtrate was added to 30 ml of ice water and extracted 3 times with 10 ml of chloroform. The chloroform solution was washed with 30 ml of water, dehydrated over anhydrous magnesium sulfate, and concentrated under reduced pressure to obtain a syrup, which was subjected to silica gel column chromatography (chloroform:
Compound (75) 49 after purification with methanol = 40: 1)
3 mg (74.6% yield) was obtained.

【0234】 m.p. 129〜130 ℃ 〔α〕25 D-11.2°(C 0.98, CHCl3) IR(KBr)cm-1 :1740 1H-NMR (CDCl3,δppm): 1.94(3H, s, NCOCH3), 2.04, 2.05(3H, s, OCOCH3), 2.30(2H, t, J=7.6Hz, CH 2 COOCH3), 3.67(3H, s, OCH3), 3.7 〜3.9(4H, m, H-2, H-5, H-6), 4.69(1H, d, J=8.3Hz, H-1), 5.00(1H, t, J=9.8Hz, H-4), 5.32(1H, t, J=9.6Hz, H-3), 5.54(1H, d, J=8.6Hz, NH)Mp 129 to 130 ° C. [α] 25 D -11.2 ° (C 0.98, CHCl 3 ) IR (KBr) cm −1 : 1740 1 H-NMR (CDCl 3 , δppm): 1.94 (3H, s, NCOCH 3 ), 2.04, 2.05 (3H, s, OCOCH 3 ), 2.30 (2H, t, J = 7.6Hz, CH 2 C OOCH 3 ), 3.67 (3H, s, OCH 3 ), 3.7 ~ 3.9 (4H, m , H-2, H-5, H-6), 4.69 (1H, d, J = 8.3Hz, H-1), 5.00 (1H, t, J = 9.8Hz, H-4), 5.32 (1H, t, J = 9.6Hz, H-3), 5.54 (1H, d, J = 8.6Hz, NH)

【0235】参考例35 8−メトキシカルボニルオクチル 2−デオキシ−3,
4−ジ−O−アセチル−6−O−(2,3,4−トリ−
O−アセチル−β−L−フコピラノシル)−2−デオキ
シ−β−D−グルコピラノシド(76)
Reference Example 35 8-methoxycarbonyloctyl 2-deoxy-3,
4-di-O-acetyl-6-O- (2,3,4-tri-
O-acetyl-β-L-fucopyranosyl) -2-deoxy-β-D-glucopyranoside (76)

【0236】1,2,3,4−テトラ−O−アセチル−
L−フコピラノース126mg(0.379ミリモル)よ
り調製した新しい2,3,4−トリ−O−アセチル−α
−L−フコピラノシルブロマイド(64)の1,2−ジ
クロロエタン8ml溶液に化合物(75)120mg(0.
252ミリモル)、銀トリフレート227mg(0.88
2ミリモル)および1,1,3,3−テトラメチル尿素
176mg(1.51ミリモル)を加え、アルゴン気流中
室温で24時間撹拌した。沈殿をろ去した後、ろ液にク
ロロホルム10mlを加え、水10mlで洗浄した。無水硫
酸マグネシウムで脱水後、減圧濃縮して得たシロップを
シリカゲルカラムクロマトグラフィー(クロロホルム:
メタノール=200:1)で精製して化合物(76)1
36mg(収率72.2%)を得た。
1,2,3,4-tetra-O-acetyl-
New 2,3,4-tri-O-acetyl-α prepared from 126 mg (0.379 mmol) L-fucopyranose
120 mg of the compound (75) (0. 0%) in 8 ml of 1,2-dichloroethane solution of -L-fucopyranosyl bromide (64).
252 mmol), silver triflate 227 mg (0.88)
2 mmol) and 176 mg (1.51 mmol) of 1,1,3,3-tetramethylurea were added, and the mixture was stirred at room temperature in an argon stream for 24 hours. After removing the precipitate by filtration, 10 ml of chloroform was added to the filtrate and the mixture was washed with 10 ml of water. Syrup obtained by dehydration over anhydrous magnesium sulfate and concentration under reduced pressure was subjected to silica gel column chromatography (chloroform:
Compound (76) 1 purified by methanol = 200: 1)
36 mg (yield 72.2%) was obtained.

【0237】 〔α〕27 D+4.5 °(C 0.81, CHCl3) IR(NaCl)cm-1:1740 1H-NMR (CDCl3,δppm): 1.19(3H, d, J=6.4Hz, H-6′), 1.92, 1.96. 1.99, 2.00, 2.10, 2.15(3H, s, COCH3), 2.29(2H, t, J=7.6Hz, CH 2 COOCH3), 5.49(1H, d, J=8.8Hz, NH), [Α] 27 D + 4.5 ° (C 0.81, CHCl 3 ) IR (NaCl) cm −1 : 1740 1 H-NMR (CDCl 3 , δppm): 1.19 (3H, d, J = 6.4Hz, H -6 ′), 1.92, 1.96. 1.99, 2.00, 2.10, 2.15 (3H, s, COCH 3 ), 2.29 (2H, t, J = 7.6H z, CH 2 C OOCH 3 ), 5.49 (1H, d, J = 8.8Hz, NH),

【0238】例 23 8−メトキシカルボニルオクチル 2−アセトアミド−
2−デオキシ−6−O−(β−L−フコピラノシル)−
β−D−グルコピラノシド(77) 化合物(76)125mg(0.167ミリモル)のメタ
ノール2ml溶液に28%ナトリウムメチラート0.04
mlを加え、室温で一晩撹拌した。アンバーライトIR−
120B(H+ 型) で中和した後、樹脂をろ去し、ろ液
を減圧濃縮して得たシロップをシリカゲルカラムクロマ
トグラフィー(クロロホルム:メタノール:水=16:
4:1)で精製して化合物(77)68.9mg(76.
7%)を得た。
Example 23 8-Methoxycarbonyloctyl 2-acetamido-
2-deoxy-6-O- (β-L-fucopyranosyl)-
β-D-Glucopyranoside (77) 28% sodium methylate 0.04 in a solution of 125 mg (0.167 mmol) of compound (76) in 2 ml of methanol.
ml was added, and the mixture was stirred at room temperature overnight. Amber Light IR-
After neutralization with 120B (H + type), the resin was filtered off, and the syrup obtained by concentrating the filtrate under reduced pressure was subjected to silica gel column chromatography (chloroform: methanol: water = 16:
4: 1) and then 68.9 mg (76.
7%).

【0239】 〔α〕27 D-16.7°(C 0.84, MeOH) IR(KBr) cm-1:3400, 1740, 1080 1H-NMR (CD3OD,δppm): 1.26(3H, d, J=6.6Hz, H-6′), 1.95(3H, s, NCOCH3), 2.30(2H, t, J=7.6Hz, CH2COOCH3), 3.7 〜3.8(2H, m, H-6), 4.24(1H, d, J=7.3Hz H- 1′), 4.40(1H, d, J=8.3Hz, H-1) [Α] 27 D -16.7 ° (C 0.84, MeOH) IR (KBr) cm -1 : 3400, 1740, 1080 1 H-NMR (CD 3 OD, δppm): 1.26 (3H, d, J = 6.6Hz, H-6 ′), 1.95 (3H, s, NCOCH 3 ), 2.30 (2H, t, J = 7.6Hz, CH 2 COOCH 3 ), 3.7 ~ 3.8 (2H, m, H-6), 4.24 (1H, d, J = 7.3Hz H-1 ′), 4.40 (1H, d, J = 8.3Hz, H-1)

【0240】参考例36 2,3,4−トリ−O−アセチル−6−0−(2,3,
4,6−テトラ−O−アセチル−α−D−ガラクトピラ
ノシル)−α−D−グルコピラノシルブロミド(アセト
ブロモメリビオース)(78)
Reference Example 36 2,3,4-tri-O-acetyl-6-0- (2,3,3
4,6-Tetra-O-acetyl-α-D-galactopyranosyl) -α-D-glucopyranosyl bromide (acetobromomelibiose) (78)

【0241】メリビオース(シグマ社製)12.5g
(36.5ミリモル)、ピリジン130mlおよび無水酢
酸38mlの溶液を室温にて24時間撹拌反応させた後、
溶媒を減圧にて留去してパーアセチルメリビオースを得
た。得たパーアセチルメリビオースを酢酸50mlに溶解
し、25%臭化水素−酢酸溶液20mlを加え、室温で2
4時間撹拌した。反応終了後、クロロホルム200mlを
加え、反応液を氷水300mlに注ぎ、よく撹拌した後分
液ロートに移してクロロホルム相を分離し、水、飽和重
曹水、飽和食塩水で順次洗浄した。得たクロロホルム溶
液を無水硫酸マグネシウムで乾燥した後、減圧下に溶媒
を留去して粗ブロミドを得た。これをシリカゲルカラム
クロマトグラフィー(酢酸エチル:ヘキサン=1:1)
で精製して無色キャラメル状の精製アセトブロモメリビ
オース(78)14.7g(収率60%)を得た。
12.5 g of melibiose (manufactured by Sigma)
(36.5 mmol), pyridine (130 ml) and acetic anhydride (38 ml) were stirred and reacted at room temperature for 24 hours.
The solvent was distilled off under reduced pressure to obtain peracetyl melibiose. The peracetylmelibiose obtained was dissolved in 50 ml of acetic acid, 20 ml of 25% hydrogen bromide-acetic acid solution was added, and the mixture was stirred at room temperature for 2
Stir for 4 hours. After completion of the reaction, 200 ml of chloroform was added, the reaction mixture was poured into 300 ml of ice water, stirred well, transferred to a separating funnel, and the chloroform phase was separated, and washed successively with water, saturated aqueous sodium hydrogen carbonate and saturated brine. After the obtained chloroform solution was dried over anhydrous magnesium sulfate, the solvent was distilled off under reduced pressure to obtain crude bromide. Silica gel column chromatography (ethyl acetate: hexane = 1: 1)
To give 14.7 g (yield 60%) of colorless acetambromomelobiose (78) in the form of a colorless caramel.

【0242】 〔α〕20 D+178.5 °(C 1.27, CHCl3) IR(CHCl3)cm-1 :1750(OAc) 1H-NMR (CDCl3,δppm): 1.99(3H, s, OAc), 2.04(3H, s, OAc), 2.05(3H, s, OAc), 2.07(3H, s, OAc), 2.10(3H, s, OAc), 2.12(3H, s, OAc), 2.14(3H, s, OAc), 3.52〜3.82(2H, m), 4.00〜4.36(4H, m), 4.79(1H, dd), 5.00〜5.20(3H, m), 5.34(1H, dd), 5.47(1H, dd), 5.56(1H, t), 6.59(1H, d, J=3.9Hz, H-1) [Α] 20 D +178.5 ° (C 1.27, CHCl 3 ) IR (CHCl 3 ) cm −1 : 1750 (OAc) 1 H-NMR (CDCl 3 , δppm): 1.99 (3H, s, OAc) , 2.04 (3H, s, OAc), 2.05 (3H, s, OAc), 2.07 (3H, s, OAc), 2.10 (3H, s, OAc), 2.12 (3H, s, OAc), 2.14 (3H, s, OAc), 3.52 ~ 3.82 (2H, m), 4.00 ~ 4.36 (4H, m), 4.79 (1H, dd), 5.00 ~ 5.20 (3H, m), 5.34 (1H, dd), 5.47 (1H, dd), 5.56 (1H, t), 6.59 (1H, d, J = 3.9Hz, H-1)

【0243】参考例37 3,4−ジ−O−アセチル−6−O−(2,3,4,6
−テトラ−O−アセチル−α−D−ガラクトピラノシ
ル)グルカール(79) アセトブロモメリビオース(78)4g(5.7ミリモ
ル)、酢酸25mlおよび水25mlの溶液を0〜5℃に冷
却下、亜鉛粉末8gを加え、4時間そのまま撹拌反応さ
せた。反応終了後セライトろ過して不溶物を除き、ろ液
を水に注ぎ析出物を酢酸エチルで抽出した。酢酸エチル
相を分離、水洗を繰り返し、飽和食塩水で洗浄した後無
水硫酸マグネシウムにて乾燥した。溶媒留去後得られた
粗生成物2.7gをフラッシュクロマトグラフィー(酢
酸エチル:ヘキサン=1:2)にて精製して1.32g
(収率41.3%)のグリカール(79)を得た。
Reference Example 37 3,4-di-O-acetyl-6-O- (2,3,4,6
-Tetra-O-acetyl-α-D-galactopyranosyl) glucal (79) Acetobromomelibiose (78) 4 g (5.7 mmol), a solution of acetic acid 25 ml and water 25 ml was cooled to 0-5 ° C. Below, 8 g of zinc powder was added, and the mixture was stirred and reacted for 4 hours. After completion of the reaction, insoluble matter was removed by filtration through Celite, and the filtrate was poured into water and the precipitate was extracted with ethyl acetate. The ethyl acetate phase was separated, washed with water repeatedly, washed with saturated brine, and then dried over anhydrous magnesium sulfate. The crude product (2.7 g) obtained after the solvent was distilled off was purified by flash chromatography (ethyl acetate: hexane = 1: 2) to give 1.32 g.
Glycal (79) was obtained (yield 41.3%).

【0244】 m.p.106 〜107 ℃ 〔α〕20 D+83.8°(C 1.00, CHCl3) IR(CHCl3)cm-1 :1740(OAc), 1650(C=C) 1H-NMR (CDCl3,δppm): 1.99(3H, s, OAc), 2.05(6H, s, OAc × 2), 2.10(3H, s, OAc), 2.11(3H, s, OAc), 2.14(3H, s, OAc), 3.60〜3.92(2H, m), 4.00〜4.12(2H, m), 4.16〜4.32(2H, m), 4.80〜4.88(1H, q), 5.00〜5.40(5H, m), 5.47(1H, d, J=3.4Hz, H-1´), 6.48(1H, d, J=7.3Hz, -OCH=CH-)Mp 106-107 ° C. [α] 20 D + 83.8 ° (C 1.00, CHCl 3 ) IR (CHCl 3 ) cm −1 : 1740 (OAc), 1650 (C = C) 1 H-NMR (CDCl 3 , δppm): 1.99 (3H, s, OAc), 2.05 (6H, s, OAc x 2), 2.10 (3H, s, OAc), 2.11 (3H, s, OAc), 2.14 (3H, s, OAc), 3.60 ~ 3.92 (2H, m), 4.00 ~ 4.12 (2H, m), 4.16 ~ 4.32 (2H, m), 4.80 ~ 4.88 (1H, q), 5.00 ~ 5.40 (5H, m), 5.47 (1H, d , J = 3.4Hz, H-1 '), 6.48 (1H, d, J = 7.3Hz, -OC H = CH-)

【0245】参考例38 1,3,4−トリ−O−アセチル−6−O−(2,3,
4,6−テトラ−O−アセチル−α−D−ガラクトピラ
ノシル)−2−アジド−2−デオキシ−α−D−グルコ
ピラノ−ス(80)及び1,3,4−トリ−O−アセチ
ル−6−O−(2,3,4,6−テトラ−O−アセチル
−α−D−ガラクトピラノシル)−2−アジド−2−デ
オキシ−α−D−マンノピラノース(82)
Reference Example 38 1,3,4-tri-O-acetyl-6-O- (2,3,3
4,6-Tetra-O-acetyl-α-D-galactopyranosyl) -2-azido-2-deoxy-α-D-glucopyranose (80) and 1,3,4-tri-O-acetyl -6-O- (2,3,4,6-tetra-O-acetyl-α-D-galactopyranosyl) -2-azido-2-deoxy-α-D-mannopyranose (82)

【0246】グリカール(79)6.8g(12.2ミ
リモル)をアセトニトリル70mlに溶解し、これをナト
リウムアジド1.2g(18.8ミリモル)および硝酸
セリウムアンモニウム20g(36.5ミリモル)の混
合物に−20℃にて滴下し激しく撹拌した。5時間反応
させた後、反応液にエーテル100mlおよび水50mlを
加えてよく振り、エーテル相を分離し、水、飽和食塩水
にて順次洗浄した。エーテル留去後、得た粗生成物7.
48gをフラッシュクロマトグラフィー(酢酸エチル:
ヘキサン=3:2)で分離精製し、4.15g(51.
5%)のアジド化合物を得た。これを酢酸25mlに溶解
し、酢酸ナトリウム1.23gを加えて100℃で2時
間反応させた。反応終了後、塩化メチレン300mlおよ
び水30mlを加えてよく振った後、塩化メチレン相を分
離し、飽和重曹水、飽和食塩水で順次洗浄した。硫酸マ
グネシウムで乾燥した後、減圧にて溶媒を留去して得た
粗生成物をフラッシュクロマトグラフィー(酢酸エチ
ル:ヘキサン=1:1)にて精製して、化合物(80)
を2.35g(収率49.2%)、化合物(82)を
1.55g(収率32.4%)をそれぞれ得た。
6.8 g (12.2 mmol) of glycal (79) was dissolved in 70 ml of acetonitrile and this was added to a mixture of 1.2 g (18.8 mmol) of sodium azide and 20 g (36.5 mmol) of ammonium cerium nitrate. The mixture was added dropwise at -20 ° C and vigorously stirred. After reacting for 5 hours, 100 ml of ether and 50 ml of water were added to the reaction solution and shaken well, the ether phase was separated, and washed successively with water and saturated brine. Crude product obtained after distilling off ether 7.
48 g flash chromatography (ethyl acetate:
Separation and purification with hexane = 3: 2), 4.15 g (51.
5%) of the azide compound was obtained. This was dissolved in 25 ml of acetic acid, 1.23 g of sodium acetate was added, and the mixture was reacted at 100 ° C for 2 hours. After completion of the reaction, 300 ml of methylene chloride and 30 ml of water were added and shaken well, the methylene chloride phase was separated, and washed successively with saturated aqueous sodium hydrogen carbonate and saturated brine. After drying over magnesium sulfate, the solvent was distilled off under reduced pressure and the obtained crude product was purified by flash chromatography (ethyl acetate: hexane = 1: 1) to give compound (80).
To give 2.35 g (yield 49.2%) of Compound (82) and 1.55 g (yield 32.4%), respectively.

【0247】 化合物(80)〔α〕20 D+145.2 °(C 1.00, CHCl3) IR(Nujol)cm-1 : 2120(N3), 1750(OAc) 1H-NMR (CDCl3,δppm): 1.99(3H, s, OAc), 2.05(3H, s, OAc), 2.06(3H, s, OAc), 2.10(3H, s, OAc), 2.11(3H, s, OAc), 2.14(3H, s, OAc), 2.21(3H, s, OAc), 3.50〜3.80(3H, m), 3.92〜4.24(4H, m), 4.96〜5.20(3H, m), 5.24〜5.56(3H, m), 6.25(1H, d, J=3.9Hz, H-1) Compound (80) [α] 20 D +145.2 ° (C 1.00, CHCl 3 ) IR (Nujol) cm −1 : 2120 (N 3 ), 1750 (OAc) 1 H-NMR (CDCl 3 , δppm) : 1.99 (3H, s, OAc), 2.05 (3H, s, OAc), 2.06 (3H, s, OAc), 2.10 (3H, s, OAc), 2.11 (3H, s, OAc), 2.14 (3H, s, OAc), 2.21 (3H, s, OAc), 3.50 ~ 3.80 (3H, m), 3.92 ~ 4.24 (4H, m), 4.96 ~ 5.20 (3H, m), 5.24 ~ 5.56 (3H, m), 6.25 (1H, d, J = 3.9Hz, H-1)

【0248】 化合物(82)〔α〕20 D+135.8 °(C 0.66, CHCl3) IR(Nujol)cm-1 : 2120(N3), 1750(OAc) 1H-NMR (CDCl3,δppm): 1.99(3H, s, OAc), 2.06(3H, s, OAc), 2.07(3H, s, OAc), 2.12(6H, s, OAc × 2), 2.14(3H, s, OAc), 2.19(3H, s, OAc), 3.50〜3.80(2H, m), 3.88〜4.32(5H, m), 5.00〜5.20(2H, m), 5.20〜5.40(3H, m), 5.45(1H, d, J=3.4Hz, H-1′), 6.04(1H, d, J=2.0Hz, H-1) Compound (82) (α) 20 D +135.8 ° (C 0.66, CHCl 3 ) IR (Nujol) cm −1 : 2120 (N 3 ), 1750 (OAc) 1 H-NMR (CDCl 3 , δppm) : 1.99 (3H, s, OAc), 2.06 (3H, s, OAc), 2.07 (3H, s, OAc), 2.12 (6H, s, OAc x 2), 2.14 (3H, s, OAc), 2.19 ( 3H, s, OAc), 3.50 ~ 3.80 (2H, m), 3.88 ~ 4.32 (5H, m), 5.00 ~ 5.20 (2H, m), 5.20 ~ 5.40 (3H, m), 5.45 (1H, d, J = 3.4Hz, H-1 ′), 6.04 (1H, d, J = 2.0Hz, H-1)

【0249】参考例39 2−アジド−2−デオキシ−3,4−ジ−O−アセチル
−6−O−(2,3,4,6−テトラ−O−アセチル−
α−D−ガラクトピラノシル)−α−Dーグルコピラノ
シルブロマイド(81)
Reference Example 39 2-Azido-2-deoxy-3,4-di-O-acetyl-6-O- (2,3,4,6-tetra-O-acetyl-
α-D-galactopyranosyl) -α-D-glucopyranosyl bromide (81)

【0250】化合物(80)2.3g(3.47ミリモ
ル)、塩化メチレン35mlおよび酢酸エチル3.5mlの
溶液に四臭化チタン1.92g(5.2ミリモル)を加
え、室温で24時間撹拌反応させた。反応終了後、反応
液をロートに移し塩化メチレン100mlおよび飽和重曹
水20mlを加えてよく振り、塩化メチレン相を分離し
た。水、飽和食塩水の順で洗浄し、無水硫酸マグネシウ
ムで乾燥後、溶媒を減圧留去して粗生成物2.37gを
得た。これをフラッシュクロマトグラフィー(シリカゲ
ル40g、溶媒系、酢酸エチル:ヘキサン=3:2)に
て精製して無色キャラメル状の臭化物(81)1.2g
(収率50.6%)を得た。
Titanium tetrabromide (1.92 g, 5.2 mmol) was added to a solution of the compound (80) (2.3 g, 3.47 mmol), methylene chloride (35 ml) and ethyl acetate (3.5 ml), and the mixture was stirred at room temperature for 24 hours. It was made to react. After completion of the reaction, the reaction solution was transferred to a funnel, 100 ml of methylene chloride and 20 ml of saturated aqueous sodium hydrogen carbonate were added and shaken well, and the methylene chloride phase was separated. The organic layer was washed with water and saturated brine in that order, dried over anhydrous magnesium sulfate, and then the solvent was distilled off under reduced pressure to obtain 2.37 g of a crude product. This was purified by flash chromatography (silica gel 40 g, solvent system, ethyl acetate: hexane = 3: 2) to obtain 1.2 g of colorless caramel bromide (81).
(Yield 50.6%) was obtained.

【0251】 〔α〕20 D+191.6 °(C 0.64, CHCl3) IR(Nujol) cm-1: 2120(N3), 1750(OAc) 1H-NMR (CDCl3,δppm): 1.99(3H, s, OAc), 2.05(3H, s, OAc), 2.07(3H, s, OAc), 2.10(3H, s, OAc), 2.12(3H, s, OAc), 2.14(3H, s, OAc), 3.52〜3.80(3H, m), 3.92〜4.32(4H, m), 4.96〜5.20(3H, m), 5.24〜5.52(3H, m), 6.39(1H, d, J=3.4Hz, H-1) [Α] 20 D +191.6 ° (C 0.64, CHCl 3 ) IR (Nujol) cm −1 : 2120 (N 3 ), 1750 (OAc) 1 H-NMR (CDCl 3 , δppm): 1.99 (3H , s, OAc), 2.05 (3H, s, OAc), 2.07 (3H, s, OAc), 2.10 (3H, s, OAc), 2.12 (3H, s, OAc), 2.14 (3H, s, OAc) , 3.52 ~ 3.80 (3H, m), 3.92 ~ 4.32 (4H, m), 4.96 ~ 5.20 (3H, m), 5.24 ~ 5.52 (3H, m), 6.39 (1H, d, J = 3.4Hz, H- 1)

【0252】参考例40 3,4−ジ−O−アセチル−6−O−(2,3,4,6
−テトラ−O−アセチル−α−D−ガラクトピラノシ
ル)−2−アジド−2−デオキシ−α−D−マンノピラ
ノシルブロマイド(83)
Reference Example 40 3,4-di-O-acetyl-6-O- (2,3,4,6
-Tetra-O-acetyl-α-D-galactopyranosyl) -2-azido-2-deoxy-α-D-mannopyranosyl bromide (83)

【0253】参考例39に記載した方法により、化合物
(82)1.5g(2.27ミリモル)、塩化メチレン
25mlおよび酢酸エチル2.5mlの溶液に四臭化チタン
1.25g(3.4ミリモル)を加えることにより、臭
化物(83)を透明油状物として得た。これはやがて結
晶し、酢酸エチル−ヘキサンにて洗浄後乾燥して無色結
晶として化合物(83)1.1g(収率71%)を得
た。
According to the method described in Reference Example 39, a solution of 1.5 g (2.27 mmol) of the compound (82), 25 ml of methylene chloride and 2.5 ml of ethyl acetate was added with 1.25 g of titanium tetrabromide (3.4 mmol). B) (83) was obtained as a clear oil. This was crystallized in time, washed with ethyl acetate-hexane and then dried to obtain 1.1 g (yield 71%) of compound (83) as colorless crystals.

【0254】 m.p.146 〜148 ℃(分解)、 〔α〕20 D+201.4 °(C 0.86, CHCl3) IR(Nujol)cm-1 : 2120(N3), 1750(OAc) 1H-NMR (CDCl3,δppm): 1.99(3H, s, OAc), 2.06(3H, s, OAc), 2.09(3H, s, OAc), 2.11(3H, s, OAc), 2.13(3H, s, OAc), 2.14(3H, s, OAc), 3.52〜3.80(2H, m), 3.96〜4.24(4H, m), 4.32(1H, q), 5.04〜5.20(2H, m), 5.24〜5.48(3H, m), 5.704(1H, q), 6.33(1H, d, J=1.0Hz, H-1) Mp146-148 ° C. (decomposition), [α] 20 D + 201.4 ° (C 0.86, CHCl 3 ) IR (Nujol) cm −1 : 2120 (N 3 ), 1750 (OAc) 1 H-NMR (CDCl 3 , δppm): 1.99 (3H, s, OAc), 2.06 (3H, s, OAc), 2.09 (3H, s, OAc), 2.11 (3H, s, OAc), 2.13 (3H, s, OAc), 2.14 (3H, s, OAc), 3.52 ~ 3.80 (2H, m), 3.96 ~ 4.24 (4H, m), 4.32 (1H, q), 5.04 ~ 5.20 (2H, m), 5.24 ~ 5.48 (3H, m ), 5.704 (1H, q), 6.33 (1H, d, J = 1.0Hz, H-1)

【0255】参考例41 8−メトキシカルボニルオクチル 3,4−ジ−O−ア
セチル−6−O−(2,3,4,6−テトラ−O−アセ
チル−α−D−ガラクトピラノシル)−2−アジド−2
−デオキシ−β−D−グルコピラノシド(86)
Reference Example 41 8-Methoxycarbonyloctyl 3,4-di-O-acetyl-6-O- (2,3,4,6-tetra-O-acetyl-α-D-galactopyranosyl)- 2-azido-2
-Deoxy-β-D-glucopyranoside (86)

【0256】8−メトキシカルボニルオクタノール38
0mg(2.0ミリモル)、ドライライト400mg、炭酸
銀310mg(1.12ミリモル)およびクロロホルム7
mlの混合物をアルゴン気流下室温にて1時間撹拌した。
次に臭化物(81)682mg(1.0ミリモル)のクロ
ロホルム3mlの溶液をゆっくり滴加し、その後室温で4
時間撹拌した。反応終了後、セライトろ過し、ろ液を減
圧にて留去して透明油状物を1.07g得た。これをフ
ラッシュクロマトグラフィー(酢酸エチル:ヘキサン=
2:3)で精製して478mg(収率60.5%)の化合
物(86)を得た。
8-Methoxycarbonyloctanol 38
0 mg (2.0 mmol), drylite 400 mg, silver carbonate 310 mg (1.12 mmol) and chloroform 7
The ml mixture was stirred at room temperature under an argon stream for 1 hour.
Then a solution of 682 mg (1.0 mmol) of bromide (81) in 3 ml of chloroform was slowly added dropwise, after which 4
Stirred for hours. After the reaction was completed, the mixture was filtered through Celite, and the filtrate was distilled off under reduced pressure to obtain 1.07 g of a transparent oily substance. This is flash chromatographed (ethyl acetate: hexane =
It was purified by 2: 3) to obtain 478 mg (yield 60.5%) of the compound (86).

【0257】 〔α〕20 D+103.2 °(C 0.62, CHCl3) IR(CHCl3)cm-1 : 2120(N3), 1750(OAc, CO2CH3) 1H-NMR (CDCl3,δppm): 1.20〜1.44(8H, broad, s), 1.50〜1.72(6H, broad, m), 1.99(3H, s, OAc), 2.03(3H, s, OAc), 2.05(3H, s, OAc), 2.08(3H, s, OAc), 2.11(3H, s, OAc), 2.24(3H, s, OAc), 2.30(2H, t, CH2CO2CH3), 3.30〜3.80(5H, m), 3.67(3H, s, CO2 CH 3 ), 3.80〜3.96(1H, m), 4.00〜4.28(3H, m), 4.38(1H, d, J=7.8Hz, H-1), 4.88〜5.20(4H, m), 5.24〜5.36(1H, dd), 5.44(1H, d, J=2.4Hz, H-1′) [Α] 20 D +103.2 ° (C 0.62, CHCl 3 ) IR (CHCl 3 ) cm −1 : 2120 (N 3 ), 1750 (OAc, CO 2 CH 3 ) 1 H-NMR (CDCl 3 , δppm): 1.20 ~ 1.44 (8H, broad, s), 1.50 ~ 1.72 (6H, broad, m), 1.99 (3H, s, OAc), 2.03 (3H, s, OAc), 2.05 (3H, s, OAc ), 2.08 (3H, s, OAc), 2.11 (3H, s, OAc), 2.24 (3H, s, OAc), 2.30 (2H, t, CH 2 CO 2 CH 3 ), 3.30 ~ 3.80 (5H, m ), 3.67 (3H, s, CO 2 CH 3 ) , 3.80 ~ 3.96 (1H, m), 4.00 ~ 4.28 (3H, m), 4.38 (1H, d, J = 7.8Hz, H-1), 4.88 ~ 5.20 (4H, m), 5.24 ~ 5.36 (1H, dd), 5.44 (1H, d, J = 2.4Hz, H-1 ')

【0258】参考例42 8−メトキシカルボニルオクチル 3,4−ジ−O−ア
セチル−6−O−(2,3,4,6−テトラ−O−アセ
チル−α−D−ガラクトピラノシル)−2−アジド−2
−デオキシ−α−D−マンノピラノシド(84)
Reference Example 42 8-Methoxycarbonyloctyl 3,4-di-O-acetyl-6-O- (2,3,4,6-tetra-O-acetyl-α-D-galactopyranosyl)- 2-azido-2
-Deoxy-α-D-mannopyranoside (84)

【0259】参考例41に記載した方法により、8−メ
トキシカルボニルオクタノール380mg(2.0ミリモ
ル)、ドライライト400mg、炭酸銀310mg(1.1
2ミリモル)およびクロロホルム7mlの混合物に臭化物
(83)682mg(1.0ミリモル)のクロロホルム3
mlの溶液をゆっくり滴下して238mg(収率30.1
%)の化合物(84)を得た。
By the method described in Reference Example 41, 380 mg (2.0 mmol) of 8-methoxycarbonyloctanol, 400 mg of drylite, 310 mg of silver carbonate (1.1
Bromide (83) 682 mg (1.0 mmol) chloroform 3 in a mixture of 2 mmol) and 7 ml chloroform.
238 mg (yield 30.1
%) Of compound (84).

【0260】 〔α〕20 D+141.6 °(C 0.74, CHCl3) IR(CHCl3)cm-1 : 2120(N3), 1750(OAc, CO2CH3) 1H-NMR (CDCl3,δppm): 1.20〜1.44(8H, broad, s), 1.48〜1.70(6H, broad, m), 1.98(3H, s, OAc), 2.06(3H, s, OAc), 2.07(3H, s, OAc), 2.09(3H, s, OAc), 2.12(3H, s, OAc), 2.14(3H, s, OAc), 2.31(2H, t, CH 2 CO2CH3), 3.30〜3.80(3H, m), 3.67(3H, s, CO2 CH 3 ), 3.80〜3.92(1H, m), 3.92〜4.32(5H, m), 4.76(1H, d, J=1.5Hz, H-1), 5.00〜5.48(6H, m) [Α] 20 D +141.6 ° (C 0.74, CHCl 3 ) IR (CHCl 3 ) cm −1 : 2120 (N 3 ), 1750 (OAc, CO 2 CH 3 ) 1 H-NMR (CDCl 3 , δppm): 1.20 ~ 1.44 (8H, broad, s), 1.48 ~ 1.70 (6H, broad, m), 1.98 (3H, s, OAc), 2.06 (3H, s, OAc), 2.07 (3H, s, OAc ), 2.09 (3H, s, OAc), 2.12 (3H, s, OAc), 2.14 (3H, s, OAc), 2.31 (2H, t, CH 2 C O 2 CH 3 ), 3.30 ~ 3.80 (3H, m), 3.67 (3H, s, CO 2 CH 3 ) , 3.80 ~ 3.92 (1H, m), 3.92 ~ 4.32 (5H, m), 4.76 (1H, d, J = 1.5Hz, H-1), 5.00 ~ 5.48 (6H, m)

【0261】参考例43 8−メトキシカルボニルオクチル 3,4−ジ−O−ア
セチル−6−O−(2,3,4,6−テトラ−O−アセ
チル−α−D−ガラクトピラノシル)−2−アセトアミ
ド−2−デオキシ−β−D−グルコピラノシド(87)
Reference Example 43 8-Methoxycarbonyloctyl 3,4-di-O-acetyl-6-O- (2,3,4,6-tetra-O-acetyl-α-D-galactopyranosyl)- 2-acetamido-2-deoxy-β-D-glucopyranoside (87)

【0262】化合物(86)450mg(0.57ミリモ
ル)、酢酸エチル7mlおよび無水酢酸5mlの溶液に10
%パラジウム−炭素触媒400mgを加え、水素気流下に
8時間撹拌した。反応終了後ろ過して触媒を除き、ろ液
を減圧にて留去し、残留物をピリジン10ml、および無
水酢酸1mlに溶解し5時間撹拌した。溶液を減圧にて留
去し得た粗生成物をフラッシュクロマトグラフィー(酢
酸エチル:ヘキサン=3:2)で精製して、化合物(8
7)を125mg(収率27.2%)得た。
To a solution of 450 mg (0.57 mmol) of compound (86), 7 ml of ethyl acetate and 5 ml of acetic anhydride was added 10 parts.
% Palladium-carbon catalyst (400 mg) was added, and the mixture was stirred under a hydrogen stream for 8 hours. After completion of the reaction, the catalyst was removed by filtration, the filtrate was evaporated under reduced pressure, and the residue was dissolved in 10 ml of pyridine and 1 ml of acetic anhydride and stirred for 5 hours. The solution was evaporated under reduced pressure and the obtained crude product was purified by flash chromatography (ethyl acetate: hexane = 3: 2) to give compound (8
125 mg (yield 27.2%) of 7) was obtained.

【0263】 〔α〕20 D+68.3°(C 1.00, CHCl3) IR(CHCl3)cm-1 : 3440(NH),1750(OAc, CO2CH3), 1680(NHCOCH3) 1H-NMR (CDCl3,δppm): 1.10〜1.40(8H, broad, s), 1.44〜1.72(6H, broad, m), 1.94(3H, s, Ac), 1.99(3H, s, Ac), 2.03(3H, s, Ac), 2.04(3H, s, Ac), 2.05(3H, s, Ac), 2.12(3H, s, Ac), 2.14(3H, s, Ac), 2.30(2H, t, CH 2 CO2CH3), 3.30〜3.90(5H, m), 3.67(3H, s, CO2 CH 3 ), 3.96〜4.12(2H, m), 4.16〜4.32(1H, m), 4.62(1H, d, J=8.3Hz,H-1), 4.90〜5.36(4H, m), 5.45(1H, d, J=2.5Hz,), 5.52(1H, d, J=8.8Hz, NH)[Α] 20 D + 68.3 ° (C 1.00, CHCl 3 ) IR (CHCl 3 ) cm −1 : 3440 (NH), 1750 (OAc, CO 2 CH 3 ), 1680 (NHCOCH 3 ) 1 H- NMR (CDCl 3 , δppm): 1.10 to 1.40 (8H, broad, s), 1.44 to 1.72 (6H, broad, m), 1.94 (3H, s, Ac), 1.99 (3H, s, Ac), 2.03 ( 3H, s, Ac), 2.04 (3H, s, Ac), 2.05 (3H, s, Ac), 2.12 (3H, s, Ac), 2.14 (3H, s, Ac), 2.30 (2H, t, CH 2 C O 2 CH 3 ), 3.30 to 3.90 (5H, m), 3.67 (3H, s, CO 2 CH 3 ) , 3.96 to 4.12 (2H, m), 4.16 to 4.32 (1H, m), 4.62 (1H , d, J = 8.3Hz, H-1), 4.90 ~ 5.36 (4H, m), 5.45 (1H, d, J = 2.5Hz,), 5.52 (1H, d, J = 8.8Hz, NH)

【0264】参考例44 8−メトキシカルボニルオクチル 3,4−ジ−O−ア
セチル−6−O−(2,3,4,6−テトラ−O−アセ
チル−α−D−ガラクトピラノシル)−2−アセトアミ
ド−2−デオキシ−α−D−マンノピラノシド(85)
Reference Example 44 8-Methoxycarbonyloctyl 3,4-di-O-acetyl-6-O- (2,3,4,6-tetra-O-acetyl-α-D-galactopyranosyl)- 2-acetamido-2-deoxy-α-D-mannopyranoside (85)

【0265】参考例43に記載した方法に準じて、化合
物(84)200mg(0.25ミリモル)を10%パラ
ジウム−炭素触媒300mgの存在下に、還元して無色の
キャラメル状の化合物(85)を86mg(収率42.1
%)得た。
According to the method described in Reference Example 43, 200 mg (0.25 mmol) of compound (84) was reduced in the presence of 300 mg of 10% palladium-carbon catalyst to give a colorless caramel compound (85). 86 mg (yield 42.1
%)Obtained.

【0266】 〔α〕20 D+113.14°(C 1.59, CHCl3) IR(CHCl3)cm-1 : 3400(NH), 1750(OAc, CO2CH3),1680(NHCOCH3) 1H-NMR (CDCl3,δppm): 1.20〜1.44(8H, broad, s), 1.48〜1.76(6H, broad, m), 1.98(3H, s, Ac), 2.00(3H, s, Ac), 2.05(3H, s, Ac), 2.07(3H, s, Ac), 2.08(3H, s, Ac), 2.15(3H, s, AC), 2.16(3H, s, Ac), 2.31(2H, t, J=7.3Hz, CH 2 CO2CH3), 3.30〜3.46(1H, m), 3.50〜3.76(1H, m), 3.67(3H, s, CO2 CH 3 ), 3.80〜3.94(1H, m), 3.98〜4.32(3H, m), 4.52〜4.68(2H, m), 4.92〜5.12(2H, m), 5.24〜5.50(4H, m), 6.30(1H, d, J=9.3Hz, NH)[Α] 20 D + 113.14 ° (C 1.59, CHCl 3 ) IR (CHCl 3 ) cm −1 : 3400 (NH), 1750 (OAc, CO 2 CH 3 ), 1680 (NHCOCH 3 ) 1 H- NMR (CDCl 3 , δppm): 1.20 to 1.44 (8H, broad, s), 1.48 to 1.76 (6H, broad, m), 1.98 (3H, s, Ac), 2.00 (3H, s, Ac), 2.05 ( 3H, s, Ac), 2.07 (3H, s, Ac), 2.08 (3H, s, Ac), 2.15 (3H, s, AC), 2.16 (3H, s, Ac), 2.31 (2H, t, J = 7.3Hz, CH 2 C O 2 CH 3), 3.30~3.46 (1H, m), 3.50~3.76 (1H, m), 3.67 (3H, s, CO 2 CH 3), 3.80~3.94 (1H, m ), 3.98 ~ 4.32 (3H, m), 4.52 ~ 4.68 (2H, m), 4.92 ~ 5.12 (2H, m), 5.24 ~ 5.50 (4H, m), 6.30 (1H, d, J = 9.3Hz, NH )

【0267】例 24 8−メトキシカルボニルオクチル 2−アセトアミド−
2−デオキシ−6−O−(α−D−ガラクトピラノシ
ル)−β−D−グルコピラノシド(88) 化合物(87)100mg(0.124ミリモル)のメタ
ノール2mlの溶液に、28%ナトリウムメトキシド−メ
タノール溶液0.05mlを加え、21時間撹拌反応させ
た。反応終了後、アンバーライトIR−120樹脂−メ
タノール3mlを加え、30分撹拌した後、ろ過して樹脂
を除き、ろ液を減圧留去して62.8mg(収率91.4
%)の脱アセチル体(88)を得た。
Example 24 8-Methoxycarbonyloctyl 2-acetamido-
2-deoxy-6-O- (α-D-galactopyranosyl) -β-D-glucopyranoside (88) A solution of 100 mg (0.124 mmol) of compound (87) in 2 ml of methanol was mixed with 28% sodium methoxide. -Methanol solution (0.05 ml) was added and the reaction was allowed to stir for 21 hours. After completion of the reaction, 3 ml of Amberlite IR-120 resin-methanol was added, stirred for 30 minutes, filtered to remove the resin, and the filtrate was evaporated under reduced pressure to obtain 62.8 mg (yield 91.4
%) Deacetylated product (88) was obtained.

【0268】 〔α〕20 D+47.7°(C 1.26, MeOH) IR(CHCl3)cm-1 : 3400, 1730(CO2CH3), 1650(NHAc) 1H-NMR (CDCl3-CD3OD,δppm): 1.20〜1.40(8H, broad, s), 1.50〜1.65(4H, m), 1.98(3H, s, NHAc), 2.31(2H, t, CH 2 CO2CH3), 3.40〜3.50(4H, m), 3.60〜3.65(1H, m), 3.66(3H, s, CO2 CH 3 ), 3.68〜3.78(5H, m), 3.80〜3.90(2H, m), 3.92(1H, broad, s), 4.03(1H, dd), 4.43(1H, d, J=8.3Hz, H-1), 4.89(1H, broad, s, H-1′) [Α] 20 D + 47.7 ° (C 1.26, MeOH) IR (CHCl 3 ) cm −1 : 3400, 1730 (CO 2 CH 3 ), 1650 (NHAc) 1 H-NMR (CDCl 3 -CD 3 OD, δppm): 1.20 ~ 1.40 (8H, broad, s), 1.50 ~ 1.65 (4H, m), 1.98 (3H, s, NHAc), 2.31 (2H, t, CH 2 C O 2 CH 3 ), 3.40 ~ 3.50 (4H, m), 3.60 ~ 3.65 (1H, m), 3.66 (3H, s, CO 2 CH 3 ) , 3.68 ~ 3.78 (5H, m), 3.80 ~ 3.90 (2H, m), 3.92 (1H , broad, s), 4.03 (1H, dd), 4.43 (1H, d, J = 8.3Hz, H-1), 4.89 (1H, broad, s, H-1 ')

【0269】例 25 8−メトキシカルボニルオクチル 2−アセトアミド−
2−デオキシ−6−O−(α−D−ガラクトピラノシ
ル)−α−D−マンノピラノシド(89) 例24に記載した方法に準じて、化合物(85)235
mg(0.29ミリモル)を脱アセチル化して140.3
mg(86.9%)の脱アセチル体(89)を得た。
Example 25 8-Methoxycarbonyloctyl 2-acetamido-
2-Deoxy-6-O- (α-D-galactopyranosyl) -α-D-mannopyranoside (89) Compound (85) 235 was prepared according to the method described in Example 24.
140.3 of deacetylation of mg (0.29 mmol)
mg (86.9%) of deacetylated product (89) was obtained.

【0270】 〔α〕20 D+91.8°(C 0.4, MeOH) IR(CHCl3) cm-1 : 3400, 1730(CO2CH3), 1650(NHAc) 1H-NMR (CDCl3,δppm): 1,28〜1.40(8H, broad, s), 1.55〜1.70(4H, m), 2.03(3H, s, NHAc), 2.32(2H, t, J=7.6Hz,CH 2 CO2CH3), 3.36〜3.42(1H, m), 3.62〜3.69(2H, m), 3.67(3H, s, CO2 CH 3 ), 3.69〜3.79(4H, m), 3.79〜3.84(2H, m), 3.90〜3.94(2H, m), 3.920(1H, dd), 4.04(1H, dd), 4.30(1H, dd), 4.69(1H, d, J=1.0Hz, H-1), 4.99(1H, d, J=3.2Hz, H-1′) [Α] 20 D + 91.8 ° (C 0.4, MeOH) IR (CHCl 3 ) cm −1 : 3400, 1730 (CO 2 CH 3 ), 1650 (NHAc) 1 H-NMR (CDCl 3 , δppm) : 1,28 ~ 1.40 (8H, broad, s), 1.55 ~ 1.70 (4H, m), 2.03 (3H, s, NHAc), 2.32 (2H, t, J = 7.6Hz, CH 2 C O 2 CH 3 ), 3.36 ~ 3.42 (1H, m), 3.62 ~ 3.69 (2H, m), 3.67 (3H, s, CO 2 CH 3 ) , 3.69 ~ 3.79 (4H, m), 3.79 ~ 3.84 (2H, m), 3.90 ~ 3.94 (2H, m), 3.920 (1H, dd), 4.04 (1H, dd), 4.30 (1H, dd), 4.69 (1H, d, J = 1.0Hz, H-1), 4.99 (1H, d, J = 3.2Hz, H-1 ′)

【0271】参考例45 8−メトキシカルボニルオクチル 2,3,4−トリ−
O−アセチル−6−O−(2,3,4,6−テトラ−O
−アセチル−α−D−ガラクトピラノシル)−β−D−
グルコピラノシド(90)および8−メトキシカルボニ
ルオクチル 2,3,4−トリ−O−アセチル−6−O
−(2,3,4,6−テトラ−O−アセチル−α−D−
ガラクトピラノシル)−α−D−グルコピラノシド(9
2)
Reference Example 45 8-Methoxycarbonyloctyl 2,3,4-tri-
O-acetyl-6-O- (2,3,4,6-tetra-O
-Acetyl-α-D-galactopyranosyl) -β-D-
Glucopyranoside (90) and 8-methoxycarbonyloctyl 2,3,4-tri-O-acetyl-6-O
-(2,3,4,6-tetra-O-acetyl-α-D-
Galactopyranosyl) -α-D-glucopyranoside (9
2)

【0272】8−メトキシカルボニルオクタノール2.
33g(12.4ミリモル)、ドライライト4.5g、
シアン化第二水銀3.2g(12.6ミリモル)および
無水ベンゼン50mlの混合物を、アルゴン気流下1時間
撹拌した。その後、アセトブロモメリビオース5g
(7.15ミリモル)のベンゼン10mlの溶液を滴下
し、室温にて4時間撹拌した。反応終了後、ろ過して不
溶物を除去し、ろ液を減圧留去して粗生成物6.88g
を得た。これをフラッシュクロマトグラフィー(酢酸エ
チル:ヘキサン=1:1)にて精製して化合物(90)
を2.55g(収率44.2%)および化合物(92)
を0.94g(収率16.3%)それぞれ得た。
8-Methoxycarbonyloctanol 2.
33 g (12.4 mmol), dry light 4.5 g,
A mixture of 3.2 g (12.6 mmol) of mercuric cyanide and 50 ml of anhydrous benzene was stirred under a stream of argon for 1 hour. After that, 5 g of acetobromomellibiose
A solution of (7.15 mmol) in 10 ml of benzene was added dropwise, and the mixture was stirred at room temperature for 4 hours. After the reaction was completed, the insoluble matter was removed by filtration, and the filtrate was distilled off under reduced pressure to give 6.88 g of a crude product.
I got This was purified by flash chromatography (ethyl acetate: hexane = 1: 1) to give compound (90).
2.55 g (yield 44.2%) and compound (92)
0.94 g (yield 16.3%) were obtained.

【0273】 化合物(90)〔α〕20 D+53.9°(C 1.14, CHCl3) IR(CHCl3) cm-1 : 750(OAc, CO2CH3) 1H-NMR (CDCl3,δppm): 1.20〜1.40(8H, broad, s), 1.40〜1.70(4H, broad, m), 1.99(3H, s, OAc), 2.00(3H, s, OAc), 2.03(3H, s, OAc), 2.04(3H, s, OAc), 2.05(3H, s, OAc), 2.12(3H, s, OAc), 2.13(3H, s, OAc), 2.31(2H, t, CH 2 CO2CH3), 3.36〜3.90(6H, m), 3.66(3H, s, CO2 CH 3 ), 4.00〜4.36(3H, m), 4.47(1H, d, J=8.3Hz, H-1), 4.84〜5.38(5H, m), 5.45(1H, d, J=2.0Hz, H-1′) Compound (90) (α) 20 D + 53.9 ° (C 1.14, CHCl 3 ) IR (CHCl 3 ) cm -1 : 750 (OAc, CO 2 CH 3 ) 1 H-NMR (CDCl 3 , δppm) : 1.20 ~ 1.40 (8H, broad, s), 1.40 ~ 1.70 (4H, broad, m), 1.99 (3H, s, OAc), 2.00 (3H, s, OAc), 2.03 (3H, s, OAc), 2.04 (3H, s, OAc), 2.05 (3H, s, OAc), 2.12 (3H, s, OAc), 2.13 (3H, s, OAc), 2.31 (2H, t, CH 2 C O 2 CH 3 ) , 3.36 ~ 3.90 (6H, m), 3.66 (3H, s, CO 2 CH 3 ) , 4.00 ~ 4.36 (3H, m), 4.47 (1H, d, J = 8.3Hz, H-1), 4.84 ~ 5.38 (5H, m), 5.45 (1H, d, J = 2.0Hz, H-1 ′)

【0274】 化合物(92)〔α〕20 D+122.3 °(C 1.46, CHCl3) IR(CHCl3) cm-1 : 1750(OAc, CO2CH3) 1H-NMR (CDCl3,δppm): 1.20〜1.40(8H, broad, s), 1.46〜1.70(4H, broad, m), 1.98(3H, s, OAc), 2.05(9H, s, OAc × 3), 2.08(3H, s, OAc), 2.10(3H, s, OAc), 2.14(3H, s, OAc), 2.31(2H, t, CH 2 CO2CH3), 3.36〜3.80(6H, m), 3.67(3H, s, CO2 CH 3 ), 3.80〜4.00(1H, m), 4.00〜4.40(3H, m), 4.87(1H, d, J=3.9Hz, H-1), 4.88〜5.36(4H, m), 5.45(1H, d, J=2.9Hz, H-1′) Compound (92) (α) 20 D +122.3 ° (C 1.46, CHCl 3 ) IR (CHCl 3 ) cm -1 : 1750 (OAc, CO 2 CH 3 ) 1 H-NMR (CDCl 3 , δppm) : 1.20 ~ 1.40 (8H, broad, s), 1.46 ~ 1.70 (4H, broad, m), 1.98 (3H, s, OAc), 2.05 (9H, s, OAc x 3), 2.08 (3H, s, OAc ), 2.10 (3H, s, OAc), 2.14 (3H, s, OAc), 2.31 (2H, t, CH 2 C O 2 CH 3 ), 3.36 ~ 3.80 (6H, m), 3.67 (3H, s, CO 2 CH 3 ) , 3.80 to 4.00 (1H, m), 4.00 to 4.40 (3H, m), 4.87 (1H, d, J = 3.9Hz, H-1), 4.88 to 5.36 (4H, m), 5.45 (1H, d, J = 2.9Hz, H-1 ′)

【0275】例 26 8−メトキシカルボニルオクチル 6−O−(α−D−
ガラクトピラノシル)−β−D−グルコピラノシド(9
1) 例24に記載した方法に準じて、化合物(90)2.0
g(2.48ミリモル)のメタノール20mlの溶液に、
28%ナトリウムメトキシド−メタノール溶液0.05
mlを加えて、脱アセチル化して無色キャラメル状の目的
物(91)1.23g(収率96.9%)を得た。
Example 26 8-Methoxycarbonyloctyl 6-O- (α-D-
Galactopyranosyl) -β-D-glucopyranoside (9
1) Compound (90) 2.0 according to the method described in Example 24.
g (2.48 mmol) in a solution of 20 ml of methanol,
28% sodium methoxide-methanol solution 0.05
The mixture was added with ml and deacetylated to obtain 1.23 g (yield 96.9%) of a colorless caramel target product (91).

【0276】 〔α〕20 D+41.3°(C 0.6, H2O) IR(KBr) cm-1 : 3400(OH),1740(CO2CH3) 1H-NMR (D2O,δppm): 1.20〜1.40(8H, broad, s), 1.44〜1.68(4H, broad, m), 2.38(2H, t, J=7.3Hz, CH 2 CO2CH3), 3.16〜3.28(1H, m), 3.30〜3.52(2H, m), 3.52〜4.00(11H, m), 3.680(3H, s, CO2 CH 3 ), 4.47(1H, d, J=8.3Hz, H-1), 4.97(1H, d, J=2.9Hz, H-1′) [Α] 20 D + 41.3 ° (C 0.6, H 2 O) IR (KBr) cm −1 : 3400 (OH), 1740 (CO 2 CH 3 ) 1 H-NMR (D 2 O, δppm) : 1.20~1.40 (8H, broad, s ), 1.44~1.68 (4H, broad, m), 2.38 (2H, t, J = 7.3Hz, CH 2 C O 2 CH 3), 3.16~3.28 (1H, m ), 3.30 ~ 3.52 (2H, m), 3.52 ~ 4.00 (11H, m), 3.680 (3H, s, CO 2 CH 3 ) , 4.47 (1H, d, J = 8.3Hz, H-1), 4.97 ( 1H, d, J = 2.9Hz, H-1 ′)

【0277】例 27 8−メトキシカルボニルオクチル 6−O−(α−D−
ガラクトピラノシル)−α−D−グルコピラノシド(9
3) 例24に記載した方法に準じて、化合物(92)940
mg(1.17ミリモル)のメタノール10mlの溶液に、
28%ナトリウムメトキシド−メタノール溶液0.05
mlを加えて脱アセチル化して無色キャラメル状の目的物
(93)546mg(収率91.5%)を得た。
Example 27 8-Methoxycarbonyloctyl 6-O- (α-D-
Galactopyranosyl) -α-D-glucopyranoside (9
3) Compound (92) 940 was prepared according to the method described in Example 24.
To a solution of mg (1.17 mmol) in 10 ml of methanol,
28% sodium methoxide-methanol solution 0.05
The mixture was added with ml and deacetylated to obtain 546 mg (yield 91.5%) of the desired product (93) as a colorless caramel.

【0278】 〔α〕20 D+114.9 °(C 0.70, H2O) IR(KBr) cm-1 : 3400(OH),1740(CO2CH3) 1H-NMR (D2O,δppm): 1.20〜1.40(8H, broad, s), 1.44〜1.72(4H, broad, m), 2.38(2H, t, J=7.3Hz,CH 2 CO2CH3), 3.16〜3.28(1H, m), 3.28〜4.00(13H, m), 3.68(3H, s, CO2 CH 3 ), 4.91(1H, d, J=3.4Hz, H-1), 4.96(1H, d, J=2.9Hz, H-1′) [Α] 20 D +114.9 ° (C 0.70, H 2 O) IR (KBr) cm −1 : 3400 (OH), 1740 (CO 2 CH 3 ) 1 H-NMR (D 2 O, δppm) : 1.20~1.40 (8H, broad, s ), 1.44~1.72 (4H, broad, m), 2.38 (2H, t, J = 7.3Hz, CH 2 C O 2 CH 3), 3.16~3.28 (1H, m ), 3.28 ~ 4.00 (13H, m), 3.68 (3H, s, CO 2 CH 3 ) , 4.91 (1H, d, J = 3.4Hz, H-1), 4.96 (1H, d, J = 2.9Hz, H-1 ′)

【0279】参考例46 8−メトキシカルボニルオクチル 2,3,4−トリ−
O−アセチル−α−D−キシロピラノシド(95)、8
−メトキシカルボニルオクチル 2,3,4−トリ−O
−アセチル−β−D−キシロピラノシド(96)
Reference Example 46 8-methoxycarbonyloctyl 2,3,4-tri-
O-acetyl-α-D-xylopyranoside (95), 8
-Methoxycarbonyloctyl 2,3,4-tri-O
-Acetyl-β-D-xylopyranoside (96)

【0280】1.J. Am. Chem. Soc., 47, 1280 (1925)
の方法により調製した2,3,4−トリ−O−アセチル
−α−D−キシロピラノシルブロマイド(94)1.2
0g(3.54ミリモル)のベンゼン10ml溶液に、シ
アン化第二水銀447mg(1.77ミリモル)、粉末化
した無水硫酸カルシウム1.0g及び8−メトキシカル
ボニルオクタノール333mg(1.77ミリモル)を加
え、アルゴン気流中室温で24時間撹拌した。反応溶液
をろ過後、ろ液に酢酸エチル20mlを加え、水20mlで
洗浄した。これを無水硫酸マグネシウムで脱水後、減圧
濃縮して得たシロップをシリカゲルカラムクロマトグラ
フィー(トルエン:酢酸エチル=8:1)で精製して、
化合物(95)426mg(収率53.9%)及び化合物
(96)98mg(収率12.4%)を得た。
1. J. Am. Chem. Soc., 47, 1280 (1925)
2,3,4-tri-O-acetyl-α-D-xylopyranosyl bromide (94) 1.2 prepared by the method of
To 10 g of 0 g (3.54 mmol) benzene was added 447 mg (1.77 mmol) mercuric cyanide, 1.0 g powdered anhydrous calcium sulfate and 333 mg (1.77 mmol) 8-methoxycarbonyloctanol. The mixture was stirred at room temperature in an argon stream for 24 hours. After filtering the reaction solution, 20 ml of ethyl acetate was added to the filtrate and washed with 20 ml of water. The syrup obtained by dehydrating this with anhydrous magnesium sulfate and concentrating under reduced pressure was purified by silica gel column chromatography (toluene: ethyl acetate = 8: 1).
426 mg of compound (95) (yield 53.9%) and 98 mg of compound (96) (yield 12.4%) were obtained.

【0281】2.化合物(94)850mg(2.51ミ
リモル)のジクロロエタン10ml溶液に、銀トリフレー
ト1.61g(6.28ミリモル)、1,1,3,3−
テトラメチル尿素875mg(7.53ミリモル)及び8
−メトキシカルボニルオクタノール236mg(1.46
ミリモル)を加え、アルゴン気流中室温で9時間撹拌し
た。反応溶液を減圧濃縮して得たシロップをクロロホル
ム20mlに溶解させ、水20mlで洗浄した。これを無水
硫酸カルシウムで脱水後、減圧濃縮して得たシロップを
シリカゲルカラムクロマトグラフィー(トルエン:酢酸
エチル=8:1)で精製して化合物(96)375mg
(収率67.0%)を得た。
2. To a solution of 850 mg (2.51 mmol) of compound (94) in 10 ml of dichloroethane, 1.61 g (6.28 mmol) of silver triflate, 1,1,3,3-
Tetramethylurea 875 mg (7.53 mmol) and 8
-Methoxycarbonyloctanol 236 mg (1.46
Was added and the mixture was stirred at room temperature for 9 hours in an argon stream. The syrup obtained by concentrating the reaction solution under reduced pressure was dissolved in 20 ml of chloroform and washed with 20 ml of water. Syrup obtained by dehydrating this with anhydrous calcium sulfate and concentrating under reduced pressure was purified by silica gel column chromatography (toluene: ethyl acetate = 8: 1) to obtain 375 mg of compound (96).
(Yield 67.0%) was obtained.

【0282】 化合物(95)〔α〕23 D+92.4°(C 1.05, CHCl3) IR(NaCl)cm-1:2940, 1760, 1230 1H-NMR (CDCl3,δppm): 2.03, 2.06(9H, 2s, OAc), 2.31(2H, t, J=7.6Hz, CH 2 COOCH3), 3.67(3H, s, OCH3) Compound (95) [α] 23 D + 92.4 ° (C 1.05, CHCl 3 ) IR (NaCl) cm −1 : 2940, 1760, 1230 1 H-NMR (CDCl 3 , δppm): 2.03, 2.06 ( 9H, 2s, OAc), 2.31 (2H, t, J = 7.6Hz, C H 2 C OOCH 3 ), 3.67 (3H, s, OCH 3 )

【0283】 元素分析 C21H34O10 計算値 C 56.49% H 7.68% 実測値 C 55.98% H 7.97% Elemental analysis C 21 H 34 O 10 Calculated value C 56.49% H 7.68% Actual value C 55.98% H 7.97%

【0284】 化合物(96)〔α〕22 D-19.5°(C 0.87, CHCl3) IR(NaCl)cm-1:2930, 1760, 1220 1H-NMR (CDCl3, δppm): 2.03, 2.05, 2.06(9H, 3s, OAc), 2.30(2H, t, J=7.4Hz, CH 2 COOCH3), 3.67(3H, s, OCH3), 4.46(1H, d, J=6.8Hz, H-1) Compound (96) (α) 22 D -19.5 ° (C 0.87, CHCl 3 ) IR (NaCl) cm -1 : 2930, 1760, 1220 1 H-NMR (CDCl 3 , δppm): 2.03, 2.05, 2.06 (9H, 3s, OAc), 2.30 (2H, t, J = 7.4Hz, C H 2 C OOCH 3 ), 3.67 (3H, s, OCH 3 ), 4.46 (1H, d, J = 6.8Hz, H -1)

【0285】 元素分析 C21H34O10 計算値 C 56.49% H 7.68% 実測値 C 56.12% H 7.91% Elemental analysis C 21 H 34 O 10 Calculated value C 56.49% H 7.68% Actual value C 56.12% H 7.91%

【0286】例 28 8−メトキシカルボニルオクチル α−D−キシロピラ
ノシド(97) 化合物(95)410mg(0.918ミリモル)のメタ
ノール4ml溶液に28%ナトリウムメチラート0.12
mlを加え、室温下3時間撹拌した。反応溶液をアンバー
ライトIR−120B(H+ 型)で中和し、沈殿をろ取
した後、ろ液を減圧濃縮した。得たシロップをシリカゲ
ルカラムクロマトグラフィー(クロロホルム:メタノー
ル=30:1)で精製して化合物(97)243mg(収
率82.8%)を得た。
Example 28 8-Methoxycarbonyloctyl α-D-xylopyranoside (97) 410 mg (0.918 mmol) of compound (95) in 4 ml of methanol was added with 28% sodium methylate 0.12.
ml was added, and the mixture was stirred at room temperature for 3 hours. The reaction solution was neutralized with Amberlite IR-120B (H + type), the precipitate was collected by filtration, and the filtrate was concentrated under reduced pressure. The obtained syrup was purified by silica gel column chromatography (chloroform: methanol = 30: 1) to obtain 243 mg of compound (97) (yield 82.8%).

【0287】 〔α〕25 D+90.9°(C 1.10, CH3OH) IR(NaCl)cm-1:3450, 2960, 1740, 1040 1H-NMR (CD3OD,δppm): 2.30(2H, t, J=7.6Hz, CH 2 COOCH3), 3.64(3H, s, OCH3) 4.69(1H, d, J=3.9Hz, H-1) [Α] 25 D + 90.9 ° (C 1.10, CH 3 OH) IR (NaCl) cm −1 : 3450, 2960, 1740, 1040 1 H-NMR (CD 3 OD, δppm): 2.30 (2H, t, J = 7.6Hz, C H 2 C OOCH 3 ), 3.64 (3H, s, OCH 3 ) 4.69 (1H, d, J = 3.9Hz, H-1)

【0288】 元素分析 C15H28O7 計算値 C 56.23% H 8.81% 実測値 C 56.11% H 9.21% Elemental analysis C 15 H 28 O 7 Calculated value C 56.23% H 8.81% Actual value C 56.11% H 9.21%

【0289】例 29 8−メトキシカルボニルオクチル β−D−キシロピラ
ノシド(98) 化合物(96)101mg(0.226ミリモル)のメタ
ノール2ml溶液に28%ナトリウムメチラート0.03
mlを加え、室温下3時間撹拌した。反応溶液をアンバー
ライトIR−120B(H+ 型)で中和し、沈澱をろ取
した後、ろ液を減圧濃縮した。得たシロップをシリカゲ
ルカラムクロマトグラフィー(クロロホルム:メタノー
ル=30:1)で精製して化合物(98)58.3mg
(収率80.5%)を得た。
Example 29 8-Methoxycarbonyloctyl β-D-xylopyranoside (98) 28% sodium methylate 0.03 in a solution of 101 mg (0.226 mmol) of compound (96) in 2 ml of methanol.
ml was added, and the mixture was stirred at room temperature for 3 hours. The reaction solution was neutralized with Amberlite IR-120B (H + type), the precipitate was collected by filtration, and the filtrate was concentrated under reduced pressure. The obtained syrup was purified by silica gel column chromatography (chloroform: methanol = 30: 1) to give compound (98) 58.3 mg.
(Yield 80.5%) was obtained.

【0290】 〔α〕24 D-10.3°(C 1.02, CH3OH) IR(NaCl)cm-1:3450, 2960, 1740, 1290, 1050 1H-NMR (CD3OD,δppm): 2.31(2H, t, J=7.3Hz, CH 2 COOCH3), 3.65(3H, s, OCH3) 4.17(1H, d, J=7.6Hz, H-1) [Α] 24 D -10.3 ° (C 1.02, CH 3 OH) IR (NaCl) cm -1 : 3450, 2960, 1740, 1290, 1050 1 H-NMR (CD 3 OD, δppm): 2.31 ( 2H, t, J = 7.3Hz, C H 2 C OOCH 3 ), 3.65 (3H, s, OCH 3 ) 4.17 (1H, d, J = 7.6Hz, H-1)

【0291】 元素分析 C15H28O7 計算値 C 56.23% H 8.81% 実測値 C 56.15% H 9.34% Elemental analysis C 15 H 28 O 7 Calculated value C 56.23% H 8.81% Actual value C 56.15% H 9.34%

【0292】参考例47 3,4−ジ−O−アセチル−L−フカール(100) Carbohydr. Res., 4, 189 (1967)の方法に従い、1,
2,3,4−テトラ−O−アセチル−L−フコピラノー
ス630mg(1.90ミリモル)より調製した新しい
2,3,4−トリ−O−アセチル−α−L−フコピラノ
シルブロマイド(99)の50%酢酸水溶液4.2mlを
−10℃に冷却した後、亜鉛末1.26g及び硫酸銅
0.13gを加え、同温で1時間激しく撹拌した。沈澱
をろ取した後、ろ液をクロロホルム10mlで2回抽出し
た。この抽出液を飽和炭酸水素ナトリウム20ml及び水
20mlで順次洗浄した。これを無水硫酸マグネシウムで
脱水後、減圧濃縮して得られたシロップをシリカゲルカ
ラムクロマトグラフィー(トルエン:酢酸エチル=3
0:1)で精製して化合物(100)284mg(収率6
9.7%)を得た。
Reference Example 47 3,4-di-O-acetyl-L-fucal (100) Carbohydr. Res., 4, According to the method of 189 (1967), 1,
New 2,3,4-tri-O-acetyl-α-L-fucopyranosyl bromide (99) prepared from 630 mg (1.90 mmol) of 2,3,4-tetra-O-acetyl-L-fucopyranose After cooling 4.2 ml of a 50% aqueous solution of acetic acid of 10 to -10 ° C, 1.26 g of zinc dust and 0.13 g of copper sulfate were added, and the mixture was vigorously stirred at the same temperature for 1 hour. After collecting the precipitate by filtration, the filtrate was extracted twice with 10 ml of chloroform. The extract was washed successively with 20 ml of saturated sodium hydrogen carbonate and 20 ml of water. The syrup obtained by dehydrating this with anhydrous magnesium sulfate and concentrating under reduced pressure was subjected to silica gel column chromatography (toluene: ethyl acetate = 3).
0: 1) to 284 mg of compound (100) (yield 6
9.7%).

【0293】 〔α〕22 D+0.9 °(C 0.98, CHCl3) IR(NaCl)cm-1:2990, 1750, 1650, 1230 1H-NMR (CDCl3,δppm): 1.28(3H, d, J=6.6Hz, H-6), 2.02, 2.17(6H, 2s, OAc), 4.64〜4.66(1H, m, H-2), 6.47(1H, d, J=8.3Hz, H-1) [Α] 22 D +0.9 ° (C 0.98, CHCl 3 ) IR (NaCl) cm −1 : 2990, 1750, 1650, 1230 1 H-NMR (CDCl 3 , δppm): 1.28 (3H, d, J = 6.6Hz, H-6), 2.02, 2.17 (6H, 2s, OAc), 4.64 ~ 4.66 (1H, m, H-2), 6.47 (1H, d, J = 8.3Hz, H-1)

【0294】参考例48 8−メトキシカルボニルオクチル 3,4−ジ−O−ア
セチル−2−アジド−2−デオキシ−α−L−フコピラ
ノシド(102)、8−メトキシカルボニルオクチル
3,4−ジ−O−アセチル−2−アジド−2−デオキシ
−β−L−フコピラノシド(103)
Reference Example 48 8-Methoxycarbonyloctyl 3,4-di-O-acetyl-2-azido-2-deoxy-α-L-fucopyranoside (102), 8-methoxycarbonyloctyl
3,4-di-O-acetyl-2-azido-2-deoxy-β-L-fucopyranoside (103)

【0295】化合物(100)1.17g(5.46ミ
リモル)のアセトニトリル30ml溶液にアジ化ナトリウ
ム532mg(8.19ミリモル)及び硝酸第二セリウム
アンモニウム10.8g(19.7ミリモル)を加え、
−15℃で4時間撹拌した。反応溶液に冷水50mlを加
え、クロロホルム30mlで2回抽出した。抽出液を冷水
50mlで洗浄し、無水硫酸マグネシウムで脱水後、減圧
濃縮して得られたシロップをシリカゲルカラムクロマト
グラフィー(トルエン:酢酸エチル=20:1)で精製
してアジド混合物(101)982mg(収率56.6
%)を得た。混合物(101)830mg(2.61ミリ
モル)のアセトニトリル80ml溶液に、臭化リチウム9
07mg(10.4ミリモル)を加え、室温下2時間撹拌
した。反応溶液を減圧濃縮して得られたシロップを冷水
30mlに懸濁し、クロロホルム30mlで抽出した。無水
硫酸マグネシウムで脱水後、減圧濃縮して得たシロップ
のベンゼン8ml溶液にシアン化第二水銀331mg(1.
31ミリモル)、無水硫酸カルシウム800mg及び8−
メトキシカルボニルオクタノール246mg(1.31ミ
リモル)を加え、アルゴン気流中室温で17時間撹拌し
た。反応溶液をろ過後、ろ液に酢酸エチル20mlを加
え、水30mlで洗浄した。これを無水硫酸マグネシウム
で脱水後、減圧濃縮して得られたシロップをシリカゲル
カラムクロマトグラフィー(n−ヘキサン:酢酸エチル
=6:1)で精製して化合物(102)187mg(収率
32.3%)及び化合物(103)249mg(収率4
3.0%)を得た。
To a solution of 1.17 g (5.46 mmol) of compound (100) in 30 ml of acetonitrile was added 532 mg (8.19 mmol) of sodium azide and 10.8 g (19.7 mmol) of ceric ammonium nitrate,
The mixture was stirred at -15 ° C for 4 hours. 50 ml of cold water was added to the reaction solution, and the mixture was extracted twice with 30 ml of chloroform. The extract was washed with 50 ml of cold water, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The resulting syrup was purified by silica gel column chromatography (toluene: ethyl acetate = 20: 1) to obtain 982 mg of azide mixture (101) ( Yield 56.6
%) Was obtained. To a solution of 830 mg (2.61 mmol) of mixture (101) in 80 ml of acetonitrile was added lithium bromide 9
07 mg (10.4 mmol) was added, and the mixture was stirred at room temperature for 2 hours. The syrup obtained by concentrating the reaction solution under reduced pressure was suspended in 30 ml of cold water and extracted with 30 ml of chloroform. 331 mg of mercuric cyanide was added to 8 ml of a benzene solution of syrup obtained by dehydration over anhydrous magnesium sulfate and concentration under reduced pressure.
31 mmol), 800 mg anhydrous calcium sulfate and 8-
Methoxycarbonyloctanol (246 mg, 1.31 mmol) was added, and the mixture was stirred at room temperature for 17 hours in an argon stream. After filtering the reaction solution, 20 ml of ethyl acetate was added to the filtrate and washed with 30 ml of water. The syrup obtained by dehydrating this with anhydrous magnesium sulfate and concentrating under reduced pressure was purified by silica gel column chromatography (n-hexane: ethyl acetate = 6: 1) to obtain 187 mg of compound (102) (yield 32.3%). ) And 249 mg of compound (103) (yield 4
3.0%) was obtained.

【0296】 化合物(102) 〔α〕23 D-121.8 °(C 1.02, CHCl3) IR(NaCl)cm-1:2930, 1760, 1220 1H-NMR (CDCl3,δppm): 1.14(3H, d, J=6.6Hz, H-6), 2.06, 2.17(6H, 2s, OAc), 2.31(2H, t, J=7.3Hz, CH 2 COOCH3), 3.58(1H, dd, J=3.4, 11.2Hz, H-2), 3.67(3H, s, OCH3), 4.94(1H, d, J=3.4Hz, H-1), 5.30(1H, m, H-4), 5.37(1H, dd, J=3.4, 11.2Hz, H-3)Compound (102) [α] 23 D -121.8 ° (C 1.02, CHCl 3 ) IR (NaCl) cm −1 : 2930, 1760, 1220 1 H-NMR (CDCl 3 , δppm): 1.14 (3H, d, J = 6.6Hz, H-6), 2.06, 2.17 (6H, 2s, OAc), 2.31 (2H, t, J = 7.3Hz, C H 2 C OOCH 3 ), 3.58 (1H, dd, J = 3.4, 11.2Hz, H-2), 3.67 (3H, s, OCH 3 ), 4.94 (1H, d, J = 3.4Hz, H-1), 5.30 (1H, m, H-4), 5.37 (1H , dd, J = 3.4, 11.2Hz, H-3)

【0297】 化合物(103) 〔α〕22 D-3.1 °(C 0.91, CHCl3) IR(NaCl)cm-1:2930, 1760, 1220 1H-NMR (CDCl3,δppm): 1.21(3H, d, J=6.4Hz, H-6), 2.05, 2.17(6H, 2s, OAc), 2.30(2H, t, J=7.3Hz, CH 2 COOCH3), 3.64(1H, dd, J=8.1, 11.0Hz, H-2), 3.67(3H, s, OCH3), 4.32(1H, d, J=8.1Hz, H-1), 4.77(1H, dd, J=3.4, 11.0Hz, H-3) 5.18(1H, m, H-4)Compound (103) [α] 22 D -3.1 ° (C 0.91, CHCl 3 ) IR (NaCl) cm −1 : 2930, 1760, 1220 1 H-NMR (CDCl 3 , δppm): 1.21 (3H, d, J = 6.4Hz, H-6), 2.05, 2.17 (6H, 2s, OAc), 2.30 (2H, t, J = 7.3Hz, C H 2 C OOCH 3 ), 3.64 (1H, dd, J = 8.1, 11.0Hz, H-2), 3.67 (3H, s, OCH 3 ), 4.32 (1H, d, J = 8.1Hz, H-1), 4.77 (1H, dd, J = 3.4, 11.0Hz, H -3) 5.18 (1H, m, H-4)

【0298】例 30 8−メトキシカルボニルオクチル 2−アセトアミド−
2−デオキシ−α−L−フコピラノシド(104) 化合物(102)180mg(0.406ミリモル)のエ
タノール10ml溶液に水素化ホウ素ナトリウム46.1
mg(1.22ミリモル)及び塩化ニッケル(6水和物)
29mgを加え、室温下4時間撹拌した。反応溶液をろ過
後、ろ液を減圧濃縮して得たシロップをシリカゲルカラ
ムクロマトグラフィー(クロロホルム:メタノール:濃
アンモニア水=50:10:1)で精製した。得た化合
物のメタノール1ml溶液に無水酢酸0.5mlを加え室温
下一晩撹拌した。反応溶液を減圧濃縮して得たシロップ
をシリカゲルカラムクロマトグラフィー(クロロホル
ム:メタノール=20:1)で精製して化合物(10
4)111mg(収率73.0%)を得た。
Example 30 8-Methoxycarbonyloctyl 2-acetamido-
2-Deoxy-α-L-fucopyranoside (104) 180 mg (0.406 mmol) of compound (102) in 10 ml of ethanol was added with sodium borohydride 46.1.
mg (1.22 mmol) and nickel chloride (hexahydrate)
29 mg was added, and the mixture was stirred at room temperature for 4 hours. After filtering the reaction solution, the syrup obtained by concentrating the filtrate under reduced pressure was purified by silica gel column chromatography (chloroform: methanol: concentrated aqueous ammonia = 50: 10: 1). 0.5 ml of acetic anhydride was added to a 1 ml solution of the obtained compound in methanol, and the mixture was stirred overnight at room temperature. The syrup obtained by concentrating the reaction solution under reduced pressure was purified by silica gel column chromatography (chloroform: methanol = 20: 1) to give the compound (10
4) 111 mg (yield 73.0%) was obtained.

【0299】 〔α〕20 D-158.3 °(C 0.53, CH3OH) m.p.92℃ IR(KBr)cm-1 :3300, 2930, 1740, 1650, 1050 1H-NMR (CD3OD,δppm): 1.21(3H, d, J=6.6Hz, H-6), 1.97(3H, s, NAc), 2.31(2H, t, J=7.3Hz, CH 2 COOCH3), 3.64(3H, s, OCH3), 3.75(1H, dd, J=3.4, 11.1Hz, H-3), 4.19(1H, dd, J=3.9, 11.1Hz, H-2), 4.73(1H, d, J=3.9Hz, H-1) [Α] 20 D -158.3 ° (C 0.53, CH 3 OH) mp 92 ° C IR (KBr) cm -1 : 3300, 2930, 1740, 1650, 1050 1 H-NMR (CD 3 OD, δppm): 1.21 (3H, d, J = 6.6Hz, H-6), 1.97 (3H, s, NAc), 2.31 (2H, t, J = 7.3Hz, C H 2 C OOCH 3 ), 3.64 (3H, s, OCH 3 ), 3.75 (1H, dd, J = 3.4, 11.1Hz, H-3), 4.19 (1H, dd, J = 3.9, 11.1Hz, H-2), 4.73 (1H, d, J = 3.9Hz , H-1)

【0300】例 31 8−メトキシカルボニルオクチル 2−アセトアミド−
2−デオキシ−β−L−フコピラノシド(105) 化合物(103)240mg(0.541ミリモル)を例
30と同様に処理して化合物(105)141mg(6
9.9%)を得た。
Example 31 8-Methoxycarbonyloctyl 2-acetamido-
2-Deoxy-β-L-fucopyranoside (105) 240 mg (0.541 mmol) of compound (103) was treated in the same manner as in Example 30 to obtain 141 mg (6) of compound (105).
9.9%).

【0301】 〔α〕20 D+3.9 °(C 0.65, CH3OH) IR(KBr)cm-1 :3300, 2930, 1730, 1650, 1070 1H-NMR (CD3OD,δppm): 1.26(3H, d, J=6.6Hz, H-6), 1.96(3H, s, NAc), 2.30(2H, t, J=7.3Hz, CH 2 COOCH3), 3.64(3H, s, OCH3), 4.31(1H, d, J=8.3Hz, H-1) [Α] 20 D +3.9 ° (C 0.65, CH 3 OH) IR (KBr) cm −1 : 3300, 2930, 1730, 1650, 1070 1 H-NMR (CD 3 OD, δppm): 1.26 ( 3H, d, J = 6.6Hz, H-6), 1.96 (3H, s, NAc), 2.30 (2H, t, J = 7.3Hz, C H 2 C OOCH 3 ), 3.64 (3H, s, OCH 3 ), 4.31 (1H, d, J = 8.3Hz, H-1)

【0302】参考例49 3−ベンンジルオキシカルボニルプロピル 2,3,
4,6−テトラ−O−ベンジル−β−D−マンノピラノ
シド(110) 2,3,4,6−テトラ−O−ベンジル−α−D−マン
ノピラノシルクロリド(106)580mg(1.04ミ
リモル)の無水塩化メチレン3ml溶液を、4−ヒドロキ
シブタン酸ベンジルエステル(107)544mg(2.
8ミリモル)、炭酸銀500mg、硫酸カルシウム500
mg及び無水塩化メチレン10mlの混合物へ窒素気流下に
滴下し、室温で8時間反応させた。反応終了後、ろ過し
て不溶物を除き、ろ液を減圧留去して粗生成物1.11
4gを得た。これをフラッシュクロマトグラフィー(ヘ
キサン:酢酸エチル=6:1)で分離精製して、化合物
(110)を462mg(収率63.8%)得た。
Reference Example 49 3-Benzyloxycarbonylpropyl 2,3,3
4,6-Tetra-O-benzyl-β-D-mannopyranoside (110) 2,3,4,6-tetra-O-benzyl-α-D-mannopyranosyl chloride (106) 580 mg (1.04) 3 ml of anhydrous methylene chloride in 3 ml of benzyl 4-hydroxybutanoic acid benzyl ester (107) (544 mg, 2.
8 mmol), silver carbonate 500 mg, calcium sulfate 500
A mixture of 10 mg of anhydrous methylene chloride and 10 ml of anhydrous methylene chloride was added dropwise under a nitrogen stream, and the mixture was reacted at room temperature for 8 hours. After completion of the reaction, the insoluble matter was removed by filtration, and the filtrate was distilled off under reduced pressure to obtain a crude product 1.11.
4 g was obtained. This was separated and purified by flash chromatography (hexane: ethyl acetate = 6: 1) to obtain 462 mg of compound (110) (yield 63.8%).

【0303】 〔α〕25 D-41.68 °(C 0.95, CHCl3) IR(CHCl3)cm-1 :3060, 3040, 1740[Α] 25 D -41.68 ° (C 0.95, CHCl 3 ) IR (CHCl 3 ) cm −1 : 3060, 3040, 1740

【0304】参考例50 11−メトキシカルボニルウンデシル 2,3,4,6
−テトラ−O−ベンジル−β−D−マンノピラノシド
(111) 化合物(110)の合成と全く同様にして、クロリド
(106)とアルコ−ル(108)とを縮合させて化合
物(111)を489.3mg(収率62.5%)得た。
Reference Example 50 11-Methoxycarbonylundecyl 2,3,4,6
-Tetra-O-benzyl-β-D-mannopyranoside (111) Chloride (106) is condensed with alcohol (108) in the same manner as in the synthesis of compound (110) to give compound (111) 489. 3 mg (yield 62.5%) was obtained.

【0305】 〔α〕25 D41.75°(C 1.20, CHCl3) IR(CHCl3)cm-1 :1740[Α] 25 D 41.75 ° (C 1.20, CHCl 3 ) IR (CHCl 3 ) cm −1 : 1740

【0306】参考例51 14−メトキシカルボニルテトラデシル 2,3,4,
6−テトラ−O−ベンジル−β−D−マンノピラノシド
(112) 化合物(110)の合成と全く同様にして、クロリド
(106)とアルコール(109)とを縮合させて化合
物(112)を478.2mg(収率57.8%)得た。
Reference Example 51 14-methoxycarbonyltetradecyl 2,3,4
6-Tetra-O-benzyl-β-D-mannopyranoside (112) Chloride (106) and alcohol (109) were condensed to 478.2 mg of compound (112) in exactly the same manner as the synthesis of compound (110). (Yield 57.8%) was obtained.

【0307】 〔α〕25 D-38.90 °(C 1.09, CHCl3) IR(CHCl3)cm-1 :1740[Α] 25 D −38.90 ° (C 1.09, CHCl 3 ) IR (CHCl 3 ) cm −1 : 1740

【0308】例 32 3−メトキシカルボニルプロピル−β−D−マンノピラ
ノシド(114) 化合物(110)758mg(1.05ミリモル)、10
%パラジウム−炭素530mg、メタノール10ml及び酢
酸エチル10mlの混合物を約5気圧の水素気流下に7時
間振盪した。反応終了後、触媒をろ過して除き、ろ液を
減圧留去して得た化合物(113)をメタノール20ml
に溶解し、ジアゾメタン/エーテル溶液を過剰に加え、
30分撹拌した。過剰のジアゾメタンを少量の酢酸にて
分解後、溶液を減圧留去して粗生成物を得た。これにイ
ソプロピルエーテルを加えて結晶化させ、化合物(11
4)を無色結晶として238mg得た。
Example 32 3-Methoxycarbonylpropyl-β-D-mannopyranoside (114) Compound (110) 758 mg (1.05 mmol), 10
% A mixture of 530 mg of palladium-carbon, 10 ml of methanol and 10 ml of ethyl acetate was shaken under a hydrogen stream at about 5 atm for 7 hours. After completion of the reaction, the catalyst was filtered off and the filtrate was distilled off under reduced pressure to obtain Compound (113) in 20 ml of methanol.
Dissolve in, add excess diazomethane / ether solution,
Stir for 30 minutes. After decomposing excess diazomethane with a small amount of acetic acid, the solution was distilled off under reduced pressure to obtain a crude product. Isopropyl ether was added to this to crystallize the compound (11
238 mg of 4) was obtained as colorless crystals.

【0309】 m.p. 102〜108 ℃, 〔α〕14 D-46.15 °(C 1.04, CH3OH) IR(KBr)cm-1 :3450, 3300, 1730 1H-NMR (CD3OD,δppm): 1.85〜1.95(2H, m), 2.45(2H, t, J=7.5Hz), 3.16〜3.21(1H, m), 3.41〜3.45(1H, dd), 3.48〜3.58(2H, m), 3.65(3H, s, CO2CH3), 3.67〜3.72(1H, dd), 3.83(1H, d, J=3.2Hz), 3.84〜3.88(1H, dd), 3.88〜3.95(1H, m), 4.48(1H, d, J=0.7Hz)Mp 102 to 108 ° C., [α] 14 D −46.15 ° (C 1.04, CH 3 OH) IR (KBr) cm −1 : 3450, 3300, 1730 1 H-NMR (CD 3 OD, δppm): 1.85 ~ 1.95 (2H, m), 2.45 (2H, t, J = 7.5Hz), 3.16 ~ 3.21 (1H, m), 3.41 ~ 3.45 (1H, dd), 3.48 ~ 3.58 (2H, m), 3.65 ( 3H, s, CO 2 CH 3 ), 3.67 ~ 3.72 (1H, dd), 3.83 (1H, d, J = 3.2Hz), 3.84 ~ 3.88 (1H, dd), 3.88 ~ 3.95 (1H, m), 4.48 (1H, d, J = 0.7Hz)

【0310】例 33 11−メトキシカルボニルウンデシル−β−D−マンノ
ピラノシド(115) 化合物(111)631mg(0.84ミリモル)、10
%パラジウム−炭素500mg及びメタノール20mlの混
合物を約5気圧の水素気流中で振盪して一晩反応させ
た。反応終了後、触媒をろ過して除き、ろ液を減圧留去
して化合物(115)を196.3mg(収率59.5
%)得た。
Example 33 11-Methoxycarbonylundecyl-β-D-mannopyranoside (115) Compound (111) 631 mg (0.84 mmol), 10
% Palladium-carbon (500 mg) and methanol (20 ml) were shaken in a hydrogen stream at about 5 atm to react overnight. After completion of the reaction, the catalyst was removed by filtration and the filtrate was distilled off under reduced pressure to obtain 196.3 mg of compound (115) (yield 59.5).
%)Obtained.

【0311】 m.p. 124.5〜125 ℃, 〔α〕18 D-32.63 °(C 1.14, CH3OH) IR(KBr)cm-1 :3400, 3300, 1735 1H-NMR (CD3OD,δppm): 1.26〜1.40(14H, broad s), 1.50〜1.65(4H, m), 2.30(2H, t, J=7.5Hz), 3.16〜3.21(1H, m), 3.41〜3.45(1H, dd), 3.48〜3.58(2H, m), 3.64(3H, s, CO2CH3), 3.67〜3.72(1H, dd), 3.83(1H, d, J=2.9Hz), 3.84〜3.88(1H, dd), 3.88〜3.92(1H, m), 4.48(1H, d, J=0.74Hz, H-1)Mp 124.5 to 125 ° C., [α] 18 D −32.63 ° (C 1.14, CH 3 OH) IR (KBr) cm −1 : 3400, 3300, 1735 1 H-NMR (CD 3 OD, δppm): 1.26 ~ 1.40 (14H, broad s), 1.50 ~ 1.65 (4H, m), 2.30 (2H, t, J = 7.5Hz), 3.16 ~ 3.21 (1H, m), 3.41 ~ 3.45 (1H, dd), 3.48 ~ 3.58 (2H, m), 3.64 (3H, s, CO 2 CH 3 ), 3.67 ~ 3.72 (1H, dd), 3.83 (1H, d, J = 2.9Hz), 3.84 ~ 3.88 (1H, dd), 3.88 ~ 3.92 (1H, m), 4.48 (1H, d, J = 0.74Hz, H-1)

【0312】例 34 14−メトキシカルボニルテトラデシル−β−D−マン
ノピラノシド(116)
Example 34 14-Methoxycarbonyltetradecyl-β-D-mannopyranoside (116)

【0313】化合物(112)620mg(0.78ミリ
モル)、10%パラジウム−炭素500mg及びメタノー
ル20mlの混合物を約5気圧の水素気流中で一晩振盪し
た。反応終了後、触媒をろ過して除き、ろ液を減圧留去
して化合物(116)を170.7mg(収率50.4
%)得た。
A mixture of 620 mg (0.78 mmol) of compound (112), 500 mg of 10% palladium-carbon and 20 ml of methanol was shaken overnight in a hydrogen stream at about 5 atm. After the reaction was completed, the catalyst was removed by filtration, and the filtrate was evaporated under reduced pressure to give 170.7 mg of compound (116) (yield: 50.4
%)Obtained.

【0314】 〔α〕18 D-26.22 °(C 0.98, CH3OH) IR(CHCl3)cm-1 :3400, 1730 1H-NMR (CD3OD,δppm): 1.26〜1.40(20H, broad s), 1.50〜1.65(4H, m), 2.30(2H, t, J=7.5Hz), 3.16〜3.21(1H, m), 3.41〜3.45(1H, dd), 3.48〜3.58(2H, m), 3.64(3H, s, CO2CH3), 3.67〜3.72(1H, dd), 3.83(1H, d, J=2.9Hz), 3.84〜3.88(1H, dd), 3.88〜3.92(1H, m), 4.48(1H, d, J=0.7Hz)[Α] 18 D -26.22 ° (C 0.98, CH 3 OH) IR (CHCl 3 ) cm −1 : 3400, 1730 1 H-NMR (CD 3 OD, δppm): 1.26 to 1.40 (20H, broad s), 1.50 ~ 1.65 (4H, m), 2.30 (2H, t, J = 7.5Hz), 3.16 ~ 3.21 (1H, m), 3.41 ~ 3.45 (1H, dd), 3.48 ~ 3.58 (2H, m) , 3.64 (3H, s, CO 2 CH 3 ), 3.67 ~ 3.72 (1H, dd), 3.83 (1H, d, J = 2.9Hz), 3.84 ~ 3.88 (1H, dd), 3.88 ~ 3.92 (1H, m ), 4.48 (1H, d, J = 0.7Hz)

【0315】参考例52 ベンジル 2−アセトアミド−3−O−(2,3,4,
6−テトラ−O−アセチル−β−D−ガラクトピラノシ
ル)−2−デオキシ−α−D−グルコピラノシド(11
9)
Reference Example 52 Benzyl 2-acetamido-3-O- (2,3,4)
6-Tetra-O-acetyl-β-D-galactopyranosyl) -2-deoxy-α-D-glucopyranoside (11
9)

【0316】ベンジル 2−アセトアミド−2−デオキ
シ−4,6−O−イソプロピリデン−α−D−グルコピ
ラノシド(118)2.26g(6.43ミリモル)、
シアン化第二水銀1.67g、無水ニトロメタン100
mlおよび無水ベンゼン130mlの混合物を加熱還流し、
ベンゼンを約30ml留去した。次に反応液を60〜65
℃に保ちながらアセトブロムガラクトース(117)3
gのベンゼン10ml溶液をゆっくり滴下した。滴下後6
時間撹拌し、さらにシアン化第二水銀250mg、アセト
ブロムガラクトース550mg/ベンゼン10ml溶液を加
え、20時間撹拌した。反応終了後、不溶物をろ過して
除き、ろ液に水を加えてよく振り、有機層を分離した。
飽和食塩水にて洗浄後、無水硫酸マグネシウムにて乾燥
し、減圧にて溶媒を留去して粗生成物を得た。これに2
−プロパノール〜イソプロピルエーテルを加えて刺激す
ると結晶化し、化合物(119)がほぼ純粋な状態で
3.375g(81.8%)得た。
2.26 g (6.43 mmol) of benzyl 2-acetamido-2-deoxy-4,6-O-isopropylidene-α-D-glucopyranoside (118),
Mercury cyanide 1.67 g, anhydrous nitromethane 100
a mixture of 100 ml of anhydrous benzene and 130 ml of anhydrous benzene is heated to reflux,
About 30 ml of benzene was distilled off. Next, the reaction solution is 60 to 65
Acetobromogalactose (117) 3 while maintaining at ℃
A 10 ml solution of g of benzene was slowly added dropwise. 6 after dropping
After stirring for an hour, 250 mg of mercuric cyanide and 550 mg of acetobromogalactose / 10 ml of benzene were added, and the mixture was stirred for 20 hours. After the reaction was completed, the insoluble matter was removed by filtration, water was added to the filtrate, and the mixture was shaken well to separate the organic layer.
After washing with saturated saline, it was dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure to obtain a crude product. 2 to this
Crystallization was carried out by adding propanol-isopropyl ether, and the compound (119) was obtained in an almost pure state in an amount of 3.375 g (81.8%).

【0317】 m.p. 193〜195 ℃, 〔α〕25 D+73.5°(C 1.0, CHCl3) IR(CHCl3)cm-1 :3500, 3450, 1750, 1690 1H-NMR (CDCl3,δppm): 1.95, 1.97, 2.05, 2.07, 2.15(3H,s, Ac), 3.54〜3.65, 3.68〜3.73(each 2H, each m), 3.73〜3.80, 3.84〜3.90, 3.93〜3.98 (each 1H, each m), 4.05〜4.18(2H, m), 4.28(1H, dt), 4.52(1H, d, J=8.1Hz), 4.45, 4.73(2H, JAB=11.5Hz,OCH2Ph), 4.98, 5.16〜5.23, 5.37(each 1H,each dd), 5.52(1H, d, J=10.0Hz, NH), 7.30〜7.45(5H, m) Mp 193-195 ° C., (α) 25 D + 73.5 ° (C 1.0, CHCl 3 ) IR (CHCl 3 ) cm −1 : 3500, 3450, 1750, 1690 1 H-NMR (CDCl 3 , δppm) : 1.95, 1.97, 2.05, 2.07, 2.15 (3H, s, Ac), 3.54 ~ 3.65, 3.68 ~ 3.73 (each 2H, each m), 3.73 ~ 3.80, 3.84 ~ 3.90, 3.93 ~ 3.98 (each 1H, each m ), 4.05 to 4.18 (2H, m), 4.28 (1H, dt), 4.52 (1H, d, J = 8.1Hz), 4.45, 4.73 (2H, J AB = 11.5Hz, OCH 2 Ph), 4.98, 5.16 ~ 5.23, 5.37 (each 1H, each dd), 5.52 (1H, d, J = 10.0Hz, NH), 7.30 ~ 7.45 (5H, m)

【0318】 元素分析 C29H39NO15 計算値 C 54.29% H 6.13% N 2.18% 実測値 C 54.01% H 6.06% N 2.01%Elemental analysis C 29 H 39 NO 15 Calculated value C 54.29% H 6.13% N 2.18% Actual value C 54.01% H 6.06% N 2.01%

【0319】参考例53 ベンジル 2−アセトアミド−3,6−ジ−O−(2,
3,4,6−テトラ−O−アセチル−β−D−ガラクト
ピラノシル)−2−デオキシ−α−D−グルコピラノシ
ド(121)
Reference Example 53 Benzyl 2-acetamido-3,6-di-O- (2,
3,4,6-Tetra-O-acetyl-β-D-galactopyranosyl) -2-deoxy-α-D-glucopyranoside (121)

【0320】化合物(119)3.2g(5ミリモ
ル)、シアン化第二水銀1.5g、無水ベンゼン80ml
及び無水ニトロメタン60mlの混合物を加熱還流撹拌
し、ベンゼンを約20ml留去した。その後窒素気流下、
内温60〜65℃にてアセトブロムガラクトース2.1
g(5ミリモル)のベンゼン10ml溶液を滴下し、その
まま撹拌反応させた。15時間後、再びシアン化第二水
銀260mg、アセトブロムガラクトース410mg/ベン
ゼン5ml溶液を加えてさらに2時間撹拌した。反応終了
後、セライトろ過して不溶物を除き、溶媒を減圧留去し
て粗生成物5.87gを得た。これをフラッシュクロマ
トグラフィー(酢酸エチル:ヘキサン=3:1)にて分
離精製して化合物(120)を1.647g、化合物
(120)と(121)の混合物を598mg、そして化
合物(121)を1.553gそれぞれ得た。混合物を
更にフラッシュクロマトグラフィー(酢酸エチル:ヘキ
サン=3:1)にて分離精製し、先に得たものと合わせ
ると化合物(120)が1.647g(収率45.4
%)、化合物(121)が1.876g(収率38.6
%)を得た。
3.2 g (5 mmol) of compound (119), 1.5 g of mercuric cyanide, 80 ml of anhydrous benzene.
A mixture of 60 ml of anhydrous nitromethane and 60 ml of anhydrous nitromethane was heated under reflux with stirring to distill off about 20 ml of benzene. Then under a nitrogen stream,
Acetobrom galactose 2.1 at an internal temperature of 60-65 ° C
A solution of 10 g of benzene (5 mmol) in benzene was added dropwise and the reaction was carried out with stirring. After 15 hours, 260 mg of mercuric cyanide and 410 mg of acetobromogalactose / 5 ml of benzene were added again, and the mixture was further stirred for 2 hours. After completion of the reaction, insoluble matter was removed by filtration through Celite, and the solvent was distilled off under reduced pressure to obtain 5.87 g of a crude product. This was separated and purified by flash chromatography (ethyl acetate: hexane = 3: 1) to give 1.647 g of compound (120), 598 mg of a mixture of compounds (120) and (121), and 1 of compound (121). 0.553 g was obtained. The mixture was further separated and purified by flash chromatography (ethyl acetate: hexane = 3: 1), and combined with the one obtained above, 1.647 g of compound (120) (yield 45.4).
%) And 1.876 g of the compound (121) (yield 38.6).
%) Was obtained.

【0321】 化合物(121) 〔α〕26 D+39.9°(C 1.0, CHCl3) IR(CHCl3)cm-1 :3500, 3450, 1750, 1685 1H-NMR (CDCl3,δppm): 1.94, 1.96, 1.97, 2.00, 2.03, 2.05, 2.05, 2.12, 2.14 (each 3H, each s, Ac), 3.42(1H, t, J=9.0Hz), 3.55(1H, s, OH), 3.56〜3.60(1H, m), 3.62〜3.68(1H, dd), 3.79〜3.86(1H, m), 3.89〜3.98(2H, m), 4.05〜4.20(4H, m), 4.21〜4.29(2H, m), 4.38, 4.70(2H, JAB=11,5Hz,OCH2Ph), 4.48(1H, d, J=8.1Hz), 4.57(1H, d, J=8.1Hz), 4.79(1H, d, J=3.7Hz, H-1), 4.95, 5.02(each 1H, dd, J=3.4Hz,10.5Hz), 5.15〜5.21(1H, dd), 5.22〜5.28(1H, dd), 5.33〜5.36, 5.37〜5.40(1H, m), 5.50(1H, d, J=9.8Hz, NH), 7.25〜7.40(5H, m) Compound (121) [α] 26 D + 39.9 ° (C 1.0, CHCl 3 ) IR (CHCl 3 ) cm −1 : 3500, 3450, 1750, 1685 1 H-NMR (CDCl 3 , δppm): 1.94 , 1.96, 1.97, 2.00, 2.03, 2.05, 2.05, 2.12, 2.14 (each 3H, each s, Ac), 3.42 (1H, t, J = 9.0Hz), 3.55 (1H, s, OH), 3.56 to 3.60 (1H, m), 3.62 to 3.68 (1H, dd), 3.79 to 3.86 (1H, m), 3.89 to 3.98 (2H, m), 4.05 to 4.20 (4H, m), 4.21 to 4.29 (2H, m) , 4.38, 4.70 (2H, J AB = 11,5Hz, OCH 2 Ph), 4.48 (1H, d, J = 8.1Hz), 4.57 (1H, d, J = 8.1Hz), 4.79 (1H, d, J = 3.7Hz, H-1), 4.95, 5.02 (each 1H, dd, J = 3.4Hz, 10.5Hz), 5.15 ~ 5.21 (1H, dd), 5.22 ~ 5.28 (1H, dd), 5.33 ~ 5.36, 5.37 ~ 5.40 (1H, m), 5.50 (1H, d, J = 9.8Hz, NH), 7.25 ~ 7.40 (5H, m)

【0322】参考例54 2−アセトアミド−1,4−ジ−O−アセチル−3,6
−ジ−O−(2,3,4−6−テトラ−O−アセチル−
β−D−ガラクトピラノシル)−2−デオキシ−D−グ
ルコピラノース(122)
Reference Example 54 2-acetamido-1,4-di-O-acetyl-3,6
-Di-O- (2,3,4-6-tetra-O-acetyl-
β-D-galactopyranosyl) -2-deoxy-D-glucopyranose (122)

【0323】化合物(121)1.47g(1.51ミ
リモル)、酢酸30ml及び10%パラジウム−炭素54
0mgを水素気流下に19時間反応させた。反応終了後、
ろ過して触媒を除き、ろ液を減圧留去して得た粗生成物
にピリジン10ml及び無水酢酸2mlを加えて室温にて7
2時間撹拌した。反応終了後、減圧にて溶媒を留去して
粗生成物を1.766g得た。これをフラッシュクロマ
トグラフィー(酢酸エチル)にて精製して化合物(12
2)を1.337g(収率91.6%)得た。
1.47 g (1.51 mmol) of compound (121), 30 ml of acetic acid and 54% of 10% palladium-carbon.
0 mg was reacted for 19 hours under hydrogen stream. After the reaction,
The catalyst was removed by filtration, and the filtrate was evaporated under reduced pressure. To the crude product obtained, 10 ml of pyridine and 2 ml of acetic anhydride were added, and the mixture was stirred at room temperature for 7 minutes.
Stir for 2 hours. After completion of the reaction, the solvent was distilled off under reduced pressure to obtain 1.766 g of a crude product. This was purified by flash chromatography (ethyl acetate) to give the compound (12
2.337 g (yield 91.6%) of 2) was obtained.

【0324】 〔α〕26 D+14.9°(C 1.0, CHCl3) IR(CHCl3)cm-1 :3450, 1750, 1690 1H-NMR (CDCl3,δppm): 1.95, 1.96, 1.99, 2.03, 2.04(each 3H,s, Ac), 2.04(6H, s, Ac× 2), 2.06, 2.11, 2.13, 2.18(each 3H, s, Ac), 3.42〜3.48(1H, dd), 3.84〜3.96(4H, m), 3.98〜4.04, 4.06〜4.12, 4.12〜4.18, 4.18〜4.25(each 1H, m), 4.45(1H, d, J=8.1Hz), 4.45〜4.52(1H, m), 4.57(1H, d, J=7.6Hz), 4.78〜4.86(1H, m), 4.90〜5.06(4H, m), 5.10〜5.18(1H, m), 5.32〜5.38(3H, m), 6.03(1H, d, J=3.7Hz)[Α] 26 D + 14.9 ° (C 1.0, CHCl 3 ) IR (CHCl 3 ) cm −1 : 3450, 1750, 1690 1 H-NMR (CDCl 3 , δppm): 1.95, 1.96, 1.99, 2.03 , 2.04 (each 3H, s, Ac), 2.04 (6H, s, Ac × 2), 2.06, 2.11, 2.13, 2.18 (each 3H, s, Ac), 3.42 ~ 3.48 (1H, dd), 3.84 ~ 3.96 (4H, m), 3.98 ~ 4.04, 4.06 ~ 4.12, 4.12 ~ 4.18, 4.18 ~ 4.25 (each 1H, m), 4.45 (1H, d, J = 8.1Hz), 4.45 ~ 4.52 (1H, m), 4.57 (1H, d, J = 7.6Hz), 4.78 ~ 4.86 (1H, m), 4.90 ~ 5.06 (4H, m), 5.10 ~ 5.18 (1H, m), 5.32 ~ 5.38 (3H, m), 6.03 (1H , d, J = 3.7Hz)

【0325】参考例55 8−メトキシカルボニルオクチル 2−アセトアミド−
3,6−ジ−O−(2,3,4,6−テトラ−O−アセ
チル−β−D−ガラクトピラノシル)−2−デオキシ−
β−D−グルコピラノシド(123)
Reference Example 55 8-Methoxycarbonyloctyl 2-acetamido-
3,6-di-O- (2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl) -2-deoxy-
β-D-glucopyranoside (123)

【0326】化合物(122)966mg(1ミリモル)
の塩化アセチル20ml溶液を−10℃に冷却し、乾燥塩
化水素ガスを1時間通じ、その後室温にて一晩放置し
た。反応終了後、塩化アセチルを減圧留去し、無水ベン
ゼンを加えて粗生成物を溶解した。再び減圧にて完全に
溶媒を留去後、得た粗クロリドを塩化メチレン15mlに
溶解、続いてトリフルオロメタンスルホン酸第一スズ4
20mg及びモレキュラーシーブ4A1.5gを加えて窒
素気流下に30分撹拌した。この混合物に8−メトキシ
カルボニルオクタノール400mg、テトラメチル尿素1
90mg及び塩化メチレン5mlの溶液を滴下し、17時間
撹拌した。反応終了後、クロロホルム10mlを加え、セ
ライトろ過し、ろ液を水洗、クロロホルム層を分離後、
無水硫酸マグネシウムにて乾燥した。減圧にて溶媒留去
して粗生成物1.15gを得た。これをフラッシュクロ
マトグラフィー(酢酸エチル)にて精製して化合物(1
23)を244mg(収率22.3%)得た。
966 mg (1 mmol) of compound (122)
20 ml of acetyl chloride solution was cooled to -10 ° C, dry hydrogen chloride gas was passed through for 1 hour, and then left at room temperature overnight. After completion of the reaction, acetyl chloride was distilled off under reduced pressure, and anhydrous benzene was added to dissolve the crude product. After the solvent was completely distilled off under reduced pressure, the obtained crude chloride was dissolved in 15 ml of methylene chloride, followed by stannous trifluoromethanesulfonate (4).
20 mg and 1.5 g of molecular sieve 4A were added, and the mixture was stirred under a nitrogen stream for 30 minutes. 400 mg of 8-methoxycarbonyloctanol and 1 part of tetramethylurea were added to this mixture.
A solution of 90 mg and 5 ml of methylene chloride was added dropwise and stirred for 17 hours. After completion of the reaction, 10 ml of chloroform was added, the mixture was filtered through Celite, the filtrate was washed with water, and the chloroform layer was separated.
It was dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure to obtain 1.15 g of a crude product. This was purified by flash chromatography (ethyl acetate) to give compound (1
23) was obtained (244 mg, yield 22.3%).

【0327】 〔α〕24 D-5.0 °(C 1.0, CHCl3) IR(CHCl3)cm-1 :3460, 1750, 1680 1H-NMR (CDCl3,δppm): 1.97, 1.98, 2.01, 2.05, 2.05, 2.06, 2.08, 2.15, 2.15 (each 3H, s, Ac), 1.30(10H, broad, s), 1.50〜1.70(4H, m), 2.31(2H, t, J=7.6Hz), 3.10〜3.20, 3.40〜3.50, 3.50〜3.60 (1H, m), 3.67(3H, s, CO2CH3), 3.80〜3.95(3H, m), 4.00〜4.20, 4.45〜4.55(each 1H, m), 4.55〜4.60 (2H, m), 4.70〜4.80, 4.80〜4.90(each 1H, m), 4.90〜5.04(2H, m), 5.04〜5.10, 5.15〜5.25(each 1H, m), 5.72(1H, d, J=6.35Hz) [Α] 24 D -5.0 ° (C 1.0, CHCl 3 ) IR (CHCl 3 ) cm −1 : 3460, 1750, 1680 1 H-NMR (CDCl 3 , δppm): 1.97, 1.98, 2.01, 2.05 , 2.05, 2.06, 2.08, 2.15, 2.15 (each 3H, s, Ac), 1.30 (10H, broad, s), 1.50 ~ 1.70 (4H, m), 2.31 (2H, t, J = 7.6Hz), 3.10 ~ 3.20, 3.40 ~ 3.50, 3.50 ~ 3.60 (1H, m), 3.67 (3H, s, CO 2 CH 3 ), 3.80 ~ 3.95 (3H, m), 4.00 ~ 4.20, 4.45 ~ 4.55 (each 1H, m) , 4.55 ~ 4.60 (2H, m), 4.70 ~ 4.80, 4.80 ~ 4.90 (each 1H, m), 4.90 ~ 5.04 (2H, m), 5.04 ~ 5.10, 5.15 ~ 5.25 (each 1H, m), 5.72 (1H , d, J = 6.35Hz)

【0328】例 35 8−メトキシカルボニルオクチル 2−アセトアミド−
3,6−ジ−O−(β−D−ガラクトピラノシル)−2
−デオキシ−β−D−グルコピラノシド(124) 化合物(123)224.4mgのメタノール10ml溶液
に28%ナトリウムメトキシド−メタノール0.05ml
を加え、室温にて24時間撹拌した。反応終了後、アン
バーライトIR120(H+ 型)−メタノール5mlを加
えて30分撹拌して中和した後、ろ過して樹脂を除い
た。続いてろ液を減圧留去して化合物(124)を無色
粉末として138mg(収率94.0%)得た。
Example 35 8-Methoxycarbonyloctyl 2-acetamido-
3,6-di-O- (β-D-galactopyranosyl) -2
-Deoxy-β-D-glucopyranoside (124) 28% sodium methoxide-methanol 0.05 ml in a solution of 224.4 mg of compound (123) 224.4 mg in methanol.
Was added, and the mixture was stirred at room temperature for 24 hours. After completion of the reaction, 5 ml of Amberlite IR120 (H + type) -methanol was added, and the mixture was stirred for 30 minutes for neutralization and then filtered to remove the resin. Then, the filtrate was distilled off under reduced pressure to obtain 138 mg (yield 94.0%) of Compound (124) as a colorless powder.

【0329】 m.p. 233〜234 ℃(CH3OH), 〔α〕25 D-18.9°(C 1.0, CH3OH) IR(KBr)cm-1 :3350, 1730, 1650 1H-NMR (CD3OD,δppm): 1.31(10H, broad s), 1.48〜1.65(4H, m), 1.95(3H, s, NHAc), 2.30(2H, t, J=7.6Hz), 3.42〜3.58(10H, m), 3.64(3H, s, CO2CH3), 3.65〜3.90(H, m), 4.16(1H, dd), 4.26, 4.34(1H, d, J=7.6Hz), 4.46(1H, d, J=8.3Hz)Mp 233-234 ° C. (CH 3 OH), [α] 25 D -18.9 ° (C 1.0, CH 3 OH) IR (KBr) cm −1 : 3350, 1730, 1650 1 H-NMR (CD 3 OD, δppm): 1.31 (10H, broad s), 1.48 ~ 1.65 (4H, m), 1.95 (3H, s, NHAc), 2.30 (2H, t, J = 7.6Hz), 3.42 ~ 3.58 (10H, m ), 3.64 (3H, s, CO 2 CH 3 ), 3.65 ~ 3.90 (H, m), 4.16 (1H, dd), 4.26, 4.34 (1H, d, J = 7.6Hz), 4.46 (1H, d, (J = 8.3Hz)

【0330】 元素分析 C30H53NO18・2H2O 計算値 C 47.93% H 7.64% N 1.86% 実測値 C 47.40% H 7.38% N 1.70%[0330] Elemental analysis C 30 H 53 NO 18 · 2H 2 O Calculated C 47.93% H 7.64% N 1.86 % Found C 47.40% H 7.38% N 1.70 %

【0331】例 50 N−アセチルマンノサミニル−β−オキシオクタノイル
アルブミン(200)
Example 50 N-Acetylmannosaminyl-β-oxyoctanoyl albumin (200)

【0332】化合物(21)85mg(0.217ミリモ
ル)のエタノール1ml溶液に、ヒドラジン水和物0.2
mlを加えて、室温に24時間放置した。反応混合物を減
圧下濃縮乾固した。残渣に少量のエタノールおよび水を
加えて溶解した後、再び減圧下にて濃縮乾固し、過剰の
ヒドラジン水和物を除去した。得られた酸ヒドラジド8
5mgをジメチルホルムアミド2.9mlに溶解し、窒素気
流下、−25℃に冷却した。4.1N 塩酸−ジオキサン
溶液0.19mlを加えた後、亜硝酸tert−ブチル28mg
のジメチルホルムアミド溶液0.28mlを加え、30分
間撹拌した。スルファミン酸20mgのジメチルホルムア
ミド溶液0.3mlを加え、5分間撹拌した。次いで、こ
の酸アジドを含む溶液を、人血清アルブミン269mgの
0.08M ホウ酸ナトリウム−0.35M 炭酸水素カリ
ウム緩衝液27mlに、氷冷下、ゆっくりと撹拌しながら
滴下した。反応混合物を4℃で24時間放置した後、ス
ペクトラポール(分子量カットオフ12,000〜1
4,000)透析膜を用いて、精製水に対して4℃で2
4時間透析した。透析内液を取り出して凍結乾固してN
−アセチルマンノサミニル−β−オキシオクタノイルア
ルブミン270mgを得た。N−アセチルマンノサミニル
−β−オキシオクタノイルアルブミンを4N 塩酸で加水
分解処理した後、エルソン−モーガン法で滴定すると4
3個のN−アセチルマンノサミニルオクチル基が導入さ
れていることが明らかとなった。
To a solution of 85 mg (0.217 mmol) of compound (21) in 1 ml of ethanol was added hydrazine hydrate 0.2.
ml was added and left at room temperature for 24 hours. The reaction mixture was concentrated to dryness under reduced pressure. A small amount of ethanol and water were added to the residue to dissolve it, and the residue was concentrated to dryness again under reduced pressure to remove excess hydrazine hydrate. The obtained acid hydrazide 8
5 mg was dissolved in 2.9 ml dimethylformamide and cooled to -25 ° C under a nitrogen stream. After adding 0.19 ml of 4.1N hydrochloric acid-dioxane solution, 28 mg of tert-butyl nitrite
0.28 ml of the dimethylformamide solution of was added and stirred for 30 minutes. 0.3 ml of a dimethylformamide solution containing 20 mg of sulfamic acid was added, and the mixture was stirred for 5 minutes. Then, the solution containing this acid azide was added dropwise to 27 ml of 0.08M sodium borate-0.35M potassium hydrogen carbonate buffer solution containing 269 mg of human serum albumin under ice cooling while slowly stirring. The reaction mixture was allowed to stand at 4 ° C. for 24 hours, after which Spectrapol (molecular weight cutoff 12,000-1
4,000) dialysis membrane at 2 ℃ against purified water 2
It was dialyzed for 4 hours. Take out the dialysis solution, freeze to dryness, and
270 mg of -acetylmannosaminyl-β-oxyoctanoyl albumin was obtained. N-acetylmannosaminyl-β-oxyoctanoyl albumin was hydrolyzed with 4N hydrochloric acid and then titrated by the Elson-Morgan method to give 4
It was revealed that three N-acetylmannosaminyloctyl groups were introduced.

【0333】例 51 化合物(9)、(11)、(12)、(20)、(2
2)、(26)、(27)、(34)、(35)、(3
6)、(37)、(41)、(48)、(53)、(5
8)、(62)、(66)、(68)、(70)、(7
3)、(77)、(88)、(89)、(91)、(9
3)、(97)、(98)、(104)、(105)、
(114)、(115)、(116)及び(124)を
用いて、例50に記載した方法と同一の方法により人血
清アルブミンへ糖残基の導入を行った。導入された糖含
量は、中性糖の場合にはフェノール硫酸法により、ヘキ
ソサミンの場合は4N 塩酸による加水分解後、エルソン
−モーガン法で行った。化合物と糖修飾アルブミン糖含
量の一覧を表1および表2に示した。
Example 51 Compounds (9), (11), (12), (20) and (2
2), (26), (27), (34), (35), (3
6), (37), (41), (48), (53), (5
8), (62), (66), (68), (70), (7
3), (77), (88), (89), (91), (9
3), (97), (98), (104), (105),
Using (114), (115), (116) and (124), a sugar residue was introduced into human serum albumin by the same method as described in Example 50. The introduced sugar content was measured by the Elsson-Morgan method after hydrolysis with a phenol-sulfuric acid method in the case of neutral sugar, and with 4N hydrochloric acid in the case of hexosamine. The compounds and sugar-modified albumin sugar contents are listed in Tables 1 and 2.

【0334】[0334]

【表1】 [Table 1]

【0335】[0335]

【表2】 [Table 2]

【0336】またこれらの化合物の物理恒数を表3及び
表4に示した。
The physical constants of these compounds are shown in Tables 3 and 4.

【0337】[0337]

【表3】 [Table 3]

【0338】[0338]

【表4】 [Table 4]

【0339】なお、糖含量の測定及び液体クロマトグラ
フィー試験法は次のとおりである。
The measurement of the sugar content and the liquid chromatography test method are as follows.

【0340】ネオグリコプロテイン(200)の糖含量
測定 人血清アルブミン1モル当りの2−アセトアミド−2−
デオキシ−D−マンノース含量をエルソン−モーガン法
により定量した。化合物(200)2.48mgを4N 塩
酸0.25mlに溶解し、100℃で4時間加熱した。反
応液は減圧下に濃縮乾固した。得られた残渣を精製水2
mlに溶解した後、その0.5mlをガラス栓付試験管にと
り、アセチルアセトン試薬1.0mlを加えて90℃に1
時間加熱した。水冷し、96%エタノール10mlを静か
に加え、ついでエールリッヒ試薬1.0mlを加えて撹拌
した。混和後、室温に1時間放置し530nmで比色定量
した。2−アセトアミド−2−デオキシ−D−マンノー
スを同様に処理して得た検量線から、化合物(200)
の2−アセトアミド−2−デオキシ−D−マンノース含
量を43個と決定した。
Sugar content of neoglycoprotein (200)
Measurements human serum albumin per mole of 2-acetamido-2
Deoxy-D-mannose content was quantified by the Elson-Morgan method. 2.48 mg of compound (200) was dissolved in 0.25 ml of 4N hydrochloric acid and heated at 100 ° C. for 4 hours. The reaction solution was concentrated to dryness under reduced pressure. The residue obtained is purified water 2
Dissolve in 0.5 ml, transfer 0.5 ml to a test tube with a glass stopper, add 1.0 ml of acetylacetone reagent, and add 1 at 90 ° C.
Heated for hours. After cooling with water, 10 ml of 96% ethanol was gently added, and then 1.0 ml of Ehrlich reagent was added and stirred. After mixing, the mixture was allowed to stand at room temperature for 1 hour and colorimetrically determined at 530 nm. From the calibration curve obtained by similarly treating 2-acetamido-2-deoxy-D-mannose, compound (200)
The 2-acetamido-2-deoxy-D-mannose content of was determined to be 43.

【0341】ネオグリコプロテイン(217)の糖含量
測定 化合物(217)における人血清アルブミン1モルに対
するフコースの結合モル数をフェノール硫酸法(マイケ
ル・ドゥボイス(Michel Dubois)ら、Anal. Chem., 28,
350-356(1956)) により測定した。
Sugar content of neoglycoprotein (217)
The number of moles of fucose bound to 1 mole of human serum albumin in the measurement compound (217) was determined by the phenol-sulfuric acid method (Michel Dubois et al., Anal. Chem., 28,
350-356 (1956)).

【0342】化合物(217)2.1mgを蒸留水に溶解
し、5%フェノール水溶液1mlを加えた後、濃硫酸5ml
を溶液中にすばやく添加した。これを10分間室温に放
置した後、20分間25℃から30℃の間に保った。こ
の溶液の吸光度(波長480nm)を測定し、文献の方法
に従い作成したフコースの検量線より糖含量を求めた。
この結果、人血清アルブミン1モルに対するフコースの
結合モル数は22と決定した。
2.1 mg of compound (217) was dissolved in distilled water, 1 ml of 5% phenol aqueous solution was added, and then 5 ml of concentrated sulfuric acid.
Was quickly added to the solution. This was left at room temperature for 10 minutes and then kept at 25 ° C to 30 ° C for 20 minutes. The absorbance (wavelength: 480 nm) of this solution was measured, and the sugar content was determined from the standard curve of fucose prepared according to the method in the literature.
As a result, the binding mole number of fucose to 1 mole of human serum albumin was determined to be 22.

【0343】液体クロマトグラフィー試験法 化合物(200)のゲルろ過液体クロマトグラフィーに
よる分子量測定を行った。使用機器、カラムは以下のも
のを使用した。ポンプ:日本分光880−PV、 検出器:日本分光870−UV、 カラム:TSK−GEL G3000SW。
Liquid Chromatography Test Method The molecular weight of compound (200) was measured by gel filtration liquid chromatography. The following equipment and columns were used. Pump: JASCO 880-PV, Detector: JASCO 870-UV, Column: TSK-GEL G3000SW.

【0344】また分析条件として、 溶離液:0.008M 等張リン酸緩衝液 pH7.4、 流速:0.4ml/分 測定波長:280nm を使用した。As analytical conditions, eluent: 0.008M isotonic phosphate buffer pH 7.4, flow rate: 0.4 ml / min, measurement wavelength: 280 nm was used.

【0345】化合物(200)を1mg/mlになるよう
に、リン酸緩衝液に溶解し、その20μl カラムに添加
した。
Compound (200) was dissolved in phosphate buffer so that the concentration was 1 mg / ml, and the solution was added to the 20 μl column.

【0346】その結果、化合物(200)は20.6分
に溶出されることが示された。また、分子量の異なる蛋
白、β−アミラーゼ(分子量200,000)、人血清
アルブミン(分子量67,000)、カルボニックアン
ハイドラーゼ(分子量29,000)について、同じ条
件で溶出時間を測定した結果、それぞれ19.5、2
1.8、26.7分であり、分子量により溶出時間が異
なることが示された。従って、化合物(120)は人血
清アルブミンよりも少し分子量の大きい化合物であるこ
とが示された。
As a result, it was shown that the compound (200) was eluted at 20.6 minutes. In addition, the elution times of proteins having different molecular weights, β-amylase (molecular weight 200,000), human serum albumin (molecular weight 67,000) and carbonic anhydrase (molecular weight 29,000) were measured under the same conditions. 19.5, 2
It was 1.8 and 26.7 minutes, and it was shown that the elution time was different depending on the molecular weight. Therefore, Compound (120) was shown to be a compound having a slightly higher molecular weight than human serum albumin.

【0347】化合物(202)〜(225)についても
同じ条件下で溶出時間を測定した。その結果も表3およ
び表4に示した。その結果、化合物(202)〜(22
5)はほぼ同程度の分子量を有することがわかった。
The elution times of the compounds (202) to (225) were measured under the same conditions. The results are also shown in Tables 3 and 4. As a result, compounds (202) to (22
It was found that 5) had almost the same molecular weight.

【0348】参考例56 N−アセチルマンノサミニルオキシオクチル人血清アル
ブミンとメトトレキセートとの複合体
Reference Example 56 N-Acetylmannosaminyloxyoctyl Human Serum Albumin Complex with Methotrexate

【0349】Biol. Cell., 51, 187(1984)に記載の方法
で合成したメトトレキセートのN−ヒドロキシサクシン
イミドの活性エステルのジメチルホルムアミド溶液を、
N−アセチルマンノサミニル−β−オキシオクチル人血
清アルブミン(200)のリン酸緩衝液に氷冷下加え、
同温度で4時間撹拌した。反応液を遠心分離し、不溶物
をろ去した後、ミリポアフィルターを用いてろ過した。
ろ過をゲルろ過(G−100)カラムクロマトグラフィ
ーで分離精製して、メトトレキセートとN−アセチルマ
ンノサミニル−オキシオクチル人血清アルブミンとの複
合体を得た。
Biol. Cell., 51, 187 (1984), a dimethylformamide solution of the active ester of N-hydroxysuccinimide of methotrexate synthesized by the method described in
N-acetylmannosaminyl-β-oxyoctyl human serum albumin (200) was added to a phosphate buffer under ice cooling,
The mixture was stirred at the same temperature for 4 hours. The reaction solution was centrifuged, insoluble matter was filtered off, and then filtered using a Millipore filter.
The filtration was separated and purified by gel filtration (G-100) column chromatography to obtain a complex of methotrexate and N-acetylmannosaminyl-oxyoctyl human serum albumin.

【0350】試験例 例50および例51で得たネオグリコプロテインを、ク
ロラミンT法を用いてヨードラベル化した。その結果、
比活性18〜30 MBq/20μg 蛋白質のヨードラベル
化ネオグリコプロテインを得た。放射性ヨードが蛋白に
結合していることを確認するために、TCA処理を行っ
た。即ち、0.5%牛の血清アルブミン含有0.1M リ
ン酸緩衝液を用いて適当に希釈した後、その300μl
を試験管に取り、15%TCA(トリクロル酢酸)溶液
600μl を加え、撹拌後3,000rpm で10分間遠
心し、上清、沈殿中に存在する放射性ヨードの活性を測
定した。その結果、全放射活性の95%以上が沈殿中に
存在しており、放射性ヨードが蛋白に結合していること
がわかった。
Test Example The neoglycoproteins obtained in Examples 50 and 51 were iodinated using the chloramine T method. as a result,
Iodolabeled neoglycoprotein with a specific activity of 18-30 MBq / 20 μg protein was obtained. TCA treatment was performed to confirm that radioactive iodine was bound to the protein. That is, after appropriately diluting with 0.1 M phosphate buffer containing 0.5% bovine serum albumin, 300 μl thereof
Was taken in a test tube, 600 μl of a 15% TCA (trichloroacetic acid) solution was added, and the mixture was stirred and then centrifuged at 3,000 rpm for 10 minutes to measure the activity of radioactive iodine present in the supernatant and the precipitate. As a result, it was found that 95% or more of the total radioactivity was present in the precipitate, and radioactive iodine was bound to the protein.

【0351】このヨードラベル化ネオグリコプロテイン
を用いて、動物における分布実験を行った。まず、ヨー
ドラベル化ネオグリコプロテイン4μg を0.5%牛の
血清アルブミン含有0.1M リン酸緩衝液(pH7.4)
1mlに溶解し、投与検液とした。またヨードラベルの比
活性が高いときは、未標識のネオグリコプロテインを用
いて希釈を行い、投与検液とした。
A distribution experiment in animals was carried out using this iodolabeled neoglycoprotein. First, 4 μg of iodolabeled neoglycoprotein was added to 0.1 M phosphate buffer containing 0.5% bovine serum albumin (pH 7.4).
It was dissolved in 1 ml to give a test solution for administration. When the specific activity of iodine label was high, it was diluted with unlabeled neoglycoprotein and used as a test solution for administration.

【0352】この溶液をSD系雄性ラット(体重240
〜300g)に、体重100g当り0.1mlになるよう
に大腿静脈より投与した。その後、正確に1分、2分、
3分後に頸静脈より採血を行い、投与後5分後に下大動
脈より全身血を採取し脱血死させる。その後、直ちに心
臓、肺臓、胸腺、脾臓、腎臓、筋肉、骨髄、皮膚、肝臓
を採取した。
This solution was added to SD male rats (body weight: 240).
˜300 g) was administered through the femoral vein to give 0.1 ml per 100 g of body weight. After that, exactly 1 minute, 2 minutes,
Blood is collected from the jugular vein 3 minutes later, and 5 minutes after administration, systemic blood is collected from the inferior aorta and bleeding to death. Immediately thereafter, the heart, lung, thymus, spleen, kidney, muscle, bone marrow, skin and liver were collected.

【0353】投与後1分、2分、3分、5分の血清及び
5分の全血液、心臓、肺臓、胸腺、脾臓、腎臓、筋肉、
骨髄、皮膚、肝臓を正確に秤量し、その放射活性を測定
した。
1 min, 2 min, 3 min, 5 min serum and 5 min whole blood, heart, lung, thymus, spleen, kidney, muscle,
Bone marrow, skin and liver were accurately weighed and their radioactivity was measured.

【0354】また、投与検液及び投与後5分の血清中に
存在する放射活性が、ネオグリコプロテインに結合して
いることを確認するために、TCA処理を行った。操作
は前述と同様に行い、全放射活性の90%以上がネオグ
リコプロテインに結合していることを確認した。
Further, in order to confirm that the radioactivity present in the administration test solution and the serum 5 minutes after the administration was bound to neoglycoprotein, TCA treatment was carried out. The procedure was performed as described above, and it was confirmed that 90% or more of the total radioactivity was bound to neoglycoprotein.

【0355】次に、得られた血清中濃度(投与後1分、
2分、3分及び5分)の結果より、投与後0分から5分
までの血清中濃度下面積(AUC0-5)を台形近似法を用
いて計算した。AUC0-5 は、次式により定義される。
AUC0-5 =∫5 0 CdtここでCはネオグリコプロテ
インの時間(t)における血清中濃度である。
Next, the obtained serum concentration (1 minute after administration,
From the results of 2 minutes, 3 minutes, and 5 minutes), the area under serum concentration (AUC 0-5 ) from 0 minute to 5 minutes after administration was calculated using the trapezoidal approximation method. AUC 0-5 is defined by the following equation.
AUC 0-5 = ∫ 5 0 Cdt where C is the serum concentration at neoglycoprotein time (t).

【0356】さらに、ネオグリコプロテインの各組織中
濃度とAUC0-5 の比から、組織分布クリアランスを計
算した。その結果を表5に示した。
Further, the tissue distribution clearance was calculated from the concentration of neoglycoprotein in each tissue and the ratio of AUC 0-5 . The results are shown in Table 5.

【0357】表5の結果から明らかなように、アルブミ
ンを糖鎖で修飾することにより、骨髄への分布クリアラ
ンスが増大していることがわかった。また、その中でも
マンノース(203)、マンノサミン(200)、フコ
ース(217)、マンノースα(1−6)マンノース
(208)及びマンノースβ(1−6)マンノース(2
09)で修飾したネオグリコプロテインにおいて、骨髄
への分布クリアランスが大きく増大しており、骨髄組織
への指向性を示していた。
As is clear from the results in Table 5, it was found that modification of albumin with sugar chains increased distribution clearance to bone marrow. In addition, among them, mannose (203), mannosamine (200), fucose (217), mannose α (1-6) mannose (208) and mannose β (1-6) mannose (2
In the neoglycoprotein modified in 09), the distribution clearance to the bone marrow was greatly increased, indicating the directivity to bone marrow tissue.

【0358】このことは、グリコシル−蛋白誘導体は骨
髄組織を標的組織とする薬物運搬担体として有用である
ことを示している。
This indicates that the glycosyl-protein derivative is useful as a drug delivery carrier targeting bone marrow tissue.

【0359】[0359]

【表5】 [Table 5]

【0360】上記化合物の組織分布を検討してみると、
大きく2つのグループに分けられる。 静脈注射後すばやく血中から消失し、骨髄、肝臓など
の組織に分布する特性を有しているもの、 血中に比較的長く存在し、ゆっくり組織へ分布する特
性を有しているもの。
Examining the tissue distribution of the above compound,
There are two main groups. Those that disappear from blood immediately after intravenous injection and have the property of being distributed to tissues such as bone marrow and liver, and those that exist in blood for a relatively long time and that slowly distribute to tissues.

【0361】の特性を有する化合物の場合には、骨髄
への分布クリアランスが大きいものほど、すばやくまた
より多く骨髄に分布することになるので、骨髄への分布
クリアランスを比較することにより評価できる。これに
属する化合物としては、(200)、(202)、(2
04)、(208)(209)、(217)、(21
8)が挙げられ、血清アルブミン(HSA)のそれに比
べ約7倍から11倍高くなっていた。
In the case of the compound having the above-mentioned characteristic, the larger the distribution clearance to the bone marrow, the quicker and the more the distribution clearance is distributed to the bone marrow. Therefore, it can be evaluated by comparing the distribution clearance to the bone marrow. The compounds belonging to this are (200), (202), (2
04), (208) (209), (217), (21
8), which was about 7 to 11 times higher than that of serum albumin (HSA).

【0362】また、の特性を有する化合物の場合に
は、骨髄への分布クリアランスが小さくても他の組織へ
の分布クリアランスも小さければ、より骨髄へ集まる化
合物となるので、骨髄への分布クリアランスと全身への
分布クリアランスの比を比較することにより評価でき
る。これに属する化合物としては、(204)、(20
5)、(212)、(213)、(215)、(21
9)が挙げられ、HSAのそれに比べて約1.3倍から
1.8倍高くなっていた。
Further, in the case of the compound having the property of (3), if the distribution clearance to the bone marrow is small, but the distribution clearance to other tissues is also small, the compound will be more concentrated in the bone marrow, so that the distribution clearance to the bone marrow will be It can be evaluated by comparing the ratio of distribution clearance to the whole body. Compounds belonging to this group include (204) and (20
5), (212), (213), (215), (21
9), which was about 1.3 to 1.8 times higher than that of HSA.

【0363】例 52 例50に記載した方法と同一の方法により、人血清アル
ブミンへ糖残基の導入を行い、表6に記載する234か
ら249までの化合物を得た。各化合物についての物理
恒数を表7に示した。
Example 52 A sugar residue was introduced into human serum albumin by the same method as that described in Example 50 to obtain the compounds 234 to 249 shown in Table 6. The physical constants for each compound are shown in Table 7.

【0364】[0364]

【表6】 [Table 6]

【0365】[0365]

【表7】 [Table 7]

【0366】試験例 2 例51で得た化合物226および例52で得た化合物2
36、238、242、245及び246を検体試料と
して、またHSAを対照試料としてそれぞれ用意した。
Test Example 2 Compound 226 obtained in Example 51 and compound 2 obtained in Example 52
36, 238, 242, 245 and 246 were prepared as specimen samples, and HSA was prepared as a control sample.

【0367】K,L,Audus らの方法 (Pharm.Res.,3,81(19
86))に従って単離した牛脳毛細血管内皮細胞(以下BB
CECsと略記する)5×104 cells/cm2 を6Well
(9.6cm2)のカルチャープレートで11日間培養した
後に、20mM HEPES0.1%リン酸緩衝液含有M
EM(pH7.4)(以下反応メディウムと略記する)で
3回洗浄した。反応メディウムを2ml添加し、30分間
プレインキュベートした後に、 125Iでラベルした試料
125I−リガンド)を、25ng/ml〜3μg/mlの濃
度において、特に化合物242及び245については更
に20μg /mlまでの濃度において添加し、インキュベ
ートした。その後残余の反応メディウムを除き、3回リ
ン酸緩衝液で洗浄し、0.1N 水酸化ナトリウム1mlを
添加した。4℃で30分間放置した後に可溶化したBB
CECsを集め、これについてガンマーカウンターで放
射活性を、また Bio-Rad プロティンアッセイキッドで
蛋白量を測定し、蛋白mg当たりの取り込み活性 (Total
Bound)を求めた。
[0367] K, L, Audus et al's method (Pharm.Res., 3,8 1 (19
86)) bovine brain capillary endothelial cells (hereinafter BB)
Abbreviated as CECs) 5 × 10 4 cells / cm 2 6 well
After culturing for 11 days on a (9.6 cm 2 ) culture plate, M containing 20 mM HEPES 0.1% phosphate buffer was added.
It was washed 3 times with EM (pH 7.4) (hereinafter abbreviated as reaction medium). After adding 2 ml of reaction medium and preincubating for 30 minutes, 125 I-labeled sample ( 125 I-ligand) was added at a concentration of 25 ng / ml to 3 μg / ml, especially 20 μg / ml for compounds 242 and 245. At concentrations up to and were incubated. Thereafter, the remaining reaction medium was removed, and the mixture was washed 3 times with a phosphate buffer solution, and 1 ml of 0.1N sodium hydroxide was added. BB solubilized after standing at 4 ° C for 30 minutes
The CECs were collected, and the radioactivity was measured with a gamma counter, and the amount of protein was measured with the Bio-Rad protein assay kit.
Bound).

【0368】別に前記各反応系に過剰量(100〜30
0倍量)の非ラベル試料(リガンド)を添加し、インキ
ュベートし、前記と同様に処理して測定し、蛋白mg当た
りの非特異的取り込み活性(+Cold)を求めた。取り込
み活性から非特異的取り込み活性を差引いて、特異的取
り込み活性(S.B.;取り込まれた蛋白mg当たりのリガン
ド量)を算出した。
Separately, an excess amount (100 to 30) is added to each reaction system.
An unlabeled sample (ligand) (0-fold amount) was added, incubated, treated in the same manner as above, and measured to determine the nonspecific uptake activity (+ Cold) per mg of protein. The specific uptake activity (SB; the amount of ligand per mg of incorporated protein) was calculated by subtracting the nonspecific uptake activity from the uptake activity.

【0369】結果を図1〜図9に示す。図中●印線、○
印線及び■印線はそれぞれ取り込み活性、非特異的取り
込み活性及び特異的取り込み活性を表す。図1から図5
は図の番号順に、それぞれHSA、化合物236、22
6、238及び246についての取り込み活性の結果
を、図6と図8は化合物245についての取り込み活性
の結果を、図7と図9は化合物242についての取り込
み活性の結果を示す。
The results are shown in FIGS. ● Marked line, ○
The solid lines and solid lines represent uptake activity, nonspecific uptake activity and specific uptake activity, respectively. 1 to 5
Are HSA, compounds 236 and 22 respectively in the order of the numbers in the figure.
6, 238 and 246 show the results of the uptake activity, FIGS. 6 and 8 show the results of the uptake activity of Compound 245, and FIGS. 7 and 9 show the results of the uptake activity of Compound 242.

【0370】図1〜図9より、化合物236、226、
238及び246では添加濃度3μg /mlで、また化合
物245では添加濃度10μg /mlで、それぞれ取り込
みに飽和が認められたが、対照試料であるHSAではB
BCECsに対して取り込み活性を持たないのに対し、
いずれの検体試料も取り込み活性を有しており、特に化
合物242の取り込み活性は添加濃度20μg /mlでも
飽和に達しないことが認められた。
From FIGS. 1 to 9, compounds 236, 226,
Saturation was observed for 238 and 246 at an addition concentration of 3 μg / ml and for compound 245 at an addition concentration of 10 μg / ml, respectively.
While it has no uptake activity for BCECs,
It was confirmed that all the specimen samples had the uptake activity, and in particular, the uptake activity of the compound 242 did not reach the saturation even at the addition concentration of 20 μg / ml.

【0371】表8は添加濃度3μg /mlにおける取り込
み活性の比較を示すものであるが、これによると糖の種
類によってBBCECsに対する取り込み認識に差のあ
ることが認められた。したがって、脳へ所定の薬物を送
達する目的および条件に応じて適宜に糖の種類を選択す
ればよいことが知られる。
Table 8 shows a comparison of the uptake activity at the addition concentration of 3 μg / ml. According to this, it was recognized that there was a difference in uptake recognition for BBCECs depending on the type of sugar. Therefore, it is known that the type of sugar may be appropriately selected according to the purpose and conditions for delivering a predetermined drug to the brain.

【0372】[0372]

【表8】 [Table 8]

【0373】試験例 3 例52で得た化合物236、237、240、241、
243及び244を試料として用意した。試験例2にお
いて、 125Iでラベルした試料( 125I−リガンド)
を,100ng/mlの濃度において添加した以外は、試験
例2に記載と同様に行い、取り込み活性、非特異的取り
込み活性及び特異的取り込み活性を求めた。結果を図1
0及び図11に示す。図10は化合物236及び23
7、すなわちManβを糖種とし、m数のみが異なる一
連の化合物群について得られた結果であり、m数と特異
的取り込み活性の関係を表す。図11は化合物240、
241、243及び244、すなわちFucβを糖種と
し、m数のみが異なる一連の化合物群について得られた
結果であり、m数と特異的取込み活性の関係を表す。図
10及び図11より、m数すなわち糖密度の増加に伴い
活性の増加が認められた。したがって、脳へ所定の薬物
を送達する目的及び条件に応じて適宜に糖密度を選択す
ればよいことが知られる。
Test Example 3 Compounds 236, 237, 240, 241 obtained in Example 52,
243 and 244 were prepared as samples. Sample labeled with 125 I in Test Example 2 ( 125 I-ligand)
Was added at a concentration of 100 ng / ml, and the uptake activity, nonspecific uptake activity and specific uptake activity were determined in the same manner as in Test Example 2. The result is shown in Figure 1.
0 and FIG. FIG. 10 shows compounds 236 and 23
7, that is, the results obtained for a series of compound groups in which Manβ is a sugar species and only the m number is different, and shows the relationship between the m number and the specific uptake activity. FIG. 11 shows compound 240,
24 shows the results obtained for a series of compounds having 241, 243, and 244, that is, Fucβ as a sugar species and differing only in the m number, and represents the relationship between the m number and the specific uptake activity. From FIG. 10 and FIG. 11, it was confirmed that the activity increased as the m number, that is, the sugar density increased. Therefore, it is known that the sugar density may be appropriately selected according to the purpose and conditions for delivering a predetermined drug to the brain.

【0374】試験例 4 例52で得た化合物245を検体試料とした。検体試料
の取り込みを阻害する目的で添加する非ラベル試料とし
て、例51で得た化合物226、例52で得た化合物2
36、238、242、245、246、247、24
8及び249並びにHSAを用意した。
Test Example 4 The compound 245 obtained in Example 52 was used as a sample. The compound 226 obtained in Example 51 and the compound 2 obtained in Example 52 were added as unlabeled samples for the purpose of inhibiting the uptake of the specimen sample.
36, 238, 242, 245, 246, 247, 24
8 and 249 and HSA were prepared.

【0375】試験例2において、 125Iでラベルした検
体試料( 125I−リガンド)を、1μg /mlの濃度にお
いて添加し、各非ラベル試料は一様に100倍量を添加
した以外は試験例2と同様に行い、取り込み活性を求め
た。結果を図12に示す。図12は阻害の目的で添加し
た化合物と検体試料245の取り込み活性との関係を表
す。図12より、検体試料の取り込みに対していくつか
の化合物が阻害効果を示すが、もっとも強い阻害効果は
検体試料自身によってもたらされており、該取り込みが
糖特異的であることが認められる。
Test Example 2 except that the sample sample labeled with 125 I ( 125 I-ligand) was added at a concentration of 1 μg / ml, and each unlabeled sample was added uniformly in 100-fold amount. The same procedure as in 2 was performed to determine the uptake activity. Results are shown in FIG. FIG. 12 shows the relationship between the compound added for the purpose of inhibition and the uptake activity of the specimen sample 245. From FIG. 12, it is confirmed that some compounds show an inhibitory effect on the uptake of the specimen sample, but the strongest inhibitory effect is brought about by the specimen sample itself, and the uptake is sugar-specific.

【0376】試験例 5(体内分布実験) 例52で得た化合物237、241、243及び245
を検体試料として、HSAを対照試料として用意した。
各試料を1mg秤量し、0.05M ホウ酸緩衝液5mlに溶
解した。一方, N−サクシニイミジル〔2,3−3H〕プ
ロピオネートのトルエン溶液100μlにモレキュラー
シーブ処理したDMF溶液100μl を混和し、上記ホ
ウ酸緩衝液に添加した。4℃にて一夜撹拌後、トルエン
層を除去し、水層をセントリコン30にて約200μl
にまで濃縮した。この濃縮液をPD−10カラムを用い
て溶出液のリン酸緩衝液でゲルろ過を行い、ボイド画分
に溶出された放射活性を回収した。この回収液の蛋白濃
度を測定し、1mg/mlとなるように各試料を加えて、動
物への投与液とした。
Test Example 5 (Biodistribution Experiment) Compounds 237, 241, 243 and 245 obtained in Example 52
Was prepared as a sample and HSA was prepared as a control sample.
1 mg of each sample was weighed and dissolved in 5 ml of 0.05M borate buffer. On the other hand, to mix the N- Sakushiniimijiru [2,3-3 H] DMF solution 100μl treated molecular sieves in toluene solution 100μl propionate was added to the borate buffer. After stirring overnight at 4 ° C, the toluene layer was removed, and the aqueous layer was about 200 µl with Centricon 30.
It was concentrated to. The concentrated solution was subjected to gel filtration using a PD-10 column with a phosphate buffer solution as an eluent to collect radioactivity eluted in the void fraction. The protein concentration of this recovered liquid was measured, and each sample was added to give a concentration of 1 mg / ml, which was used as a liquid for administration to animals.

【0377】H3化した試料を1mg/kgとなるようにラ
ット(雄 SD系6週例) に大腿静脈より投与した。投
与30分後に下大動脈より脱血させることによりラット
を屠殺し、組織濃度を測定した。プラズマ中及び組織中
の放射活性は、サンプルオキシダイザーを用いて燃焼
後、液体シンチレーションカウンターで測定した。
The H 3 -converted sample was administered to rats (male SD strain 6 weeks) at 1 mg / kg through the femoral vein. Thirty minutes after the administration, the rat was sacrificed by removing blood from the inferior aorta, and the tissue concentration was measured. Radioactivity in plasma and tissue was measured with a liquid scintillation counter after burning using a sample oxidizer.

【0378】なお、前記の方法により作成した検体は、
10%トリクロル酢酸溶液中において放射活性の99.
5%が沈殿することが認められた。
The sample prepared by the above method is
99. Radioactive in 10% trichloroacetic acid solution.
It was observed that 5% was precipitated.

【0379】結果を図13に示す。図13は投与30分
後における脳中濃度とプラズマ中濃度との比(Kp値)を
試料毎に示すグラフである。図13より、糖の修飾によ
り脳への移行を高める可能性があることがわかる。
The results are shown in FIG. FIG. 13 is a graph showing the ratio (Kp value) between the brain concentration and the plasma concentration 30 minutes after administration for each sample. From FIG. 13, it can be seen that there is a possibility that sugar modification may enhance the transfer to the brain.

【0380】例 53 p−アミノフェニル α−D−グルコピラノシド(30
1) p−ニトロフェニル α−D−グルコピラノシド500
mgの水7ml−メタノール15ml溶液に、10%パラジウ
ム−炭素75mgを加え、室温で16時間水素ガスを吹き
込んだ。触媒をろ去した後、ろ液を減圧下濃縮乾固する
と、結晶性残渣490mgが得られた。残渣を少量のメタ
ノールで洗浄して結晶を集めると、表記化合物(30
1)210mg(47%)が得られた。同様の方法で表9
に示す化合物301〜308を得た。その物理恒数は表
9に示す。
Example 53 p-Aminophenyl α-D-glucopyranoside (30
1) p-nitrophenyl α-D-glucopyranoside 500
To a solution of 7 mg of water in 15 ml of methanol, 75 mg of 10% palladium-carbon was added, and hydrogen gas was blown into the solution at room temperature for 16 hours. After removing the catalyst by filtration, the filtrate was concentrated to dryness under reduced pressure to obtain 490 mg of a crystalline residue. The residue was washed with a small amount of methanol to collect crystals, and the title compound (30
1) 210 mg (47%) was obtained. Table 9
To obtain compounds 301 to 308. The physical constants are shown in Table 9.

【0381】[0380]

【表9】 [Table 9]

【0382】例 54 p−イソチオシアナトフェニル α−D−グルコピラノ
シド(309) 化合物(301)200mg(0.737ミリモル)の8
0%含水エタノール溶液40mlに、チオホスゲン0.3
2ml(4.196ミリモル)を加え、室温で2時間撹拌
した。反応混合物に窒素ガスを吹き込んで過剰のチオホ
スゲンを追い出した後、水酸化ナトリウム溶液を加えて
pH 値を6に調整した。反応液を減圧下約10mlまで濃
縮すると表記化合物(309)を含む水溶液が得られ
た。この化合物の水溶液はそのまま人血清アルブミンと
の縮合反応に用いた。同様の方法で表10に示す化合物
309〜316を得た。
Example 54 p-Isothiocyanatophenyl α-D-glucopyranoside (309) Compound (301) 200 mg (0.737 mmol) 8
Thiophosgene 0.3% in 40 ml of 0% hydrous ethanol solution
2 ml (4.196 mmol) was added, and the mixture was stirred at room temperature for 2 hours. Nitrogen gas was blown into the reaction mixture to drive off excess thiophosgene, and sodium hydroxide solution was added to adjust the pH value to 6. The reaction solution was concentrated under reduced pressure to about 10 ml to obtain an aqueous solution containing the title compound (309). The aqueous solution of this compound was directly used for the condensation reaction with human serum albumin. Compounds 309 to 316 shown in Table 10 were obtained by the same method.

【0383】例 55 1−〔p−(α−D−グルコピラノシルオキシ)フェニ
ルアミノ〕メタンチオアミド人血清アルブミン(31
7) 化合物(309)を含む水溶液を、人血清アルブミン1
12mg(0.00167ミリモル)の0.08M ホウ酸
ナトリウム−0.35M 炭酸水素カリウム緩衝液60ml
に滴下した。反応混合物を室温に18時間放置した後、
透析膜スペクトラポール2(分子量カットオフ12,0
00〜14,000)を用いて精製水に対して4℃で2
4時間透析した。透析内液を取り出して凍結乾燥すると
表記化合物(317)120mgが得られた。導入された
グルコース含量をフェノール−硫酸法で定量すると、グ
ルコース含量(モル比)は32であった。同様の方法で
表10に示す化合物317〜324を得た。これら化合
物の物理恒数は表11に示す。
Example 55 1- [p- (α-D-glucopyranosyloxy) phenylamino] methanethioamide Human serum albumin (31
7) An aqueous solution containing the compound (309) was added to human serum albumin 1
12 mg (0.00167 mmol) of 0.08 M sodium borate-0.35 M potassium hydrogen carbonate buffer 60 ml
Was added dropwise. After leaving the reaction mixture at room temperature for 18 hours,
Dialysis membrane Spectrapol 2 (Molecular weight cutoff 12,0
00 to 14,000) against purified water at 4 ° C for 2
It was dialyzed for 4 hours. The dialyzed solution was taken out and freeze-dried to obtain 120 mg of the title compound (317). When the glucose content introduced was quantified by the phenol-sulfuric acid method, the glucose content (molar ratio) was 32. Compounds 317 to 324 shown in Table 10 were obtained by the same method. The physical constants of these compounds are shown in Table 11.

【0384】[0384]

【表10】 [Table 10]

【0385】[0385]

【表11】 [Table 11]

【0386】試験例 6 例53で得られたフェニルチオウレアをアームとするネ
オグリコプロティン318、320、322及び324
を検体試料として、またHSAを対照試料として用意し
た。試験例1と同一の方法により試料をヨードラベル化
し、動物における分布実験を行った。結果を表12に示
す。
Test Example 6 Neoglycoproteins 318, 320, 322 and 324 having phenylthiourea as an arm obtained in Example 53
Was prepared as a specimen sample and HSA was prepared as a control sample. The sample was iodine-labeled by the same method as in Test Example 1 and a distribution experiment in animals was conducted. The results are shown in Table 12.

【0387】[0387]

【表12】 [Table 12]

【0388】表12より、フェニルチオウレアを介して
アルブミンを糖で修飾することにより、骨髄組織への分
布クリアランスが増大することが知られる。フェニルチ
オウレアを介した場合には分布クリアランスが大きくな
り、骨髄組織への指向性が著しい。
From Table 12, it is known that modification of albumin with sugar via phenylthiourea increases distribution clearance to bone marrow tissue. When it is mediated by phenylthiourea, the distribution clearance is large and the directivity to bone marrow tissue is remarkable.

【0389】以上のことはフェニルチオウレアをアーム
とする本発明のグリコシル−蛋白誘導体が、骨髄組織を
標的組織とする薬物運搬担体として有用であることを示
している。
The above shows that the glycosyl-protein derivative of the present invention having phenylthiourea as an arm is useful as a drug delivery carrier targeting bone marrow tissue.

【0390】参考例 57 2−(2−ベンジルオキシエトキシ)エトキシエタノー
ル(402) 無水ジメチルホルムアミド300mlに60%水素化ナト
リウム13.5g (0.338モル)を懸濁させた溶液
に、トリエチレングリコール(401)50.0g
(0.33モル)を滴下した。室温で1時間撹拌した後
に、臭化ベンジル56.0g (0.33モル)を滴下
し、さらに室温で1時間撹拌した。反応終了後減圧にて
溶媒を留去し、得られた残留物を酢酸エチル200mlに
溶解し、水200mlで洗浄した。有機相を無水硫酸ナト
リウムで乾燥し、これを減圧下濃縮乾固すると油状粗生
成物が得られた。これをシリカゲルカラムクロマトグラ
フィー〔シリカゲル70−230メッシュ500g 、溶
媒系:ヘキサン/酢酸エチル(1:1)〕で精製する
と、表記化合物(402)が27.5g (34%)得ら
れた。
Reference Example 57 2- (2-benzyloxyethoxy) ethoxyethanol (402) Triethylene glycol was added to a solution prepared by suspending 13.5 g (0.338 mol) of 60% sodium hydride in 300 ml of anhydrous dimethylformamide. (401) 50.0 g
(0.33 mol) was added dropwise. After stirring at room temperature for 1 hour, 56.0 g (0.33 mol) of benzyl bromide was added dropwise, and the mixture was further stirred at room temperature for 1 hour. After completion of the reaction, the solvent was distilled off under reduced pressure, the obtained residue was dissolved in 200 ml of ethyl acetate, and washed with 200 ml of water. The organic phase was dried over anhydrous sodium sulfate and concentrated to dryness under reduced pressure to give an oily crude product. This was purified by silica gel column chromatography [silica gel 70-230 mesh 500 g, solvent system: hexane / ethyl acetate (1: 1)] to obtain 27.5 g (34%) of the title compound (402).

【0391】 1H-NMR(CDCl3, δppm): 7.26 〜7.35(5H, m), 4.57(2H, s), 3.73(2H, t, J=4.5Hz), 3.66 〜3.71(6H, m), 3.63 〜3.65(2H, m), 3.62(2H, t, J=4.5Hz), 2.25(1H, br) IR(neat)cm-1: 3450(OH), 1099(C-O-C) 1 H-NMR (CDCl 3 , δppm): 7.26 ~ 7.35 (5H, m), 4.57 (2H, s), 3.73 (2H, t, J = 4.5Hz), 3.66 ~ 3.71 (6H, m) , 3.63 ~ 3.65 (2H, m), 3.62 (2H, t, J = 4.5Hz), 2.25 (1H, br) IR (neat) cm -1 : 3450 (OH), 1099 (COC)

【0392】参考例 58 2−(2−ベンジルオキシエトキシ)エトキシエチルブ
ロミド(403) 化合物(402)36.0g (0.15モル)の無水エ
ーテル100ml溶液に、氷冷下に三臭化リン14.0g
(0.052モル)を加えて1時間撹拌した。さらに1
時間室温にて撹拌後、反応液に水100mlを加えて、酢
酸エチルで抽出した。有機相を無水硫酸ナトリウムで乾
燥し,減圧下濃縮乾固するとシロップ状の粗生成物が得
られた。これをシリカゲルカラムクロマトグラフィー
〔シリカゲル70−230メッシュ250g 、溶媒系:
ヘキサン/酢酸エチル(9:1)〕で精製すると、表記
化合物(403)が13.6g (36%)得られた。
Reference Example 58 2- (2-benzyloxyethoxy) ethoxyethyl bromide (403) A solution of 36.0 g (0.15 mol) of compound (402) in 100 ml of anhydrous ether was added to phosphorus tribromide 14 under ice-cooling. 0.0 g
(0.052 mol) was added and stirred for 1 hour. 1 more
After stirring at room temperature for 100 hours, 100 ml of water was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic phase was dried over anhydrous sodium sulfate and concentrated to dryness under reduced pressure to obtain a syrupy crude product. This was subjected to silica gel column chromatography [silica gel 70-230 mesh 250 g, solvent system:
Purification with hexane / ethyl acetate (9: 1)] afforded 13.6 g (36%) of the title compound (403).

【0393】 1H-NMR(CDCl3, δppm): 7.26 〜7.35(7H, m), 4.58(2H, s), 3.81(2H, t, J=7.0Hz), 3.66 〜3.71(6H, m), 3.61 〜3.63(2H, m), 3.47(2H, t, J=6.7Hz) IR(neat)cm-1: 1112(C-O-C) 1 H-NMR (CDCl 3 , δppm): 7.26 ~ 7.35 (7H, m), 4.58 (2H, s), 3.81 (2H, t, J = 7.0Hz), 3.66 ~ 3.71 (6H, m) , 3.61 ~ 3.63 (2H, m), 3.47 (2H, t, J = 6.7Hz) IR (neat) cm -1 : 1112 (COC)

【0394】参考例 59 メチル 4−〔2−(2−ベンジルオキシエトキシ)エ
トキシ〕−2−メトキシカルボニルブタノエート(40
4) 60%水素化ナトリウム10.0g (0.25モル)の
無水ジメチルホルムアミド300ml懸濁液に、マロン酸
ジメチル33.0g を加えて、40℃で1時間撹拌し
た。これに化合物(403)41.1g (0.136モ
ル)を一度に加えて、さらに40℃で6時間撹拌後、室
温で一晩放置した。反応混合物を10%塩酸で中和し、
溶媒を減圧下に留去して得られた残留物を水100mlお
よび酢酸エチル200mlで分配した。有機相を分離後、
無水硫酸ナトリウムで乾燥し、減圧下溶媒を留去すると
シロップ状の粗生成物が得られた。これをシリカゲルカ
ラムクロマトグラフィー〔シリカゲル70−230メッ
シュ250g 、溶媒系:ヘキサン/酢酸エチル(20:
1)〕で精製すると、表記化合物(404)が36.8
g(77%)得られた。
Reference Example 59 Methyl 4- [2- (2-benzyloxyethoxy) ethoxy] -2-methoxycarbonylbutanoate (40
4) To a suspension of 60 g of sodium hydride 10.0 g (0.25 mol) in anhydrous dimethylformamide (300 ml) was added dimethyl malonate (33.0 g), and the mixture was stirred at 40 ° C. for 1 hour. To this was added 41.1 g (0.136 mol) of compound (403) all at once, and the mixture was further stirred at 40 ° C. for 6 hours and then left overnight at room temperature. Neutralize the reaction mixture with 10% hydrochloric acid,
The solvent was evaporated under reduced pressure and the obtained residue was partitioned with 100 ml of water and 200 ml of ethyl acetate. After separating the organic phase,
It was dried over anhydrous sodium sulfate and the solvent was distilled off under reduced pressure to obtain a syrupy crude product. This was subjected to silica gel column chromatography [silica gel 70-230 mesh 250 g, solvent system: hexane / ethyl acetate (20:
1)], the title compound (404) was 36.8.
g (77%) was obtained.

【0395】 1H-NMR(CDCl3, δppm): 7.26 〜7.34(5H, m), 4.56(2H, s), 3.72(3H, s), 3.52(2H, t, J=5.9Hz), 2.18(2H, m) IR(neat)cm-1: 1754(C=O), 1735(CO2CH3) 1 H-NMR (CDCl 3 , δppm): 7.26 to 7.34 (5H, m), 4.56 (2H, s), 3.72 (3H, s), 3.52 (2H, t, J = 5.9Hz), 2.18 (2H, m) IR (neat) cm -1 : 1754 (C = O), 1735 (CO 2 CH 3 )

【0396】参考例 60 メチル 4−〔2−(2−ベンジルオキシエトキシ)エ
トキシ〕ブタノエート(405) 化合物(404)23.2g (65.5ミリモル)およ
び塩化ナトリウム4.5g (76.9ミリモル)を水4
mlとジメチルスルホキシド80mlの混合液に加え、15
0〜160℃で4時間加熱撹拌した。反応終了後、溶媒
を減圧下に留去し、得られた残留物を水100mlおよび
酢酸エチル100mlで分配し、有機相を分離後無水硫酸
ナトリウムで乾燥した。溶媒を減圧下に留去して得られ
たシロップ状の粗生成物をシリカゲルカラムクロマトグ
ラフィー〔シリカゲル70−230メッシュ250g 、
溶媒系:ヘキサン/酢酸エチル(5:1)〕で精製する
と、表記化合物(405)が17.0g (87%)得ら
れた。
Reference Example 60 Methyl 4- [2- (2-benzyloxyethoxy) ethoxy] butanoate (405) Compound (404) 23.2 g (65.5 mmol) and sodium chloride 4.5 g (76.9 mmol). The water 4
ml and dimethylsulfoxide 80ml mixture, add 15
The mixture was heated and stirred at 0 to 160 ° C for 4 hours. After completion of the reaction, the solvent was distilled off under reduced pressure, the obtained residue was partitioned with 100 ml of water and 100 ml of ethyl acetate, and the organic phase was separated and dried over anhydrous sodium sulfate. The syrupy crude product obtained by distilling off the solvent under reduced pressure was subjected to silica gel column chromatography [silica gel 70-230 mesh 250 g,
Purification with solvent system: hexane / ethyl acetate (5: 1)] gave 17.0 g (87%) of the title compound (405).

【0397】 1H-NMR(CDCl3, δppm): 7.24 〜7.33(5H, m), 4.57(2H, s), 3.66(3H, s), 3.63 〜3.68 (6H, m), 3.57 〜3.58(2H, m), 3.50(2H, t, J=6.2Hz), 2.42(2H, t, J=7.3Hz), 1.90(2H, m) IR(neat)cm-1: 1738(CO2CH3), 1113(C-O-C) 1 H-NMR (CDCl 3 , δppm): 7.24 to 7.33 (5H, m), 4.57 (2H, s), 3.66 (3H, s), 3.63 to 3.68 (6H, m), 3.57 to 3.58 ( 2H, m), 3.50 (2H, t, J = 6.2Hz), 2.42 (2H, t, J = 7.3Hz), 1.90 (2H, m) IR (neat) cm -1 : 1738 (CO 2 CH 3 ) , 1113 (COC)

【0398】参考例 61 メチル 4−〔2−(2−ヒドロキシエトキシ)エトキ
シ〕ブタノエート(406) 化合物(405)16.6g (56.0ミリモル)のメ
タノール20ml溶液に、10%パラジウム炭素2.0g
を加え、室温にて4時間水素添加した。反応終了後、触
媒をろ過し、ろ液を減圧下に濃縮乾固すると、無色油状
物の表記化合物406が11.3g (99%)得られ
た。
Reference Example 61 Methyl 4- [2- (2-hydroxyethoxy) ethoxy] butanoate (406) Compound (405) 16.6 g (56.0 mmol) in methanol 20 ml solution, 10% palladium carbon 2.0 g.
Was added and hydrogenated at room temperature for 4 hours. After the reaction was completed, the catalyst was filtered off, and the filtrate was concentrated to dryness under reduced pressure to obtain 11.3 g (99%) of the title compound 406 as a colorless oily substance.

【0399】 1H-NMR(CDCl3, δppm): 3.73(2H, t, J=4.5Hz), 3.68(3H, s), 3.65 〜3.68(2H, m), 3.57 〜3.63(4H, m), 3.51(2H, t, J=6.2Hz), 2.42(2H, t, J=7.3Hz), 1.92(2H, m), 1.70(1H, br) IR(neat)cm-1: 3450(OH), 1738(CO2CH3), 1119(C-O-C) MS(EI)m/z : 207(M+H+) 1 H-NMR (CDCl 3 , δppm): 3.73 (2H, t, J = 4.5Hz), 3.68 (3H, s), 3.65 ~ 3.68 (2H, m), 3.57 ~ 3.63 (4H, m) , 3.51 (2H, t, J = 6.2Hz), 2.42 (2H, t, J = 7.3Hz), 1.92 (2H, m), 1.70 (1H, br) IR (neat) cm -1 : 3450 (OH) , 1738 (CO 2 CH 3 ), 1119 (COC) MS (EI) m / z: 207 (M + H + )

【0400】例 56 2−〔2−(3−メトキシカルボニルプロピルオキシ)
エトキシ〕エチル−2,3,4,6−テトラ−O−ベン
ジル−β−D−マンノピラノシド(409)及び2−
〔2−(3−メトキシカルボニルプロピルオキシ)エト
キシ〕エチル−2,3,4,6−テトラ−O−ベンジル
−α−D−マンノピラノシド(408)
Example 56 2- [2- (3-methoxycarbonylpropyloxy)
Ethoxy] ethyl-2,3,4,6-tetra-O-benzyl-β-D-mannopyranoside (409) and 2-
[2- (3-Methoxycarbonylpropyloxy) ethoxy] ethyl-2,3,4,6-tetra-O-benzyl-α-D-mannopyranoside (408)

【0401】化合物(406)577mg(2.8ミリモ
ル)、炭酸銀500mg(1.79ミリモル)及びドライ
ライト500mgの塩化メチレン5ml溶液を窒素気流下0
℃にて30分間撹拌した後、Koto, Morishima, Miyata,
and Zen, Bull.Chem.Soc.Jpn.,49,2639(1976)の方法で
得た、2,3,4,6−テトラ−O−ベンジル−α/β
−マンノピラノシル p−ニトロベンゾエートの塩化メ
チレン溶液に、乾燥塩化水素ガスを吹き込んで合成した
2,3,4,6−テトラ−O−ベンジル−α−D−マン
ノピラノシルクロリド(407)580mg(0.84ミ
リモル)の塩化メチレン溶液3mlをゆっくり滴下した。
その後、内温0〜5℃にて4時間撹拌した。反応終了後
反応物をセライトを用いてろ過し、不溶物を塩化メチレ
ンでよく洗浄した。ろ液および洗液を合し、溶媒を減圧
下留去すると粗生成物1.1048g が得られた。粗生
成物をフラッシュクロマトグラフィー〔シリカゲル23
0〜400メッシュ60g 、溶媒系:酢酸エチル/ヘキ
サン(2:3)〕にて分離精製すると表記化合物(40
9)520mg(81.2%)および表記化合物(40
8)120mg(18.8%)が得られた。
A solution of 577 mg (2.8 mmol) of the compound (406), 500 mg (1.79 mmol) of silver carbonate and 500 mg of drylite in 5 ml of methylene chloride was placed under a nitrogen stream.
After stirring at ℃ for 30 minutes, Koto, Morishima, Miyata,
and Zen, Bull. Chem. Soc. Jpn., 49, 2639 (1976), 2,3,4,6-tetra-O-benzyl-α / β.
580 mg of 2,3,4,6-tetra-O-benzyl-α-D-mannopyranosyl chloride (407) synthesized by blowing dry hydrogen chloride gas into a methylene chloride solution of -mannopyranosyl p-nitrobenzoate. 3 ml of methylene chloride solution (0.84 mmol) was slowly added dropwise.
Then, the mixture was stirred at an internal temperature of 0 to 5 ° C for 4 hours. After completion of the reaction, the reaction product was filtered through Celite, and the insoluble material was washed well with methylene chloride. The filtrate and washings were combined and the solvent was distilled off under reduced pressure to obtain 1.1048 g of a crude product. The crude product is flash chromatographed [silica gel 23
0 to 400 mesh 60 g, solvent system: ethyl acetate / hexane (2: 3)] to separate and purify the title compound (40
9) 520 mg (81.2%) and the title compound (40
8) 120 mg (18.8%) was obtained.

【0402】 化合物 (409) 〔α〕24 D - 44.6°(C O.67, CHCl3) 1H-NMR(CDCl3,δppm): 7.18〜7.50(20H, m, aromatic H), 4.85〜4.97(2H, AB-q, J=12.5Hz, benzyl-CH2), 4.54〜4.62(2H, AB-q, J=12Hz, benzyl-CH2), 4.50〜4.90(2H, AB-q, J=12Hz, benzyl-CH2), 4.41〜4.51(2H, AB-q, J=12Hz, benzyl-CH2), 4.44(1H, s, H-1), 4.02〜4.08(1H, m, H-2), 3.64〜3.93(7H, m), 3.63(3H, s, CO2CH3), 3.40〜3.64(8H, m), 2.35〜2.40(2H, m, CH2CO-), 1.80〜1.95(2H, m, CH2CH2CO-) IR(CHCl3)cm-1: 1726(CO2CH3) MS(FAB)m/z : 751(M+Na+), 727(M-1) Compound (409) [α] 24 D −44.6 ° (C O.67, CHCl 3 ) 1 H-NMR (CDCl 3 , δppm): 7.18 to 7.50 (20H, m, aromatic H), 4.85 to 4.97 (2H, AB-q, J = 12.5Hz, benzyl-CH 2 ), 4.54 ~ 4.62 (2H, AB-q, J = 12Hz, benzyl-CH 2 ), 4.50 ~ 4.90 (2H, AB-q, J = 12Hz, benzyl-CH 2 ), 4.41 ~ 4.51 (2H, AB-q, J = 12Hz, benzyl-CH 2 ), 4.44 (1H, s, H-1), 4.02 ~ 4.08 (1H, m, H-2 ), 3.64 ~ 3.93 (7H, m), 3.63 (3H, s, CO 2 CH 3 ), 3.40 ~ 3.64 (8H, m), 2.35 ~ 2.40 (2H, m, CH 2 CO-), 1.80 ~ 1.95 ( 2H, m, CH 2 CH 2 CO-) IR (CHCl 3 ) cm -1 : 1726 (CO 2 CH 3 ) MS (FAB) m / z: 751 (M + Na + ), 727 (M-1)

【0403】 化合物 (408) 〔α〕24 D + 13.9°(C O.70, CHCl3) 1H-NMR(CDCl3,δppm): 7.18〜7.50(20H, m, aromatic H), 4.91(1H, d, J=1.71Hz, H-1), 4.68〜4.75(2H, AB-q, J=12.5Hz, benzyl-CH2), 4.604(2H, s, benzyl-CH2), 4.47〜4.86(2H, AB-q, J=10.75Hz, benzyl-CH2), 4.51〜4.65(2H, AB-q, J=12Hz, benzyl-CH2), 3.65〜4.00(8H, m), 3.63(3H, s, CO2CH3), 3.44〜3.60(8H, m), 2.30〜2.40(2H, m, CH2CO-), 1.80〜1.90(2H, m, CH2CH2CO-) IR(CHCl3)cm-1: 1725(CO2CH3) MS(FAB)m/z : 727(M-1) Compound (408) [α] 24 D + 13.9 ° (C O.70, CHCl 3 ) 1 H-NMR (CDCl 3 , δppm): 7.18 to 7.50 (20H, m, aromatic H), 4.91 (1H , d, J = 1.71Hz, H-1), 4.68 to 4.75 (2H, AB-q, J = 12.5Hz, benzyl-CH 2 ), 4.604 (2H, s, benzyl-CH 2 ), 4.47 to 4.86 ( 2H, AB-q, J = 10.75Hz, benzyl-CH 2 ), 4.51 ~ 4.65 (2H, AB-q, J = 12Hz, benzyl-CH 2 ), 3.65 ~ 4.00 (8H, m), 3.63 (3H, s, CO 2 CH 3 ), 3.44 to 3.60 (8H, m), 2.30 to 2.40 (2H, m, CH 2 CO-), 1.80 to 1.90 (2H, m, CH 2 CH 2 CO-) IR (CHCl 3 ) cm -1 : 1725 (CO 2 CH 3 ) MS (FAB) m / z: 727 (M-1)

【0404】例 57 2−〔2−(3−メトキシカルボニルプロピルオキシ)
エトキシ〕エチル−β−D−マンノピラノシド(41
0) 化合物(409)500mg(0.686ミリモル)をメ
タノール10mlに溶解し、10%パラジウム−炭素50
0mgを加えて、水素気流下室温にて激しく40時間撹拌
した。反応終了後触媒をろ去し、ろ液を減圧下濃縮乾固
すると、表記化合物(410)232.4mg(92%)
が得られた。
Example 57 2- [2- (3-methoxycarbonylpropyloxy)
Ethoxy] ethyl-β-D-mannopyranoside (41
0) 500 mg (0.686 mmol) of the compound (409) was dissolved in 10 ml of methanol, and 10% palladium-carbon 50 was added.
0 mg was added, and the mixture was vigorously stirred at room temperature under a hydrogen stream for 40 hours. After completion of the reaction, the catalyst was filtered off and the filtrate was concentrated to dryness under reduced pressure to give the title compound (410) 232.4 mg (92%)
was gotten.

【0405】 化合物 (410) 〔α〕23 D - 22.3°(C 2.18, MeOH) 1H-NMR(CD3OD,δppm): 4.53(1H, s, H-1), 3.30〜4.00(14H, m), 3.62(3H, s, CO2CH3), 3.10〜3.25(2H, m), 2.37(2H, t, J=7.3Hz, CH2CO-), 1.83(2H, t, J=7.3Hz, CH2CH2CO-) IR(CHCl3)cm-1: 3350(OH), 1732(CO2CH3) MS(FAB)m/z : 391(M+Na+) Compound (410) [α] 23 D -22.3 ° (C 2.18, MeOH) 1 H-NMR (CD 3 OD, δppm): 4.53 (1H, s, H-1), 3.30 to 4.00 (14H, m), 3.62 (3H, s, CO 2 CH 3 ), 3.10 to 3.25 (2H, m), 2.37 (2H, t, J = 7.3Hz, CH 2 CO-), 1.83 (2H, t, J = 7.3 Hz, CH 2 CH 2 CO-) IR (CHCl 3 ) cm -1 : 3350 (OH), 1732 (CO 2 CH 3 ) MS (FAB) m / z: 391 (M + Na + )

【0406】例 58 2−〔2−(3−メトキシカルボニルプロキシオキシ)
エトキシ〕エチル 2,3,4−トリ−O−アセチル−
β−L−フコピラノシド(412) H.M.Flowers らの方法〔Carbohydr.Res.,4,189-195(196
7)〕により調製した2,3,4−トリ−O−アセチル−
α−L−フコピラノシルブロマイド(411)166mg
(0.469ミリモル)のベンゼン10ml溶液に化合物
(406)100mg(0.485ミリモル)、シアン化
第二水銀123mg(0.485ミリモル)及び粉末化し
た無水硫酸カルシウム350mgを加え、アルゴン気流中
室温で24時間撹拌した。反応溶液をろ過後、ろ液に酢
酸エチル5mlを加え、水5mlで洗浄した。無水硫酸マグ
ネシウムで乾燥後、減圧濃縮して得られたシロップをシ
リカゲルカラムクロマトグラフィー(クロロホルム:メ
タノール=200:1)で精製すると表記化合物(41
2)が136mg(58.6%)得られた。
Example 58 2- [2- (3-methoxycarbonylproxyoxy)
Ethoxy] ethyl 2,3,4-tri-O-acetyl-
β-L-fucopyranoside (412) HMFlowers et al. [Carbohydr. Res., 4, 189-195 (196
7)], 2,3,4-tri-O-acetyl-
α-L-fucopyranosyl bromide (411) 166 mg
To a solution of (0.469 mmol) in 10 ml of benzene, 100 mg (0.485 mmol) of the compound (406), 123 mg (0.485 mmol) of mercuric cyanide and 350 mg of powdered anhydrous calcium sulfate were added, and the mixture was heated at room temperature in an argon stream. It was stirred for 24 hours. After filtering the reaction solution, 5 ml of ethyl acetate was added to the filtrate, and the mixture was washed with 5 ml of water. The syrup obtained by drying over anhydrous magnesium sulfate and concentration under reduced pressure was purified by silica gel column chromatography (chloroform: methanol = 200: 1) to give the title compound (41
2) was obtained in 136 mg (58.6%).

【0407】 化合物 (412) 〔α〕25 D -2.9°(C 1.1, CHCl3) 1H-NMR(CDCl3,δppm): 1.22(3H, d, J=6.4Hz, H-6), 1.99, 2.06, 2.18(9H, 3s, OAc), 2.42(2H, t, J=7.3Hz, CH 2 , COOCH3), 3.68(3H, s, OCH3), 4.76(1H, d, J=8.1Hz, H-1) IR(NaCl)cm-1 : 1750, 1700 Compound (412) [α] 25 D -2.9 ° (C 1.1, CHCl 3 ) 1 H-NMR (CDCl 3 , δppm): 1.22 (3H, d, J = 6.4Hz, H-6), 1.99 , 2.06, 2.18 (9H, 3s, OAc), 2.42 (2H, t, J = 7.3Hz, C H 2 , COOCH 3 ), 3.68 (3H, s, OCH 3 ), 4.76 (1H, d, J = 8.1 Hz, H-1) IR (NaCl) cm -1 : 1750, 1700

【0408】例 59 2−〔2−(3−メトキシカルボニルプロピルオキシ)
エトキシ〕エチル 2,3,4−β−L−フコピラノシ
ド(413) 化合物(412)180mg(0.376ミリモル)をメ
タノール2mlに溶解させた後、28%ナトリウムメチラ
ート0.05mlを加え、室温で2時間撹拌した。反応溶
液をアンバーライトIR−120B(H+)で中和し、イ
オン交換樹脂をろ取した後、ろ液を減圧濃縮すると表記
化合物(413)が109mg(82.3%)得られた。
Example 59 2- [2- (3-methoxycarbonylpropyloxy)
Ethoxy] ethyl 2,3,4-β-L-fucopyranoside (413) 180 mg (0.376 mmol) of compound (412) was dissolved in 2 ml of methanol, and then 0.05 ml of 28% sodium methylate was added, and the mixture was stirred at room temperature. Stir for 2 hours. The reaction solution was neutralized with Amberlite IR-120B (H + ), the ion exchange resin was filtered off, and the filtrate was concentrated under reduced pressure to give the title compound (413) 109 mg (82.3%).

【0409】 〔α〕26 D -2.1°(C 1.3, MeOH) 1H-NMR(CD3OD,δppm): 1.23(3H, d, J=6.6Hz, H-6), 2.37(2H, t, J=7.6Hz, CH 2 COOCH3), 3.67(3H, s, OCH3), 4.19(1H, d, J=7.3Hz, H-1) IR(NaCl)cm-1 : 3450, 1740, 1070 [Α] 26 D -2.1 ° (C 1.3, MeOH) 1 H-NMR (CD 3 OD, δppm): 1.23 (3H, d, J = 6.6Hz, H-6), 2.37 (2H, t , J = 7.6Hz, C H 2 COOCH 3 ), 3.67 (3H, s, OCH 3 ), 4.19 (1H, d, J = 7.3Hz, H-1) IR (NaCl) cm -1 : 3450, 1740, 1070

【0410】例 60 2−〔2−(3−メトキシカルボニルプロピルオキシ)
エトキシ〕エチル 3,4,6−トリ−O−アセチル−
2−アジド−2−デオキシ−α−D−マンノピラノシド
(414)及び2−〔2−(3−メトキシカルボニルプ
ロピルオキシ)エトキシ〕エチル 3,4,6−トリ−
O−アセチル−2−アジド−2−デオキシ−β−D−マ
ンノピラノシド(415)
Example 60 2- [2- (3-methoxycarbonylpropyloxy)
Ethoxy] ethyl 3,4,6-tri-O-acetyl-
2-Azido-2-deoxy-α-D-mannopyranoside (414) and 2- [2- (3-methoxycarbonylpropyloxy) ethoxy] ethyl 3,4,6-tri-
O-acetyl-2-azido-2-deoxy-β-D-mannopyranoside (415)

【0411】Carbohydr.Res.,136,153(1985)の方法で合
成した3,4,6−トリ−O−アセチル−2−アジド−
2−デオキシ−α−D−マンノピラノシルブロマイド9
30mg(2.35ミリモル)とメチル 4−〔2−(2
−ヒドロキシエトキシ)エトキシ〕ブタノエート(40
6)485mg(2.35ミリモル)のトルエン20ml溶
液に、銀シリケート700mg及び粉末状モレキュラーシ
ーブ4Aを500mg加え、室温で16時間撹拌した。反
応溶液をセライトを用いてろ過した後、ろ液を減圧下に
濃縮乾固し、得られた残渣をローバーカラム(ヘキサ
ン:酢酸エチル=1:1)で精製すると表記化合物(4
14)525mg(43%)及び表記化合物(415)1
43mg(11.7%)が得られた。
Carbohydr. Res., 136, 153 (1985), 3,4,6-tri-O-acetyl-2-azide-
2-deoxy-α-D-mannopyranosyl bromide 9
30 mg (2.35 mmol) and methyl 4- [2- (2
-Hydroxyethoxy) ethoxy] butanoate (40
6) To a solution of 485 mg (2.35 mmol) in 20 ml of toluene, 700 mg of silver silicate and 500 mg of powdery molecular sieve 4A were added, and the mixture was stirred at room temperature for 16 hours. The reaction solution was filtered through Celite, the filtrate was concentrated to dryness under reduced pressure, and the obtained residue was purified by a Rover column (hexane: ethyl acetate = 1: 1) to give the title compound (4
14) 525 mg (43%) and the title compound (415) 1
43 mg (11.7%) was obtained.

【0412】 化合物 (414) 〔α〕24 D + 58.2°(C O.57, CHCl3) 1H-NMR(CDCl3,δppm): 5.39(1H, dd, J3,4=10Hz, J2,3=4.0Hz, H-3), 5.32(1H, t, J=10Hz, H-4), 4.91(1H, s, H-1), 4.25(1H, dd, J5,6a=4.5Hz, J6a,6b=12Hz, H-6a), 4.02(1H, m, H-5), 2.40(2H, t, J=7.5Hz, -CH 2 CO-), 2.10, 2.09, 2.04(each 3H, each s, 3 × OAc) IR(film)cm-1 : 2110, 1747, 1438, 1369, 1230, 1049 Compound (414) [α] 24 D + 58.2 ° (C O.57, CHCl 3 ) 1 H-NMR (CDCl 3 , δppm): 5.39 (1H, dd, J 3,4 = 10Hz, J 2 , 3 = 4.0Hz, H-3 ), 5.32 (1H, t, J = 10Hz, H-4), 4.91 (1H, s, H-1), 4.25 (1H, dd, J 5,6a = 4.5Hz , J 6a, 6b = 12Hz, H-6a), 4.02 (1H, m, H-5), 2.40 (2H, t, J = 7.5Hz, -C H 2 C O-), 2.10, 2.09, 2.04 ( each 3H, each s, 3 × OAc) IR (film) cm -1 : 2110, 1747, 1438, 1369, 1230, 1049

【0413】 化合物 (415) 〔α〕24 D - 60.1°(C O.9, CHCl3) 1H-NMR(CDCl3,δppm): 5.24(1H, t, J3,4=9.5Hz, H-4), 4.99(1H, dd, J2,3=3.5Hz, H-3), 4.79(1H, s, H-1), 4.25(1H, dd, J5,6a=5.5Hz, J6a,6b=12Hz, H-6a), 4.00(1H, m, H-5), 2.40(2H, t, J=7.5Hz, -CH 2 CO-), 2.10, 2.08, 2.03(each 3H, each s, 3 × OAc) IR(film)cm-1 : 2112, 1743, 1371, 1236, 1055 Compound (415) [α] 24 D -60.1 ° (C O.9, CHCl 3 ) 1 H-NMR (CDCl 3 , δppm): 5.24 (1H, t, J 3,4 = 9.5Hz, H -4), 4.99 (1H, dd , J 2,3 = 3.5Hz, H-3), 4.79 (1H, s, H-1), 4.25 (1H, dd, J 5,6a = 5.5Hz, J 6a , 6b = 12Hz, H-6a), 4.00 (1H, m, H-5), 2.40 (2H, t, J = 7.5Hz, -C H 2 C O-), 2.10, 2.08, 2.03 (each 3H, each s, 3 × OAc) IR (film) cm -1 : 2112, 1743, 1371, 1236, 1055

【0414】例 61 2−〔2−(3−メトキシカルボニルプロピルオキシ)
エトキシ〕エチル 2−アジド−2−デオキシ−α−D
−マンノピラノシド(416) 化合物(415)525mg(1.01ミリモル)の無水
メタノール10ml溶液に、1M ナトリウムメトキシド−
メタノール溶液0.25mlを加え、室温に4時間放置し
た。反応液にイオン交換樹脂アンバーライトIR−12
0B(H+型)を加えて中和した後、樹脂をろ去し、少量
のメタノールで洗浄した。ろ液及び洗液を合し、減圧下
で溶媒を留去すると、シロップ状の表記化合物(41
6)154mgが得られた。
Example 61 2- [2- (3-methoxycarbonylpropyloxy)
Ethoxy] ethyl 2-azido-2-deoxy-α-D
-Mannopyranoside (416) To a solution of 525 mg (1.01 mmol) of compound (415) in 10 ml of anhydrous methanol, 1M sodium methoxide-
0.25 ml of methanol solution was added, and the mixture was left at room temperature for 4 hours. Ion exchange resin Amberlite IR-12 for reaction liquid
After neutralizing by adding 0B (H + type), the resin was filtered off and washed with a small amount of methanol. The filtrate and washings were combined, and the solvent was distilled off under reduced pressure to give the syrup-like title compound (41
6) 154 mg was obtained.

【0415】例 62 2−〔2−(3−メトキシカルボニルプロピルオキシ)
エトキシ〕エチル 2−アセタミド−2−デオキシ−α
−D−マンノピラノシド(417) 化合物(416)150mg(0.381ミリモル)のエ
タノール4ml溶液に、塩化ニッケル六水和物380mg
(1.6ミリモル)をエタノール10mlに溶解した液
0.1mlを加えた後、水素化ホウ素ナトリウム43mg
(1.143ミリモル)のエタノール溶液に4mlを撹拌
しながら加えた。室温で30分間撹拌した後、反応液に
酢酸を加えて中和した。次いで無水酢酸0.5mlを加え
て室温に1時間放置した。反応混合物を減圧下で濃縮乾
固して、残渣をシリカゲルカラムクロマトグラフィー
(クロロホルム:メタノール=7:1)で精製すると表
記化合物(417)が157mgが得られた。
Example 62 2- [2- (3-methoxycarbonylpropyloxy)
Ethoxy] ethyl 2-acetamido-2-deoxy-α
-D-mannopyranoside (417) Compound (416) 150 mg (0.381 mmol) in ethanol 4 ml solution, nickel chloride hexahydrate 380 mg
After adding 0.1 ml of a solution of (1.6 mmol) in 10 ml of ethanol, 43 mg of sodium borohydride
4 ml was added to a solution of (1.143 mmol) in ethanol with stirring. After stirring at room temperature for 30 minutes, acetic acid was added to the reaction solution to neutralize it. Then, 0.5 ml of acetic anhydride was added and the mixture was left at room temperature for 1 hour. The reaction mixture was concentrated to dryness under reduced pressure, and the residue was purified by silica gel column chromatography (chloroform: methanol = 7: 1) to obtain 157 mg of the title compound (417).

【0416】 〔α〕26 D + 26.4°(C 0.62, MeOH) 1H-NMR(CD3OD,δppm): 4.72(d, 1H, J=1Hz, H-1), 4.31(dd, 1H, J1,2=1Hz, J2,3=4.7Hz), 2.01(s, 3H, NAc) IR(KBr)cm-1: 3446, 1730, 1660, 1550, 1132, 1068 [Α] 26 D + 26.4 ° (C 0.62, MeOH) 1 H-NMR (CD 3 OD, δppm): 4.72 (d, 1H, J = 1Hz, H-1), 4.31 (dd, 1H, J 1,2 = 1Hz, J 2,3 = 4.7Hz), 2.01 (s, 3H, NAc) IR (KBr) cm -1 : 3446, 1730, 1660, 1550, 1132, 1068

【0417】例 63 ネオグリコプロティン(419) 化合物(413)85mg(0.241ミリモル)のエタ
ノール0.8ml溶液に,ヒドラジンヒドラート0.24
mlを加え、室温で24時間撹拌した。反応溶液を減圧濃
縮した後、水1mlを加え,さらに減圧濃縮することによ
り2−〔2−(3−ヒドラジノカルボニルプロピルオキ
シ)エトキシ〕エチル β−L−フコピラノシド85mg
を得た。これにDMF3mlを加えて溶解させ、−25℃
に冷却後、4N 塩化水素のジオキサン溶液0.14mlを
加えた。さらに同温で亜硝酸t−ブチル35.5mg
(0.241ミリモル)のDMF0.2ml溶液を加えて
30分間撹拌した後、スルファミン酸16.8mgのDM
F0.2ml溶液を加え、15分間撹拌することにより、
対応する酸アジドを含む反応溶液を得た。これを0℃に
冷却した人血清アルブミン(HSA)332mg(4.8
2×10-3ミリモル)のホウ酸緩衝液(0.08M Na2
B4O7,0.35M KHCO3)20mlに加え、同温で24時
間撹拌した。4℃で一晩透析後、凍結乾燥することによ
りフコース修飾アルブミン(419)343mgの粉末を
得た。フェノール−硫酸法によりHSA/モルに結合し
た糖鎖のモル数は28であることがわかった。
Example 63 Neoglycoprotein (419) To a solution of 85 mg (0.241 mmol) of compound (413) in 0.8 ml of ethanol was added 0.24 of hydrazine hydrate.
ml was added, and the mixture was stirred at room temperature for 24 hours. The reaction solution was concentrated under reduced pressure, 1 ml of water was added, and the mixture was further concentrated under reduced pressure to give 2- [2- (3-hydrazinocarbonylpropyloxy) ethoxy] ethyl β-L-fucopyranoside 85 mg.
I got To this, add 3 ml of DMF and dissolve, then at -25 ° C.
After cooling to 0.14 ml of 4N hydrogen chloride in dioxane was added. Furthermore, at the same temperature, t-butyl nitrite 35.5 mg
(0.241 mmol) of DMF (0.2 ml) was added and stirred for 30 minutes, and then 16.8 mg of sulfamic acid in DM
Add 0.2 ml F solution and stir for 15 minutes
A reaction solution containing the corresponding acid azide was obtained. 332 mg (4.8 mg) of human serum albumin (HSA) cooled to 0 ° C.
2 × 10 −3 mmol) borate buffer (0.08 M Na 2
B 4 O 7 , 0.35M KHCO 3 ) (20 ml) and the mixture was stirred at the same temperature for 24 hours. After dialysis at 4 ° C. overnight, lyophilization gave powder of fucose-modified albumin (419) 343 mg. It was found by the phenol-sulfuric acid method that the number of moles of sugar chains bound to HSA / mol was 28.

【0418】ネオグリコプロティンと使用した中間体の
一覧を表13に示した。導入された糖含量は、中性糖の
場合にはフェノール−硫酸法により、ヘキソサミンの場
合には4N 塩酸による加水分解後、エルソン−モーガン
法で行った。またこれらのネオグリコプロティンの物理
恒数を表14に示した。
A list of neoglycoprotein and the intermediates used is shown in Table 13. The introduced sugar content was measured by the Elson-Morgan method after hydrolysis with a phenol-sulfuric acid method in the case of neutral sugar and with 4N hydrochloric acid in the case of hexosamine. Table 14 shows the physical constants of these neoglycoproteins.

【0419】[0419]

【表13】 [Table 13]

【0420】[0420]

【表14】 [Table 14]

【0421】試験例 7 例54で得られたエチレンオキサイドをアームとするネ
オグリコプロティン418、419および420を検体
試料として、またHSAを対照試料として用意した。試
験例1と同一の方法により試料をヨードラベル化し、動
物における分布実験を行った。結果を表15に示す。
Test Example 7 Neoglycoproteins 418, 419 and 420 having the ethylene oxide arm obtained in Example 54 as the sample were prepared, and HSA was prepared as the control sample. The sample was iodine-labeled by the same method as in Test Example 1 and a distribution experiment in animals was conducted. The results are shown in Table 15.

【0422】[0422]

【表15】 [Table 15]

【0423】表15より,エチレンオキサイドを介して
アルブミンを糖で修飾することにより、骨髄組織への分
布クリアランスが増大することが知られる。エチレンオ
キサイドを介した場合、静脈内投与後の血中濃度持続性
がHSAにおけるものにほぼ匹敵するので、骨髄組織へ
は緩除に分布して行くという特徴がある。
From Table 15, it is known that modification of albumin with sugar through ethylene oxide increases distribution clearance to bone marrow tissue. When mediated by ethylene oxide, the blood concentration persistence after intravenous administration is almost comparable to that in HSA, and therefore, it is characterized in that it is slowly distributed to bone marrow tissue.

【0424】以上のことは、エチレンオキサイドをアー
ムとする本発明のグリコシルー蛋白誘導体が、骨髄組織
を標的組織とする薬物運搬担体として有用であることを
示している。
The above shows that the glycosyl protein derivative of the present invention having ethylene oxide as an arm is useful as a drug delivery carrier targeting bone marrow tissue.

【図面の簡単な説明】[Brief description of drawings]

【図1】HSAの取り込み活性を示すグラフである。FIG. 1 is a graph showing HSA uptake activity.

【図2】化合物236の取り込み活性を示すグラフであ
る。
FIG. 2 is a graph showing the uptake activity of compound 236.

【図3】化合物226の取り込み活性を示すグラフであ
る。
FIG. 3 is a graph showing the uptake activity of compound 226.

【図4】化合物238の取り込み活性を示すグラフであ
る。
FIG. 4 is a graph showing the uptake activity of compound 238.

【図5】化合物246の取り込み活性を示すグラフであ
る。
FIG. 5 is a graph showing the uptake activity of compound 246.

【図6】化合物245の取り込み活性を示すグラフであ
る。
FIG. 6 is a graph showing the uptake activity of compound 245.

【図7】化合物242の取り込み活性を示すグラフであ
る。
FIG. 7 is a graph showing the uptake activity of compound 242.

【図8】化合物245の取り込み活性を示すグラフであ
る。
FIG. 8 is a graph showing the uptake activity of compound 245.

【図9】化合物242の取り込み活性を示すグラフであ
る。
FIG. 9 is a graph showing the uptake activity of compound 242.

【図10】m数が異なる( Man β-O(CH2)8CO)m-HASの特
異的取り込み活性の比較を示すグラフである。
FIG. 10 is a graph showing a comparison of specific uptake activities of (Man β-O (CH 2 ) 8 CO) m -HAS having different m numbers.

【図11】m数が異なる( Fuc β-O(CH2)8CO)m-HASの特
異的取り込み活性の比較を示すグラフである。
FIG. 11 is a graph showing a comparison of specific uptake activities of (Fuc β-O (CH 2 ) 8 CO) m -HAS having different m numbers.

【図12】化合物245に対する各種ネオグリコプロテ
ィンの阻害効果を示すグラフである。
FIG. 12 is a graph showing the inhibitory effect of various neoglycoproteins on compound 245.

【図13】各種ネオグリコプロティンの脳中濃度とプラ
ズマ中濃度との比(Kp値)を示すグラフである。
FIG. 13 is a graph showing the ratio (Kp value) between brain concentration and plasma concentration of various neoglycoproteins.

───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.6 識別記号 庁内整理番号 FI 技術表示箇所 C07K 14/52 8318−4H 14/76 8318−4H // C07H 15/04 F (72)発明者 加藤 隆 千葉県柏市東1−7−1 グランドール亜 梨104 (56)参考文献 特開 昭63−152393(JP,A)─────────────────────────────────────────────────── ─── Continuation of the front page (51) Int.Cl. 6 Identification code Internal reference number FI Technical indication C07K 14/52 8318-4H 14/76 8318-4H // C07H 15/04 F (72) Inventor Takashi Kato 1-7-1, Higashi, Kashiwa-shi, Chiba 104, Grand Ari 104 (56) References JP-A-63-152393 (JP, A)

Claims (5)

【特許請求の範囲】[Claims] 【請求項1】 式(I): 〔R−O−(CH2)n −CO−〕m −Z (I) (式中、Rはグリコシル基を表し、Zは蛋白を表し、n
は3〜14を表し、mは10〜50を表す)で示される
グリコシル−蛋白誘導体を含有する薬剤運搬担体。
1. A formula (I): [R-O- (CH 2) n -CO- ] m -Z (I) (wherein, R represents a glycosyl group, Z is expressed protein, n
Represents 3 to 14 and m represents 10 to 50), and is a drug delivery carrier containing the glycosyl-protein derivative.
【請求項2】 請求項1のグリコシル−蛋白誘導体を含
有する骨髄への薬剤運搬担体。
2. A carrier for drug delivery to bone marrow, which comprises the glycosyl-protein derivative of claim 1.
【請求項3】 mが20〜50である請求項1のグリコ
シル−蛋白誘導体を含有する脳への薬剤運搬担体。
3. A carrier for drug delivery to the brain containing the glycosyl-protein derivative according to claim 1, wherein m is 20 to 50.
【請求項4】 グリコシル基が、キシロピラノシル基、
マンノピラノシル基、フコピラノシル基、ガラクトピラ
ノシル基、2−アセトアミド−2−デオキシ−フコピラ
ノシル基、2−アセトアミド−2−デオキシ−マンノピ
ラノシル基、2−アセトアミド−2−デオキシ−ガラク
トピラノシル基、マンノピラノシル−マンノピラノシル
基、(2−アセトアミド−2−デオキシ−マンノピラノ
シル)−マンノピラノシル基、(2−アセトアミド−2
−デオキシ−グルコピラノシル)−マンノピラノシル
基、フコピラノシル−(2−アセトアミド−2−デオキ
シ−グルコピラノシル)基、ガラクトピラノシル−(2
−アセトアミド−2−デオキシ−グルコピラノシル)
基、ガラクトピラノシル−(2−アセトアミド−2−デ
オキシ−マンノピラノシル)基、ガラクトピラノシル−
グルコピラノシル基、ジ(2−アセトアミド−2−デオ
キシ−グルコピラノシル)−マンノピラノシル基又はジ
(ガラクトピラノシル)−2−アセトアミド−2−デオ
キシーグルコピラノシル基である、請求項1〜3のいず
れか1項記載の薬剤運搬担体。
4. The glycosyl group is a xylopyranosyl group,
Mannopyranosyl group, fucopyranosyl group, galactopyranosyl group, 2-acetamido-2-deoxy-fucopyranosyl group, 2-acetamido-2-deoxy-mannopyranosyl group, 2-acetamido-2-deoxy-galactopyranosyl group, mannopyranosyl- Mannopyranosyl group, (2-acetamido-2-deoxy-mannopyranosyl) -mannopyranosyl group, (2-acetamido-2
-Deoxy-glucopyranosyl) -mannopyranosyl group, fucopyranosyl- (2-acetamido-2-deoxy-glucopyranosyl) group, galactopyranosyl- (2
-Acetamido-2-deoxy-glucopyranosyl)
Group, galactopyranosyl- (2-acetamido-2-deoxy-mannopyranosyl) group, galactopyranosyl-
A glucopyranosyl group, a di (2-acetamido-2-deoxy-glucopyranosyl) -mannopyranosyl group or a di (galactopyranosyl) -2-acetamido-2-deoxy-glucopyranosyl group, which is any one of claims 1 to 3. The drug delivery carrier according to item 1.
【請求項5】 蛋白が、アルブミン、サイトカイン類又
は酵素である、請求項1〜4のいずれか1項記載の薬剤
運搬担体。
5. The drug delivery carrier according to any one of claims 1 to 4, wherein the protein is albumin, cytokines or enzymes.
JP3040810A 1990-02-16 1991-02-14 Glycosyl-protein derivative Expired - Lifetime JPH085914B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP3040810A JPH085914B2 (en) 1990-02-16 1991-02-14 Glycosyl-protein derivative

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP3385290 1990-02-16
JP2-33852 1990-02-16
JP3040810A JPH085914B2 (en) 1990-02-16 1991-02-14 Glycosyl-protein derivative

Publications (2)

Publication Number Publication Date
JPH04211099A JPH04211099A (en) 1992-08-03
JPH085914B2 true JPH085914B2 (en) 1996-01-24

Family

ID=26372622

Family Applications (1)

Application Number Title Priority Date Filing Date
JP3040810A Expired - Lifetime JPH085914B2 (en) 1990-02-16 1991-02-14 Glycosyl-protein derivative

Country Status (1)

Country Link
JP (1) JPH085914B2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2602607B2 (en) * 1992-09-09 1997-04-23 株式会社ディ・ディ・エス研究所 Sugar modified peptide
TW263437B (en) * 1992-09-24 1995-11-21 Takeda Pharm Industry Co Ltd
AU1122897A (en) * 1995-11-13 1997-06-05 Glycomed Incorporated Novel oligosaccharide glycosides having mammalian immunosuppressive and tolerogenic properties
JP4532618B2 (en) * 1999-02-25 2010-08-25 株式会社グライコメディクス Novel sugar primer
KR101660059B1 (en) 2008-08-22 2016-09-26 박스알타 인코퍼레이티드 Polymeric benzyl carbonate-derivatives

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59500914A (en) * 1983-01-27 1984-05-24 ユニバ−シテイ・オブ・フロリダ Delivery of specific drugs to the brain
JPH01149718A (en) * 1987-12-07 1989-06-12 Yoshikatsu Eto Liposome preparation easily passing through blood-brain barrier

Also Published As

Publication number Publication date
JPH04211099A (en) 1992-08-03

Similar Documents

Publication Publication Date Title
CA2344652C (en) Carboxymethylgalactose derivatives
US5658880A (en) Sialic acid/fucose based medicaments
US5591835A (en) Substituted lactose derivatives
WO1996005209A9 (en) Sialic acid/fucose based medicaments
HUT74506A (en) Sialyl lewis-x analogues as inhibitors of cellular adhesion
USRE34091E (en) Sialic acid derivatives having active carbonyl group
EP2424873A1 (en) Novel galactoside inhibitors of galectins
EP0069678A2 (en) 3-Fucosyl-N-acetyl-lactosamine derivatives, their preparation and their biological applications
JP3141693B2 (en) Ganglioside GM3 analogs in which 9-position of sialic acid is substituted by fluorine and intermediates thereof
Iijima et al. Synthesis of a mucin-type O-glycosylated amino acid, β-Gal-(1→ 3)-[α-Neu5Ac-(2→ 6)]-α-GalNAc-(1→ 3)-Ser
AU678373B2 (en) Substituted lactose derivatives as cell adhesion inhibitors
JPH07108911B2 (en) Novel oligosaccharides and methods for their synthesis and biological applications
US5849709A (en) Saccharopeptides and derivatives thereof
JPH085914B2 (en) Glycosyl-protein derivative
JP2648584B2 (en) Glycosyl-protein derivatives
JP2791001B2 (en) Glycosyl-protein derivatives
JP2589431B2 (en) Sugar-modified polyglutamic acid derivative and production method thereof
JP2003519628A (en) Method for synthesizing α-D-GAL (1 → 3) GAL-containing oligosaccharide
JP2589435B2 (en) Sugar-modified polylysine derivative
US5134230A (en) 2-Deoxy-2-aminoglucopyranoside derivatives
Wang et al. Stereocontrolled syntheses of O-glycans of core class 2 with a linear tetrameric lactosamine chain and with three lactosamine branches
JP2001512737A (en) Substituted tetrahydropyran derivatives, processes for their preparation, their use as medicaments or diagnostics and medicaments containing them
EP0812855B1 (en) Fluorinated ganglioside gm3 analogues and intermediates therefor
JPH0560474B2 (en)
JP2698570B2 (en) Production method of glutamic acid derivative